2019年09月, 日本癌学会, JCA-CHAAO賞　　　　　　　　　　　　　　　
白土 博樹;清水 伸一;鬼丸 力也;品川 尚文;阿保 大介;加藤 徳雄;梅垣 菊男;石川 正純;宮本 直樹;青山 英史

2013年10月, 日本放射線腫瘍学会, 梅垣賞　　　　　　　　　　　　　　　
加藤徳雄

Proton beam therapy for intrahepatic and perihilar cholangiocarcinoma: a multicenter prospective registry study: -Potential candidates for high-dose proton beam therapy.
Hideya Yamazaki, Kei Shibuya, Takuya Kimoto, Motohisa Suzuki, Masao Murakami, Kazuki Terashima, Tomoaki Okimoto, Takashi Iizumi, Hideyuki Sakurai, Masaru Wakatsuki, Takashi Ogino, Takeshi Arimura, Masaru Takagi, Masayuki Araya, Takahiro Waki, Sae Matsumoto, Hiroyuki Ogino, Norio Katoh, Takayuki Hashimoto, Hidehiro Hojo, Nobuyoshi Fukumitsu, Shigeyuki Murayama
International journal of radiation oncology, biology, physics, 2025年12月04日, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: As dose-escalation radiotherapy can improve local control, stereotactic body radiotherapy has achieved better results than conventional radiotherapy in liver malignancies. This study aimed to investigate the role of dose-escalation proton beam therapy (PT) in patients with intrahepatic cholangiocarcinoma (CCA) (iCCA) and perihilar CCA (pCCA). METHODS AND MATERIALS: We analyzed data from a multi-institutional prospective registry that included all Japanese proton beam facilities between May 2016 and May 2021. Endpoints were local control (LC), progression-free survival (PFS), overall survival (OS), and toxicity. RESULTS: We included 236 patients with unresectable CCA (133 iCCA and 103 pCCA) treated with PT with a median prescribed dose of 72.6 Gy (RBE) (range, 50-76 Gy (RBE)) in 25 fractions (range, 10-38 fractions). With a median follow-up of 20.0 months for surviving patients, the median OS was 19 months and the 2-year OS was 44.8%. For iCCA and pCCA, the median OSs were 17 and 20 months, respectively. Two-year PFS and LC rates were 20.6% and 66.5%, respectively. Multivariable analyses revealed that liver function and the distance between the tumor and the gastrointestinal (GI) tract were significantly associated with OS, while overall treatment time (OTT) was associated with LC. Furthermore, liver function and tumor diameter were associated with progression-free survival. The median OS for patients with GI distance ≥ 2 cm and a higher prescribed dose (≥74 Gy in EQD2) was 37 months (2-year OS 61.8%), compared with 18.0 months (33.1%) for the other patients (p < 0.001). Twenty-one patients experienced adverse reactions of grade 3 or higher (8.9%). CONCLUSION: PT showed good efficacy with acceptable toxicity for unresectable iCCA and pCCA without distant metastasis. Especially in patients with GI distance ≥ 2 cm, high dose PT was associated with improved OS.

Scanned particle-beam tracking with beam correction based on predictive volumetric imaging: A simulation study.
Takahisa Osanai, Seishin Takao, Kohei Yokokawa, Ye Chen, Taeko Matsuura, Keiji Kobashi, Norio Katoh, Takayuki Hashimoto, Hidefumi Aoyama, Naoki Miyamoto
Medical physics, 52, 9, e18096, 2025年09月, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Tracking irradiation to moving targets in spot-scanning particle therapy, which corrects the spot position and energy in real-time, may decrease treatment time and increase accuracy. However, because of the temporal performance of the system, clinical translation remains challenging. Processing time, including image acquisition, volumetric image synthesis, correction assessment, and system response, is required to control the actual treatment system. These processing delays cause millimeter-order discrepancies due to tumor motion. Predicting future states may compensate for this latency. However, research on predicting volumetric images required for energy correction assessment has not been reported. PURPOSE: This study aimed to investigate the dosimetric effectiveness of particle-beam tracking irradiation according to predictive volumetric imaging under various latency conditions. METHODS: Surrogate-driven volumetric image synthesis is combined with surrogate position prediction in the predictive volumetric imaging technique. A linear regression model in volumetric imaging that can derive internal deformation from surrogate displacement is established for each voxel from a four-dimensional computed tomography (4DCT) dataset in the modeling process. A volumetric image is predictively synthesized during the imaging process using the surrogate position predicted by a pretrained long short-term memory network. This predictively synthesized image enables the prospective assessment of beam parameter correction, including spot position and energy. In this study, 4DCT datasets and time-series trajectory data of the internal marker from three patients each with lung, liver, and pancreatic cancers were utilized for the dosimetric simulation. An intensity-modulated proton therapy plan was generated for each patient. Dosimetric simulations were conducted assuming the latencies of 133.3, 266.6, and 400.0 ms. Assessments included (1) tracking irradiation without latency as a benchmark, (2) tracking irradiation with latency but without prediction, and (3) tracking irradiation with latency and prediction. Further, dose-volume histograms and dose metrics of the clinical target volume (CTV) were compared. RESULTS: Doses in tracking with prediction were comparable to those in the benchmark. Differences in D99%, D95%, and D5% of the CTV in the lungs between the treatment plan and tracking irradiation without prediction exceeded 5% at all latencies. Differences in D95% and D5% in tracking irradiation with prediction were less than 5% in most cases. Differences in D99%, D95%, and D5% in the liver and pancreas exceeded 5% at a latency of 400.0 ms without prediction but remained below 3% with prediction. Doses to organs at risk showed only minor deviations from the treatment plan in tracking irradiation. CONCLUSIONS: The proposed tracking irradiation technique based on predictive volumetric imaging in spot-scanning particle therapy demonstrated tracking doses comparable to doses in the treatment plan across all latency conditions in the lung, liver, and pancreas. Further research and development of treatment devices and treatment planning protocols are warranted for the proposed tracking irradiation technique to become an effective motion management technique in terms of both dosimetric accuracy and treatment efficiency.

Fiducial Marker Placement for Gated Radiotherapy Using Real-Time Tumor-Tracking in Pancreatic Cancer: A Comparative Analysis of Transarterial and Percutaneous Approaches.
Daisuke Kato, Daisuke Abo, Ryo Morita, Norio Katoh, Naoki Miyamoto, Ryota Yamada, Naoya Kinota, Takaaki Fujii, Kouji Yamasaki, Motoma Kanaya, Hidefumi Aoyama, Kohsuke Kudo
Journal of vascular and interventional radiology : JVIR, 36, 12, 2021, 2029, 2025年08月22日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: To assess and compare the feasibility and safety of transarterial and percutaneous fiducial marker placements for gated radiotherapy using real-time tumor-tracking (RTRT) in patients with pancreatic cancer. MATERIALS AND METHODS: This retrospective cohort study included 61 patients with inoperable pancreatic cancer who underwent transarterial (n = 34) or percutaneous (n = 27) fiducial marker placement between 2015 and 2023. Technical and clinical success, adverse events (AEs), procedure time, number of markers, tumor-to-marker distance, migration, per-marker availability for RTRT, and reasons for marker unavailability were assessed. RESULTS: Both approaches achieved high technical and clinical success rates (transarterial, 91.4% and 97.1%; percutaneous, 96.3% and 96.3%; P = 0.626 and 1.000) without moderate or severe AEs. Mild AEs occurred in 2.9% and 7.4% of patients in the transarterial and percutaneous groups (P = 0.575). The procedure time was shorter in the percutaneous group (35 vs. 50 min [median], P = 0.006). The percutaneous group used more markers (3 vs. 1 [median], P < 0.001). The tumor-to-marker distance was comparable between groups (transarterial, 21 mm; percutaneous, 26 mm [median], P = 0.317). Migration occurred in only one percutaneous case (1.4%). On a per-marker basis, the transarterial group had higher marker availability for RTRT (97.1%) than the percutaneous group (70.8%, P = 0.001). Marker unavailability was due to untraceable shape (transarterial, 1; percutaneous, 12), lack of synchronization with tumor motion (percutaneous, 6), or others (percutaneous, 3). CONCLUSION: Transarterial and percutaneous fiducial marker placements are safe and feasible for administering RTRT in pancreatic cancer.

Comprehensive analysis of data from a nationwide Japanese cohort on particle therapy for metastatic liver tumors.
Nobuyoshi Fukumitsu, Shintaro Shiba, Kei Shibuya, Daijiro Kobayashi, Yuhei Miyasaka, Hisashi Yamaguchi, Haruko Numajiri, Masaru Wakatsuki, Hiroyuki Ogino, Norio Katoh, Takayuki Hashimoto
International journal of radiation oncology, biology, physics, 123, 5, 1316, 1322, 2025年07月26日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: This study evaluated the efficacy and safety of particle therapy (PT) for treating metastatic liver tumors. Conducted by the xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx, this nationwide, multi-institutional analysis examined PT outcomes, including overall survival (OS) rates and adverse events, to determine its potential as a treatment option for patients with limited liver metastases. METHODS AND MATERIALS: This nationwide, multi-institutional prospective cohort included patients treated with proton beam therapy and carbon-ion radiotherapy between 2016 and 2019. This is a retrospective cohort study utilizing registry data of metastatic liver tumors. PT dose schedules used varied based on tumor location. Outcomes assessed included OS, progression-free survival (PFS), local control (LC) and late treatment-related toxicities of grade 3 or higher. RESULTS: Among 322 eligible patients, the 2- and 5-year estimated OS rates were 55.7% and 32.8%, respectively, with a median survival time (MST) of 28.6 months. Patients with single lesions, particularly those with colorectal or breast cancer, demonstrated higher survival rates than those with multiple lesions. Patients with smaller tumors (<5 cm), especially in colorectal, pancreatic, gastric, and esophageal cancers, also showed improved survival compared to those with tumors ≥5 cm. Cox proportional hazards model analysis showed significant difference in maximal tumor diameter in colorectal cancer and pancreatic cancer (both P = 0.002) and number of lesions in breast cancer (P = 0.02). In a condition-specific subgroup analysis, MST exceeded 5 years in patients with breast cancer who had a single lesion or who did not receive concurrent systemic therapy. The 2- and estimated 5-year PFS rates were 23.5% and 12.8%, respectively, with MST of 9 months. The 2- and estimated 5-year LC rates were 74.3% and 66.4%, respectively. Recurrence was observed in 223 patients (local only: 43, distant only: 163, both: 17). Adverse events occurred in 3.1% of patients, primarily dermatitis and hepatobiliary disorders, with no grade 5 toxicities observed. CONCLUSIONS: PT is expected to provide excellent local control and low rates of serious adverse events for metastatic liver tumors. Promising OS rates, particularly in cases of colorectal and breast cancer, suggest that PT offers a survival advantage to carefully selected patients.

Updated Japanese multicenter registry study evaluates the efficacy and safety of proton beam therapy for treating extrahepatic cholangiocarcinoma.
Hideya Yamazaki, Kei Shibuya, Takuya Kimoto, Motohisa Suzuki, Masao Murakami, Kazuki Terashima, Tomoaki Okimoto, Takashi Iizumi, Hideyuki Sakurai, Masaru Wakatsuki, Takashi Ogino, Takeshi Arimura, Masaru Takagi, Masayuki Araya, Takahiro Waki, Sae Matsumoto, Hiroyuki Ogino, Norio Katoh, Takayuki Hashimoto, Hidehiro Hojo, Nobuyoshi Fukumitsu, Takumi Fukumoto, Masayuki Ohtsuka
Scientific reports, 15, 1, 23250, 23250, 2025年07月02日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, This study aimed to analyze the efficacy and safety of a prospective, multicenter registry study of proton beam therapy (PBT) for extrahepatic cholangiocarcinoma (EHC) in Japan. Patients who underwent PBT for EHC between May 2016 and June 2021 were registered in the Particle Beam Therapy Committee and Subcommittee of the Japanese Society for Radiation Oncology. We updated the overall survival (OS), progression-free survival (PFS), local control rate (LC), and toxicity. Among 201 registered cases, 124 cases including elder population (median age 76 years old, range; 44-91) with initial definitive PBT were evaluated. The follow-up period for survivors was 18.3 months, the median OS time was 20.0 months (95% CI: 17.3-22.8 months), and the 2-year OS rate was 36.9% (27.3-46.4%). The 2-year LC and PFS were 65.2% and 23.0%. The OS was significantly higher for tumor size < 3 cm vs. ≥ 3 cm (p = 0.015); liver function Child-Pugh score normal/A vs. B/C (p < 0.001); and distance of the tumor from the gastrointestinal tract > 2 cm vs. ≤ 2 cm (p = 0.008) in multivariate analysis. Elderly patients age > 75 years underwent less chemotherapy and showed a 2-year OS of 41.3%, whereas young patients with age ≤ 75 years showed a 2-year OS of 32.0%. A higher prescribed dose (biologically effective dose: BED) > 89 Gy10 was associated with better LC and PFS but not OS. PBT-related grade 3 acute and late adverse events occurred in 4.0 and 12.1% of the patients, respectively. These updated multicenter prospective registry data demonstrate that PBT is an effective treatment for unresectable EHC, including in elderly patients.

Mathematical mechanistic model representing the cancer immunity cycle under radiation effects.
Taisuke Takayanagi, Koichi Miyazaki, Kana Yamasaki, Takahiro Yamada, Futaro Ebina, Takahiro Kanehira, Yasuhito Onodera, Keiji Kobashi, Hiroshi Taguchi, Koichi Yasuda, Norio Katoh, Takayuki Hashimoto, Hidefumi Aoyama, Hiroki Shirato, Kenji Chamoto
Scientific reports, 15, 1, 19940, 19940, 2025年06月06日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Combining radiotherapy with immune checkpoint inhibitors is a promising approach to improve the effectiveness of cancer treatment. However, the success rates of these clinical studies are limited. It is essential to determine the optimal irradiation scheme that maximizes the therapeutic effect by taking into account the balance between the positive and negative effects of radiation on immunity. In this context, we developed a mathematical mechanistic model that simulates (1) the balance between effector and exhausted cytotoxic T-lymphocytes (CTLs), (2) the number of neoantigens released by high-dose irradiation, and (3) the impact of radiation on draining lymph nodes (DLNs) for systemic anti-tumor immunity, and tested whether this mathematic model fits in several animal experiments. Our mechanistic model reproduced the anti-tumor effects of several cancer treatment models for combination therapies with radiation, immune checkpoint inhibitors, and/or a metabolic modulator. Furthermore, this mechanistic model simulated that tumor suppression in distant metastatic foci, known as the abscopal effect, was dysregulated by hypofractionated high-dose irradiation or by the direct radiation exposure on DLN. The mechanistic model successfully reproduced tumor control under various treatment conditions with appropriate parameters, indicating that it may be useful for optimizing immunoradiotherapy prescriptions.

Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning.
Keiichi Jingu, Keiji Nihei, Yoshinori Ito, Masahiko Okamoto, Hiroshi Doi, Hirofumi Ogawa, Masakatsu Onozawa, Terufumi Kawamoto, Norio Katoh, Atsuya Takeda, Hirokazu Makishima, Hiroshi Mayahara, Hideya Yamazaki, Keiko Nemoto Murofushi, Kayoko Tsujino, Hiroshi Igaki, Takashi Uno
Journal of radiation research, 2025年06月03日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, The Japanese Society for Radiation Oncology (JASTRO) Guidelines for Radiotherapy Treatment Planning have been revised every four years to incorporate the latest findings since the publication of the first edition in 2004. This is a review which presents the 2024 JASTRO Guidelines for radiotherapy treatment planning for esophageal cancer in English. Regarding the treatment of esophageal cancer, various new findings have emerged over the past 4 years, leading to significant updates in the 2020 edition, particularly in the following six areas: (i) additional details on indications for superficial cancer, (ii) inclusion of clinical trial results (JCOG1109) for neoadjuvant chemotherapy and chemoradiotherapy in locally advanced cases in Japan, (iii) updated references on prophylactic lymph node irradiation, (iv) updates on IMRT, (v) revisions in accordance with the 5th edition of the Esophageal Cancer Treatment Guidelines, and (vi) additions of FOLFOX to concurrent chemotherapy regimens.

Contouring atlas and essential points for radiotherapy in rectal cancer.
Keiko Nemoto Murofushi, Kayoko Tsujino, Yoshinori Ito, Masahiko Okamoto, Hiroshi Doi, Hirofumi Ogawa, Masakatsu Onozawa, Terufumi Kawamoto, Norio Katoh, Keiichi Jingu, Atsuya Takeda, Keiji Nihei, Hirokazu Makishima, Hiroshi Mayahara, Hideya Yamazaki, Hiroshi Igaki
Journal of radiation research, 66, 3, 203, 211, 2025年05月23日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, In the last decade, the role of radiotherapy in rectal cancer has changed significantly with the introduction of total neoadjuvant therapy (TNT) and nonoperative management (NOM). For the setting of irradiation field in rectal cancer, the pararectal, lateral lymph nodes, and those along the inferior mesenteric artery (IMA) are most important. In total mesorectal excision (TME), the root of the IMA is dissected. In the atlas of pelvic irradiation for rectal cancer, the setting of the upper margin of the mesorectum varies from atlas to atlas, and no atlas sets the upper margin of the mesorectum to the root of the IMA. In particular, there is no consensus on the definition of anatomical boundaries regarding the lymph nodes along the superior rectal artery (SRA). The upper margin of the irradiation field in clinical trials of preoperative radiotherapy and TNT is generally set at the level of the internal and external iliac artery branches, L5/S1, or S2/S3. However, it is not necessary to include the entire mesorectum to the root of the IMA in patients undergoing preoperative radiotherapy plus TME. Conversely, for patients receiving NOM, the irradiation field may have to include the mesorectum to the IMA root, though the incidence of lymph node metastasis and gastrointestinal adverse events merits consideration. It is increasingly important to determine the extent of clinical target volume around the SRA region and the setting of the upper margin of the irradiation field after formulating the treatment policy together with the surgeons and medical oncologists.

Health Utility of Pain Response Versus Nonresponse to Palliative Radiation Therapy for Symptomatic Bone Metastases: Analyses Based on Real-World Data from 26 Centers.
Tetsuo Saito, Naoto Shikama, Takeo Takahashi, Hideyuki Harada, Naoki Nakamura, Akifumi Notsu, Hiroki Shirato, Kazunari Yamada, Haruka Uezono, Yutaro Koide, Hikaru Kubota, Takuya Yamazaki, Kei Ito, Joichi Heianna, Yukinori Okada, Ayako Tonari, Norio Katoh, Hitoshi Wada, Yasuo Ejima, Kayo Yoshida, Takashi Kosugi, Shigeo Takahashi, Takafumi Komiyama, Nobue Uchida, Misako Miwa, Miho Watanabe, Hisayasu Nagakura, Hiroko Ikeda, Isao Asakawa, Naoyuki Shigematsu
Journal of palliative medicine, 2024年12月27日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Background: Utility values of responders and nonresponders are essential inputs in cost-effectiveness studies of radiation therapy for painful bone metastases but, to our knowledge, they have not been reported separately. Objective: We sought to determine the utility values of responders and nonresponders using data from a prospective observational study on bone metastases. Methods: The original prospective observational study was conducted at 26 centers in Japan. Of 232 enrolled patients, 181 whose pain scores at baseline were ≥2 were analyzed. Health-related quality of life (QOL) was measured using the EuroQol 5-dimensions 5-levels (EQ-5D-5L) instrument at baseline and 2- and 6-month follow-up assessments. At follow-up assessments, patients were categorized as responders or nonresponders. Pain response was assessed using the International Consensus Pain Response Endpoints. Results: Of the 181 patients analyzed, 133 (73%) and 84 (46%) were evaluable at the 2- and 6-month follow-up assessment, respectively. The EQ-5D-5L index score (utility) increased from baseline to the 2- and 6-month follow-up assessments; regarding opioid analgesic use, no clear trend was observed during the same period. The mean utility was significantly higher in responders than in nonresponders at both follow-up times. The mean daily oral morphine equivalent dose was significantly lower in responders than in nonresponders at both follow-up times. Conclusion: We determined utility values for responders and nonresponders. Pain response was associated with better QOL and less opioid use. Our utility values according to response status can be used for model input in future cost-effectiveness studies on radiation therapy for bone metastases.

Final results of a multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma (the STRSPH study): Stereotactic body radiotherapy for newly diagnosed single primary liver cancer.
Naoko Sanuki, Tomoki Kimura, Atsuya Takeda, Keisuke Ariyoshi, Shunsuke Oyamada, Takuhiro Yamaguchi, Yuichiro Tsurugai, Yoshiko Doi, Masaki Kokubo, Toshiyuki Imagumbai, Norio Katoh, Takahisa Eriguchi, Satoshi Ishikura
International journal of radiation oncology, biology, physics, 2024年12月18日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, AIM: To report final results of a prospective study of stereotactic body radiotherapy (SBRT) in patients with previously untreated solitary primary hepatocellular carcinoma (HCC). METHODS: This prospective, single-arm, multicenter phase II trial recruited patients with HCC who were unsuitable for, or refused, surgery and radiofrequency ablation, with 3-year overall survival (OS) rates as the primary endpoint and survival outcomes and adverse events as secondary endpoints. The prescribed SBRT dose was 40 Gy in five fractions. The final data were analyzed in November 2022. RESULTS: Between 2014 and 2018, 36 patients (median age, 73.5 years) were registered; enrollment was closed before full recruitment owing to slow accrual. Overall, 34 patients were analyzed for efficacy evaluation after excluding 2 patients. The median tumor size was 2.3 cm. The median follow-up times for all patients and for survivors were 49 and 56 months, respectively. The 3-year OS rate was 82% (95% confidence interval [CI]: 65%-92%). The 3-year local control rate was 93% (95% CI: 76%-98%). Grade 3 or higher SBRT-related non-laboratory toxicities were observed in four patients (11%). No Grade 5 adverse events were observed. CONCLUSIONS: Final results of this phase II trial suggest the efficacy and safety of SBRT for newly diagnosed early-stage HCC that is unfit for other local therapies. Although this study was underpowered by the small number of registrations, the excellent results indicate that SBRT may be an alternative option for the management of early-stage HCC.

Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiotherapy
Fuki Koizumi, Norio Katoh, Takahiro Kanehira, Yasuyuki Kawamoto, Toru Nakamura, Tatsuhiko Kakisaka, Miyako Myojin, Noriaki Nishiyama, Akio Yonesaka, Manami Otsuka, Rikiya Takashina, Hideki Minatogawa, Hajime Higaki, Yusuke Uchinami, Hiroshi Taguchi, Kentaro Nishioka, Koichi Yasuda, Naoki Miyamoto, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama
Physics and Imaging in Radiation Oncology, 100690, 100690, Elsevier BV, 2024年12月, ［査読有り］, ［責任著者］
英語, 研究論文（学術雑誌）

Quality of life improvement after radiotherapy for bone metastases assessed using real-world data: a secondary analysis of a Nationwide Multicenter Cohort Study.
Nobuko Utsumi, Tetsuo Saito, Naoto Shikama, Takeo Takahashi, Hideyuki Harada, Naoki Nakamura, Shuichi Ueno, Akifumi Notsu, Hiroki Shirato, Kazunari Yamada, Haruka Uezono, Yutaro Koide, Hikaru Kubota, Takuya Yamazaki, Kei Ito, Joichi Heianna, Yukinori Okada, Ayako Tonari, Norio Katoh, Hitoshi Wada, Yasuo Ejima, Kayo Yoshida, Takashi Kosugi, Shigeo Takahashi, Takafumi Komiyama, Nobue Uchida, Misako Miwa, Miho Watanabe, Hisayasu Nagakura, Hiroko Ikeda, Isao Asakawa, Naoyuki Shigematsu
Japanese journal of clinical oncology, 2024年10月30日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, OBJECTIVE: Single-center studies or randomized controlled trials have evaluated the impact of radiotherapy for bone metastases on quality of life (QOL). We investigated the real-world impact of radiotherapy for bone metastases on QOL using nationwide multicenter cohort data. METHODS: We conducted a prospective observational study at 26 centers in Japan. Of 333 patients who received radiotherapy for bone metastases between December 2020 and March 2021, 232 (70%) were enrolled in the study. Patient-reported QOL was evaluated at enrollment and at two- and six-month follow-up using the European Organization for Research and Treatment of Cancer (EORTC) QOL Questionnaire Core 15-Palliative and the EORTC QOL Questionnaire Bone Metastases module (QLQ-BM22). Possible predictors (patient-, tumor -, and treatment-related factors) of QOL improvement were screened using logistic regression models. RESULTS: QOL scores showed significant improvement at two-month follow-up in seven (global health status/QOL, emotional functioning, pain, insomnia, painful sites, pain characteristics and functional interference) of the 14 scales. Of these seven scales, mean improvement ≥ the minimal clinically important difference (defined by a change of 10 or more on the 0 to 100 scale) was seen in four scales (pain, insomnia, pain characteristics and functional interference). We did not find any predictors of QOL improvement in the functional interference scale of QLQ-BM22. CONCLUSION: Radiotherapy for bone metastases performed in daily practice is effective in improving some scales of QOL.

Investigation of interfractional range variation owing to anatomical changes with beam directions based on water equivalent thickness in proton therapy for pancreatic cancer.
Yuhei Kikkawa, Hideaki Ueda, Yusuke Uchinami, Norio Katoh, Hidefumi Aoyama, Yoichi M Ito, Kohei Yokokawa, Ye Chen, Taeko Matsuura, Naoki Miyamoto, Seishin Takao
Journal of radiation research, 65, 6, 813, 823, 2024年10月08日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, To assess the interfractional anatomical range variations (ARVs) with beam directions and their impact on dose distribution in intensity modulated proton therapy, we analyzed water equivalent thickness (WET) from 10 patients with pancreatic cancer. The distributions of the interfractional WET difference ($\Delta{\mathrm{WET } }^{\theta }$) across 360° were visualized using polar histograms. Interfractional ARVs were evaluated using the mean absolute error and ΔWET pass rate, indicating the percentage of $\Delta \mathrm{WE},{\mathrm{T } }^{\theta }$ < thresholds. The impact on dose distribution in proton therapy was evaluated based on two treatment plans for 40 Gy(RBE)/5 fractions: 'Plan A', using two beam angles, in which the target was closest to the body surface among four perpendicular directions; and 'Plan B', using two beam angles with small ARVs. Analysis revealed individual variations in angular trends of interfractional ARVs. Three distinct trends were identified: Group 1 exhibited small ARVs around posterior directions; Group 2 exhibited small ARVs except ~60°; Group 3 demonstrated minimal ARVs only ~90°. In dose evaluation, while 150° and 210° were selected in Plan B for 9 out of 10 patients, for the remaining patient, 60° and 90° were chosen. Comparing dose volume histogram parameters for all patients, Plan B significantly reduced target coverage loss while maintaining organ-at-risk sparing comparable to Plan A. These results demonstrated that selecting beam angles with small interfractional ARVs for each patient enhances the robustness of dose distribution, reducing target coverage loss.

Application of motion prediction based on a long short-term memory network for imaging dose reduction in real-time tumor-tracking radiation therapy.
Kazuki Numakura, Seishin Takao, Taeko Matsuura, Kouhei Yokokawa, Ye Chen, Yusuke Uchinami, Hiroshi Taguchi, Norio Katoh, Hidefumi Aoyama, Satoshi Tomioka, Naoki Miyamoto
Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB), 125, 104507, 104507, 2024年09月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: To demonstrate the possibility of using a lower imaging rate while maintaining acceptable accuracy by applying motion prediction to minimize the imaging dose in real-time image-guided radiation therapy. METHODS: Time-series of three-dimensional internal marker positions obtained from 98 patients in liver stereotactic body radiation therapy were used to train and test the long-short-term memory (LSTM) network. For real-time imaging, the root mean squared error (RMSE) of the prediction on three-dimensional marker position made by LSTM, the residual motion of the target under respiratory-gated irradiation, and irradiation efficiency were evaluated. In the evaluation of the residual motion, the system-specific latency was assumed to be 100 ms. RESULTS: Except for outliers in the superior-inferior (SI) direction, the median/maximum values of the RMSE for imaging rates of 7.5, 5.0, and 2.5 frames per second (fps) were 0.8/1.3, 0.9/1.6, and 1.2/2.4 mm, respectively. The median/maximum residual motion in the SI direction at an imaging rate of 15.0 fps without prediction of the marker position, which is a typical clinical setting, was 2.3/3.6 mm. For rates of 7.5, 5.0, and 2.5 fps with prediction, the corresponding values were 2.0/2.6, 2.2/3.3, and 2.4/3.9 mm, respectively. There was no significant difference between the irradiation efficiency with and that without prediction of the marker position. The geometrical accuracy at lower frame rates with prediction applied was superior or comparable to that at 15 fps without prediction. In comparison with the current clinical setting for real-time image-guided radiation therapy, which uses an imaging rate of 15.0 fps without prediction, it may be possible to reduce the imaging dose by half or more. CONCLUSIONS: Motion prediction can effectively lower the frame rate and minimize the imaging dose in real-time image-guided radiation therapy.

Particle Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study, Systematic Review and Meta-Analysis
Masashi Mizumoto, Kei Shibuya, Kazuki Terashima, Masao Murakami, Motohiro Murakami, Yoshiyuki Shioyama, Yoshiro Matsuo, Takashi Ogino, Tatsuya Ohno, Takahiro Waki, Hiroyuki Ogino, Hiroyasu Tamamura, Norio Katoh, Masaru Wakatsuki, Tomoaki Okimoto, Motohisa Suzuki, Takashi Saito, Shingo Toyama, Takayuki Hashimoto, Hisateru Ohba, Shoji Kubo, Kiyoshi Hasegawa, Kazushi Maruo, Hideyuki Sakurai
Liver Cancer, 1, 12, S. Karger AG, 2024年08月28日, ［査読有り］
研究論文（学術雑誌）, Introduction: A prospective study was started in May 2016 to evaluate the efficacy and safety of particle therapy for intrahepatic cholangial carcinoma (ICC). To compare treatment modalities, we also conducted a meta-analysis of literature data and a systematic comparison using registry data. Methods: Patients who received particle therapy for ICC from May 2016 to June 2018 were registered. Nineteen manuscripts (4 particle therapy, 8 3D-CRT, 7 SBRT) were selected for the meta-analysis. Results: A total of 85 cases (proton beam therapy 59, carbon therapy 26) were registered. The median overall survival (OS) of the 85 patients was 22.1 months (95% CI: 12.9–31.3); the 1-, 2-, 3-, and 4-year OS rates were 70.9% (95% CI: 61.1–80.7%), 47.6% (36.8–58.4%), 37.7% (26.7–48.7%), and 22.7% (10.2–35.2%), respectively; and the 1-, 2-, 3-, and 4-year local recurrence rates were 8.2% (1.1–15.3%), 21.6% (9.3–33.9%), 33.4% (16.7–50.1%), and 33.4% (16.7–50.1%), respectively. In the meta-analysis and registry data, the 1-year OS for particle therapy, SBRT and 3D-CRT were 71.8% (95% CI: 64.6–77.8%), 59.2% (53.0–64.9%, p = 0.0573), and 47.2% (36.8–56.9%, p = 0.0004), respectively. The incidence of grade 3 or higher late non-hematological toxicity in the meta-analysis and registry data were 7.4–12% for particle therapy, 6.7–16.7% for SBRT, and 8.1–14.3% for 3D-CRT. Conclusions: Particle therapy achieved a good therapeutic effect for ICC, and a meta-analysis indicated that particle therapy is a better treatment modality than SBRT and 3D-CRT.

Multi-institutional prospective observational study of radiotherapy for metastatic bone tumor.
Hideyuki Harada, Naoto Shikama, Akifumi Notsu, Hiroki Shirato, Kazunari Yamada, Haruka Uezono, Yutaro Koide, Hikaru Kubota, Takuya Yamazaki, Kei Ito, Joichi Heianna, Yukinori Okada, Ayako Tonari, Norio Katoh, Hitoshi Wada, Yasuo Ejima, Kayo Yoshida, Takashi Kosugi, Shigeo Takahashi, Takafumi Komiyama, Nobue Uchida, Misako Miwa, Miho Watanabe, Hisayasu Nagakura, Hiroko Ikeda, Tetsuo Saito, Isao Asakawa, Takeo Takahashi, Naoyuki Shigematsu
Journal of radiation research, 2024年08月20日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Purpose of this study is to evaluate patient characteristics, treatments and outcomes in bone metastasis radiotherapy practice. Patients for whom radiotherapy for bone metastasis was planned at 26 institutions in Japan between December 2020 and March 2021 were consecutively registered in this prospective, observational study. Study measures included patient characteristics, pain relief, skeletal-related events (SREs), overall survival and incidence of radiation-related adverse events. Pain was evaluated using a numerical rating scale (NRS) from 0 to 10. Irradiated dose was analyzed by the biologically effective dose (BED) assuming α/β = 10. Overall, 232 patients were registered; 224 patients and 302 lesions were fully analyzed. Eastern Cooperative Oncology Group Performance Status was 0/1/2/3/4 in 23%/38%/22%/13%/4%; 59% of patients had spinal metastases and 84% had painful lesions (NRS ≥ 2). BED was <20 Gy (in 27%), 20-30 Gy (24%), 30-40 Gy (36%) and ≥ 40 Gy (13%); 9% of patients were treated by stereotactic body radiotherapy. Grade 3 adverse events occurred in 4% and no grade 4-5 toxicity was reported. Pain relief was achieved in 52% at 2 months. BED is not related to pain relief. The cumulative incidence of SREs was 6.5% (95% confidence interval (CI) 3.1-9.9) at 6 months; no factors were significantly associated with SREs. With spinal lesions, 18% of patients were not ambulatory at baseline and 50% of evaluable patients in this group could walk at 2 months. The 6-month overall survival rate was 70.2% (95% CI 64.2-76.9%). In conclusion, we report real-world details of radiotherapy in bone metastasis.

Clinical application of real-time tumor-tracking for stereotactic volumetric modulated arc therapy for liver tumors.
Naoki Miyamoto, Norio Katoh, Takahiro Kanehira, Kohei Yokokawa, Ryusuke Suzuki, Yusuke Uchinami, Hiroshi Taguchi, Daisuke Abo, Hidefumi Aoyama
Physics and imaging in radiation oncology, 31, 100623, 100623, 2024年07月, ［査読有り］, ［国際共著］, ［国際誌］
英語, 研究論文（学術雑誌）, Real-time tumor-tracking volumetric modulated arc therapy (RT-VMAT) enabling beam-gating based on continuous X-ray tracking of the three-dimensional position of internal markers is relevant for moving tumors. Dose-volume characteristics and treatment time were evaluated in ten consecutive patients who underwent liver stereotactic body radiation therapy with RT-VMAT. Target dose conformity and sparing of the stomach and the intestine were improved comparing RT-VMAT with RT-3D conformal radiotherapy. The mean treatment time for each fraction was less than 10 min. RT-VMAT could be effective, especially for targets located adjacent to organs at risk.

EVALUATION OF THE EFFICACY OF ADAPTIVE STRATEGY IN STEREOTACTIC BODY PROTON BEAM THERAPY FOR PANCREATIC CANCER
Yuto Matsuo, Naoki Miyamoto, Norio Katoh, Yusuke Uchinami, Taeko Matsuura, Keiji Nakazato, Hidefumi Aoyama, Seishin Takao
International Journal of Particle Therapy, 12, 100500, 100500, Elsevier BV, 2024年06月
研究論文（学術雑誌）

A Single-Institution Prospective Study To Evaluate the Safety and Efficacy of Real- Time Image-Gated Spot-Scanning Proton Therapy (RGPT) for Prostate Cancer.
Kentaro Nishioka, Takayuki Hashimoto, Takashi Mori, Yusuke Uchinami, Rumiko Kinoshita, Norio Katoh, Hiroshi Taguchi, Koichi Yasuda, Yoichi M Ito, Seishin Takao, Masaya Tamura, Taeko Matsuura, Shinichi Shimizu, Hiroki Shirato, Hidefumi Aoyama
Advances in radiation oncology, 9, 5, 101464, 101464, 2024年05月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: In real-time image-gated spot-scanning proton therapy (RGPT), the dose distribution is distorted by gold fiducial markers placed in the prostate. Distortion can be suppressed by using small markers and more than 2 fields, but additional fields may increase the dose to organs at risk. Therefore, we conducted a prospective study to evaluate the safety and short-term clinical outcome of RGPT for prostate cancer. METHODS AND MATERIALS: Based on the previously reported frequency of early adverse events (AE) and the noninferiority margin of 10%, the required number of cases was calculated to be 43 using the one-sample binomial test by the Southwest Oncology Group statistical tools with the one-sided significance level of 2.5% and the power 80%. Patients with localized prostate cancer were enrolled and 3 to 4 pure gold fiducial markers of 1.5-mm diameter were inserted in the prostate. The prescribed dose was 70 Gy(relative biologic effectiveness) in 30 fractions, and treatment was performed with 3 fields from the left, right, and the back, or 4 fields from either side of slightly anterior and posterior oblique fields. The primary endpoint was the frequency of early AE (≥grade 2) and the secondary endpoint was the biochemical relapse-free survival rate and the frequency of late AE. RESULTS: Forty-five cases were enrolled between 2015 and 2017, and all patients completed the treatment protocol. The median follow-up period was 63.0 months. The frequency of early AE (≥grade 2) was observed in 4 cases (8.9%), therefore the noninferiority was verified. The overall 5-year biochemical relapse-free survival rate was 88.9%. As late AE, grade 2 rectal bleeding was observed in 8 cases (17.8%). CONCLUSIONS: The RGPT for prostate cancer with 1.5-mm markers and 3- or 4- fields was as safe as conventional proton therapy in early AE, and its efficacy was comparable with previous studies.

Proton Beam Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study in Japan.
Masashi Mizumoto, Kazuki Terashima, Hirokazu Makishima, Motohisa Suzuki, Takashi Ogino, Takahiro Waki, Hiromitsu Iwata, Hiroyasu Tamamura, Yusuke Uchinami, Tetsuo Akimoto, Tomoaki Okimoto, Takashi Iizumi, Masao Murakami, Norio Katoh, Kazushi Maruo, Kei Shibuya, Hideyuki Sakurai
Liver cancer, 13, 2, 161, 168, S. Karger AG, 2024年04月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, <b><i>Introduction:</i></b> Intrahepatic cholangiocarcinoma (ICC) can be treated with chemotherapy in unresectable cases, but outcomes are poor. Proton beam therapy (PBT) may provide an alternative treatment and has good dose concentration that may improve local control. <b><i>Methods:</i></b> Fifty-nine patients who received initial PBT for ICC from May 2016 to June 2018 at nine centers were included in the study. The treatment protocol was based on the policy of the Japanese Society for Radiation Oncology. Forty patients received 72.6–76 Gy (RBE) in 20–22 fr, 13 received 74.0–76.0 Gy (RBE) in 37–38 fr, and 6 received 60–70.2 Gy (RBE) in 20–30 fr. Overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier analysis. <b><i>Results:</i></b> The 59 patients (35 men, 24 women; median age: 71 years; range: 41–91 years) had PS of 0 (<i>n</i> = 47), 1 (<i>n</i> = 10), and 2 (<i>n</i> = 2). Nine patients had hepatitis and all 59 cases were considered inoperable. The Child-Pugh class was A (<i>n</i> = 46), B (<i>n</i> = 7), and unknown (<i>n</i> = 6); the median maximum tumor diameter was 5.0 cm (range 2.0–15.2 cm); and the clinical stage was I (<i>n</i> = 12), II (<i>n</i> = 19), III (<i>n</i> = 10), and IV (<i>n</i> = 18). At the last follow-up, 17 patients were alive (median follow-up: 36.7 months; range: 24.1–49.9 months) and 42 had died. The median OS was 21.7 months (95% CI: 14.8–34.4 months). At the last follow-up, 37 cases had recurrence, including 10 with local recurrence. The median PFS was 7.5 months (95% CI: 6.1–11.3 months). In multivariable analyses, Child-Pugh class was significantly associated with OS and PFS, and Child-Pugh class and hepatitis were significantly associated with local recurrence. Four patients (6.8%) had late adverse events of grade 3 or higher. <b><i>Conclusion:</i></b> PBT gives favorable treatment outcomes for unresectable ICC without distant metastasis and may be particularly effective in cases with large tumors.

Probability of normal tissue complications for hematologic and gastrointestinal toxicity in postoperative whole pelvic radiotherapy for gynecologic malignancies using intensity-modulated proton therapy with robust optimization.
Takaaki Yoshimura, Ryota Yamada, Rumiko Kinoshita, Taeko Matsuura, Takahiro Kanehira, Hiroshi Tamura, Kentaro Nishioka, Koichi Yasuda, Hiroshi Taguchi, Norio Katoh, Keiji Kobashi, Takayuki Hashimoto, Hidefumi Aoyama
Journal of radiation research, 2024年03月17日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, This retrospective treatment-planning study was conducted to determine whether intensity-modulated proton therapy with robust optimization (ro-IMPT) reduces the risk of acute hematologic toxicity (H-T) and acute and late gastrointestinal toxicity (GI-T) in postoperative whole pelvic radiotherapy for gynecologic malignancies when compared with three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated X-ray (IMXT) and single-field optimization proton beam (SFO-PBT) therapies. All plans were created for 13 gynecologic-malignancy patients. The prescribed dose was 45 GyE in 25 fractions for 95% planning target volume in 3D-CRT, IMXT and SFO-PBT plans and for 99% clinical target volume (CTV) in ro-IMPT plans. The normal tissue complication probability (NTCP) of each toxicity was used as an in silico surrogate marker. Median estimated NTCP values for acute H-T and acute and late GI-T were 0.20, 0.94 and 0.58 × 10-1 in 3D-CRT; 0.19, 0.65 and 0.24 × 10-1 in IMXT; 0.04, 0.74 and 0.19 × 10-1 in SFO-PBT; and 0.06, 0.66 and 0.15 × 10-1 in ro-IMPT, respectively. Compared with 3D-CRT and IMXT plans, the ro-IMPT plan demonstrated significant reduction in acute H-T and late GI-T. The risk of acute GI-T in ro-IMPT plan is equivalent with IMXT plan. The ro-IMPT plan demonstrated potential clinical benefits for reducing the risk of acute H-T and late GI-T in the treatment of gynecologic malignances by reducing the dose to the bone marrow and bowel bag while maintaining adequate dose coverage to the CTV. Our results indicated that ro-IMPT may reduce acute H-T and late GI-T risk with potentially improving outcomes for postoperative gynecologic-malignancy patients with concurrent chemotherapy.

Impact of adaptive radiotherapy on survival in locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiotherapy.
Yusuke Uchinami, Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Noboru Nishikawa, Rumiko Kinoshita, Kentaro Nishioka, Norio Katoh, Takashi Mori, Manami Otsuka, Naoki Miyamoto, Ryusuke Suzuki, Keiji Kobashi, Yasushi Shimizu, Jun Taguchi, Nayuta Tsushima, Satoshi Kano, Akihiro Homma, Hidefumi Aoyama
Radiation oncology journal, 42, 1, 74, 82, 2024年03月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: To investigate the clinical significance of adaptive radiotherapy (ART) in locally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT). MATERIALS AND METHODS: Eligible patients were treated with concurrent chemoradiotherapy using IMRT. Planning computed tomography in ART was performed during radiotherapy, and replanning was performed. Since ART was started in May 2011 (ART group), patients who were treated without ART up to April 2011 (non-ART group) were used as the historical control. The Kaplan-Meier method was used to calculate overall survival (OS), locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS). LRFS for the primary tumor (LRFS_P) and regional lymph node (LRFS_LN) were also studied for more detailed analysis. Statistical significance was evaluated using the log-rank test for survival. RESULTS: The ART group tended to have higher radiation doses. The median follow-up period was 127 months (range, 10 to 211 months) in the non-ART group and 61.5 months (range, 5 to 129 months) in the ART group. Compared to the non-ART group, the ART group showed significantly higher 5-year PFS (53.8% vs. 81.3%, p = 0.015) and LRFS (61.2% vs. 85.3%, p = 0.024), but not OS (80.7% vs. 80.8%, p = 0.941) and DMFS (84.6% vs. 92.7%, p = 0.255). Five-year LRFS_P was higher in the ART group (61.3% vs. 90.6%, p = 0.005), but LRFS_LN did not show a significant difference (91.9% vs. 96.2%, p = 0.541). CONCLUSION: Although there were differences in the patient backgrounds between the two groups, this study suggests the potential effectiveness of ART in improving locoregional control, especially in the primary tumor.

Real-time tumor-tracking radiotherapy with SyncTraX for primary liver tumors requiring isocenter shift†.
Yusuke Uchinami, Naoki Miyamoto, Daisuke Abo, Ryo Morita, Koji Ogawa, Tatsuhiko Kakisaka, Ryusuke Suzuki, Tomohiko Miyazaki, Hiroshi Taguchi, Norio Katoh, Hidefumi Aoyama
Journal of radiation research, 2023年11月22日, ［査読有り］, ［責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, The SyncTraX series enables real-time tumor-tracking radiotherapy through the real-time recognition of a fiducial marker using fluoroscopic images. In this system, the isocenter should be located within approximately 5-7.5 cm from the marker, depending on the version, owing to the limited field of view. If the marker is placed away from the tumor, the isocenter should be shifted toward the marker. This study aimed to investigate stereotactic body radiotherapy (SBRT) outcomes of primary liver tumors treated with SyncTraX in cases where the isocenter was shifted marginally or outside the planning target volume (PTV). Twelve patients with 13 liver tumors were included in the analysis. Their isocenter was shifted toward the marker and was placed marginally or outside the PTV. The prescribed doses were generally 40 Gy in four fractions or 48 Gy in eight fractions. The overall survival (OS) and local control (LC) rates were calculated using the Kaplan-Meier method. All patients completed the scheduled SBRT. The median distance between the fiducial marker and PTV centroid was 56.0 (interquartile range [IQR]: 52.7-66.7) mm. By shifting the isocenter toward the marker, the median distance between the marker and isocenter decreased to 34.0 (IQR: 33.4-39.7) mm. With a median follow-up period of 25.3 (range: 6.9-70.0) months, the 2-year OS and LC rates were 100.0% (95% confidence interval: 100-100). An isocenter shift makes SBRT with SyncTraX feasible in cases where the fiducial marker is distant from the tumor.

Daily fraction dose-adjusted radiotherapy policy to avoid prolonging the overall treatment time for early glottic squamous cell carcinoma: a single-institutional retrospective study.
Yasuhiro Dekura, Koichi Yasuda, Hideki Minatogawa, Yusuke Uchinami, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Takashi Mori, Kentaro Nishioka, Keiji Kobashi, Norio Katoh, Akihiro Homma, Hidefumi Aoyama
Journal of radiation research, 2023年11月10日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, The objective of this study was to determine the outcomes of radical radiotherapy for early glottic squamous cell carcinoma (EGSCC) with the policy of increasing the fraction size during radiotherapy when the overall treatment time (OTT) was expected to be prolonged. Patients diagnosed with clinical T1-2N0M0 EGSCC, who were treated with radical radiotherapy between 2008 and 2019 at Hokkaido University Hospital, were included. Patients received 66 Gy in 33 fractions for T1 disease and 70 Gy in 35 fractions for T2 disease as our standard regimen (usual group [UG]). If the OTT was expected to extend for >1 week, the dose fraction size was increased from 2.0 to 2.5 Gy from the beginning or during radiotherapy (adjusted group [AG]). At this time, we performed a statistical analysis between UG and AG. In total, 116 patients were identified, and the treatment schedules of 29 patients were adjusted. The median follow-up was 60.9 months. In the T1 group, the cumulative 5-year local failure rate was 12.0% in the AG and 15.4% in the UG, and in the T2 group, the rate was 40.7% in the AG and 25.3% in the UG. There were no significant differences between the AG and UG. Similarly, no significant differences were observed for overall survival and progression-free survival rates. Our single-institutional retrospective analysis of EGSCC patients suggested that a method of adjusting the radiotherapy schedule to increase fraction size from the beginning or during the course may be effective in maintaining treatment outcomes.

Factors associated with quality of life in patients receiving palliative radiotherapy for bone metastases: a secondary cross-sectional analysis of data from a prospective multicenter observational study.
Tetsuo Saito, Naoto Shikama, Takeo Takahashi, Hideyuki Harada, Shuichi Ueno, Akifumi Notsu, Hiroki Shirato, Kazunari Yamada, Haruka Uezono, Yutaro Koide, Hikaru Kubota, Takuya Yamasaki, Kei Ito, Joichi Heianna, Yukinori Okada, Ayako Tonari, Norio Katoh, Hitoshi Wada, Yasuo Ejima, Kayo Yoshida, Takashi Kosugi, Shigeo Takahashi, Takafumi Komiyama, Nobue Uchida, Misako Miwa, Miho Watanabe, Hisayasu Nagakura, Hiroko Ikeda, Isao Asakawa, Naoyuki Shigematsu
The British journal of radiology, 20230351, 20230351, 2023年10月03日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, OBJECTIVE: To identify factors significantly associated with quality of life (QOL) and determine if these associations are strong enough to predict certain aspects of QOL without measuring them. METHODS: We conducted an exploratory secondary analysis of baseline data of 224 patients (enrolled between December 2020 and March 2021) from a previously published prospective observational study on radiotherapy for bone metastases at 26 centres. Using univariable linear regression, we assessed the association between patient/treatment factors and QOL scale scores as measured by the European Organization for Research and Treatment of Cancer (EORTC) QOL Questionnaire Core 15-Palliative (QLQ-C15-PAL) and the EORTC QOL Questionnaire Bone Metastases module (QLQ-BM22). RESULTS: Age and sex were not significantly associated with QOL. Worse performance status, higher pain scores, and opioid and single-fraction use were significantly associated with most QOL scales; these four factors were associated with worse global QOL, worse functioning status, and more severe symptoms. The coefficients of determination for most QOL scales were less than 0.2, indicating that most of the variability in QOL scores was not explained by any of the explanatory variables. CONCLUSION: Performance status, pain intensity, and opioid and single-fraction use were significantly associated with most QOL scales. However, the associations were not strong enough to estimate QOL. ADVANCES IN KNOWLEDGE: To date, the association between treatment factors and QOL in patients with bone metastases has not been fully studied. We identified the factors that were significantly associated with QOL and found that these associations were not strong enough to predict QOL.

Proton beam therapy for hepatocellular carcinoma: Multicenter prospective registry study in Japan.
Masashi Mizumoto, Hiroyuki Ogino, Toshiyuki Okumura, Kazuki Terashima, Masao Murakami, Takashi Ogino, Hiroyasu Tamamura, Tetsuo Akimoto, Takahiro Waki, Norio Katoh, Masayuki Araya, Tsuyoshi Onoe, Masaru Takagi, Hiromitsu Iwata, Haruko Numajiri, Tomoaki Okimoto, Yusuke Uchinami, Kazushi Maruo, Kei Shibuya, Hideyuki Sakurai
International journal of radiation oncology, biology, physics, 2023年09月29日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, INTRODUCTION: A prospective multicenter registry study was started in May 2016 in Japan to evaluate the efficacy and safety of proton beam therapy (PBT) for hepatocellular carcinoma (HCC). METHODS: Patients who received PBT for HCC from May 2016 to June 2018 were registered in the database of the Particle Beam Therapy Committee and Subcommittee of the Japanese Society for Radiation Oncology (JASTRO). Overall survival (OS), progression-free survival (PFS) and local recurrence were evaluated. RESULTS: Of the 755 registered cases, 576 with initial PBT and no duplicate cancer were evaluated. At final follow-up, 322 patients were alive and 254 had died. The median follow-up period for survivors was 39 months (0-58 months). The median OS time of the 576 patients was 48.8 months (95% CI 42.0-55.6 months) and the 1-, 2-, 3- and 4-year OS rates were 83.8% (95% CI 80.5-86.6%), 68.5% (64.5-72.2%), 58.2% (53.9-62.2%), and 50.1% (44.9-55.0%), respectively. Recurrence was observed in 332 cases, including local recurrence in 45 cases. The median PFS time was 14.7 months (95% CI 12.4-17.0 months) and the 1-, 2-, 3- and 4-year PFS rates were 55.2% (95% CI 51.0-59.2%), 37.5% (33.5-41.5%), 30.2% (26.3-34.2%), and 22.8% (18.5-27.4%), respectively. The 1-, 2-, 3- and 4-year OS rates were significantly higher for tumor size <5 vs. 5-10 cm (p<0.001) and <5 vs. ≥10 cm (p<0.001); Child-Pugh score A/B vs. C (p<0.001); and distance of the tumor from the gastrointestinal tract <1 vs. 1-2 cm (p<0.008) and <1 vs. >2 cm (p<0.001). At final follow-up, 27 patients (4.7%) had late adverse events of grade 3 or higher, with liver failure (n=7) and dermatitis (n=7) being most common. CONCLUSION: This multicenter prospective data registry indicated that PBT for HCC gives good therapeutic effects (3-year local control rate of 90%) with a low risk of severe late adverse events.

The Japanese nationwide cohort data of proton beam therapy for liver oligometastasis in esophagogastric cancer patients.
Hisashi Yamaguchi, Nobuyoshi Fukumitsu, Haruko Numajiri, Hiroyuki Ogino, Norio Katoh, Tomoaki Okimoto, Motohisa Suzuki, Hideyuki Sakurai
Journal of radiation research, 2023年09月11日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, A nationwide multicenter cohort study on particle therapy was launched by the Japanese Society for Radiation Oncology in Japan in May 2016. We analyzed the outcome of proton beam therapy (PBT) for liver oligometastasis of esophagogastric cancers. Cases in which PBT was performed at all PBT facilities in Japan between May 2016 and February 2019 were enrolled. The patients were selected based on the following criteria: controlled primary cancer, liver recurrence without extrahepatic tumors and no more than three liver lesions. Twenty-two males and two females with a median age of 69 (range, 52-80) years and 35 lesions were included. This study included 6 patients with esophageal and 18 patients with gastric cancer. The median lesion size, fraction size and biological effective dose (BED)10 were 32 (7-104) mm, 3.8 gray (relative biological effect)/fractions (Gy (RBE)/fr) (2-8 Gy (RBE)/fr) and 96.9 (88.8-115.2) Gy, respectively. The median follow-up period was 18 (4-47) months. The 1-, 2- and 3-year overall survival (OS) rates were 75, 51.8 and 45.3%, respectively, and the median OS was 25.3 months. The 1-, 2- and 3-year cumulative local recurrence (LR) rates were 3, 6 and 6%, respectively. Patients' age (P < 0.01), performance status (P = 0.017) and tumor size (P = 0.024) were significant OS-related factors. No Grade 3 or higher adverse events (AEs) were observed. Owing to the low incidence of AEs and the low LR cumulative incidence, PBT is a feasible option for liver oligometastasis of esophagogastric cancers.

Predicting the daily gastrointestinal doses of stereotactic body radiation therapy for pancreatic cancer based on the shortest distance between the tumor and the gastrointestinal tract using daily computed tomography images
Yusuke Uchinami, Takahiro Kanehira, Keiji Nakazato, Yoshihiro Fujita, Fuki Koizumi, Shuhei Takahashi, Manami Otsuka, Koichi Yasuda, Hiroshi Taguchi, Kentaro Nishioka, Naoki Miyamoto, Kohei Yokokawa, Ryusuke Suzuki, Keiji Kobashi, Keita Takahashi, Norio Katoh, Hidefumi Aoyama
BJR|Open, 5, 1, British Institute of Radiology, 2023年08月, ［査読有り］, ［責任著者］
研究論文（学術雑誌）, Objectives:

We aimed to investigate whether daily computed tomography (CT) images could predict the daily gastroduodenal, small intestine, and large intestine doses of stereotactic body radiation therapy (SBRT) for pancreatic cancer based on the shortest distance between the gross tumor volume (GTV) and gastrointestinal (GI) tract.

Methods:

Twelve patients with pancreatic cancer received SBRT of 40 Gy in five fractions. We recalculated the reference clinical SBRT plan (PLAN_ref) using daily CT images and calculated the shortest distance from the GTV to each GI tract. The maximum dose delivered to 0.5 cc (D_0.5cc) was evaluated for each planning at-risk volume of the GI tract. Spearman’s correlation test was used to determine the association between the daily change in the shortest distance (Δshortest distance) and the ratio of ΔD_0.5cc dose to D_0.5cc dose in PLAN_ref (ΔD_0.5cc/PLAN_ref) for quantitative analysis.

Results:

The median shortest distance in PLAN_ref was 0 mm in the gastroduodenum (interquartile range, 0–2.7), 16.7 mm in the small intestine (10.0–23.7), and 16.7 mm in the large intestine (8.3–28.1 mm). The D_0.5cc of PLAN_ref in the gastroduodenum was >30 Gy in all patients, with 10 (83.3%) having the highest dose. A significant association was found between the Δshortest distance and ΔD_0.5cc/ PLAN_ref in the small or large intestine (p < 0.001) but not in the gastroduodenum (p = 0.404).

Conclusions:

The gastroduodenum had a higher D_0.5cc and predicting the daily dose was difficult. Daily dose calculations of the GI tract are recommended for safe SBRT.

Advances in knowledge:

This study aimed to predict the daily doses in SBRT for pancreatic cancer from the shortest distance between the GTV and the gastrointestinal tract. Daily changes in the shortest distance can predict the daily dose to the small or large intestines, but not to the gastroduodenum.

Proton beam therapy for extrahepatic biliary tract cancer: Analysis with prospective multi-institutional patients' registration database, Proton-Net.
Hideya Yamazaki, Kei Shibuya, Takuya Kimoto, Motohisa Suzuki, Masao Murakami, Kazuki Terashima, Tomoaki Okimoto, Takashi Iizumi, Hideyuki Sakurai, Masaru Wakatsuki, Osamu Suzuki, Norio Katoh, Takeshi Arimura, Takashi Ogino, Masaru Takagi, Masayuki Araya, Takahiro Waki, Sae Matsumoto, Hiroyuki Ogino, Takumi Fukumoto, Masayuki Ohtsuka
Clinical and translational radiation oncology, 41, 100634, 100634, 2023年07月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND AND PURPOSE: To examine the role of proton beam therapy (PBT) in the treatment of extrahepatic biliary tract cancer (EBC). METHODS AND MATERIALS: We analyzed the data accumulated in the Proton-Net database, which prospectively registered all individual patient data treated with PBT in all Japanese proton institutions from May 2016 to June 2019. The primary endpoint was overall survival (OS), and the secondary endpoints were local control (LC), progression-free survival (PFS), and toxicity. RESULTS: Ninety-three patients with unresectable and/or recurrent EBC were treated with PBT using a median prescribed dose of 67.5 Gy (RBE) (range, 50-72.6 Gy) in 25 (22-30 fractions). With a median follow-up of 16.3 months, the median survival time was 20.1 months and the 2-year OS was 37.8%. Two-year PFS and LC rates were 20.6% and 66.5%, respectively. Poor liver function (Child-Pugh B, C), a narrower distance between the tumor and digestive tract (2 cm >), and a larger tumor diameter (2 cm <) were identified as poor prognostic factors for OS. PBT-related grade 3 ≤ acute and late adverse events occurred in 5.4% and 4.3% of patients, respectively, including one gastrointestinal late toxicity (duodenal ulcer). CONCLUSIONS: This is the largest prospectively accumulated series of PBT for EBC, and PBT showed favorable outcomes with acceptable toxicity profiles.

Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy.
Norihiro Aibe, Hiroyuki Ogino, Masaru Wakatsuki, Kei Fujikawa, Satoshi Teramukai, Nobuyoshi Fukumitsu, Shintaro Shiba, Naoyoshi Yamamoto, Akihiro Nomoto, Takashi Ono, Masanosuke Oguri, Hisashi Yamaguchi, Haruko Numajiri, Kei Shibuya, Shohei Okazaki, Yuhei Miyasaka, Noriyuki Okonogi, Kazutoshi Murata, Hitoshi Tatebe, Atsushi Motegi, Tomoaki Okimoto, Takayuki Yoshino, Masaki Mandai, Norio Katoh, Hiroshi Tsuji, Hideyuki Sakurai
Journal of radiation research, 64, Supplement_1, i69-i83, 2023年06月16日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Japanese national oncological experts convened to evaluate the efficacy and safety of particle beam therapy (PT) for pulmonary, liver and lymph node oligometastases (P-OM, L-OM and LN-OM, respectively) and to conduct a statistically comparative analysis of the local control (LC) rate and overall survival (OS) rate of PT versus those of X-ray stereotactic body radiotherapy (X-SBRT) and X-ray intensity-modulated radiotherapy (X-IMRT). They conducted [1] an analysis of the efficacy and safety of metastasis-directed therapy with PT for P-OM, L-OM and LN-OM using a Japanese nationwide multi-institutional cohort study data set; [2] a systematic review of X-ray high-precision radiotherapy (i.e. X-SBRT/X-IMRT) and PT for P-OM, L-OM and LN-OM; and [3] a statistical comparison between LC and OS of the cohort data set in PT and that of the extracted historical data set in X-SBRT/X-IMRT from the preceding systematic review. Safety was evaluated as the incidence of grade ≥ 3 adverse events, while statistical comparisons of LC and OS were conducted by estimating the incidence rate ratios (IRR) for local progression and mortality, respectively. This study demonstrated that PT provided durable LC (3-year LC rate: 72.8-83.2%) with acceptable OS (3-year OS rate: 38.5-68.1%) and risk of severe toxicity incidence of 0.8-3.5% in radical metastasis-directed therapy for P-OM, L-OM and LN-OM. Compared to LC with X-SBRT or X-IMRT, LC with PT was potentially superior for P-OM; superior for L-OM; and equivalent for LN-OM. In particular, this study demonstrated that PT may be a new treatment option for L-OM tumors measuring > 5 cm.

Effectiveness of CT-image guidance in proton therapy for liver cancer and the importance of daily dose monitoring for tumors and organs at risk.
Yoshikazu Maeda, Keiji Kobashi, Yoshitaka Sato, Hiroyasu Tamamura, Kazutaka Yamamoto, Keiichiro Matsushita, Makoto Sasaki, Hitoshi Tatebe, Tomoko Asahi, Sae Matsumoto, Shigeyuki Takamatsu, Koichi Miyazaki, Rintaro Fujimoto, Yusuke Uchinami, Norio Katoh, Hidefumi Aoyama
Medical physics, 50, 6, 3274, 3288, 2023年04月26日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: It is important to have precise image guidance throughout proton therapy in order to take advantage of the therapy's physical selectivity. PURPOSE: We evaluated the effectiveness of computed tomography (CT)-image guidance in proton therapy for patients with hepatocellular carcinoma (HCC) by assessing daily proton dose distributions. The importance of daily CT image-guided registration and daily proton dose monitoring for tumors and organs at risk (OARs) was investigated. METHODS: A retrospective analysis was conducted using 570 sets of daily CT (dCT) images throughout whole treatment fractions for 38 HCC patients who underwent passive scattering proton therapy with either a 66 cobalt gray equivalent (GyE)/10 fractions (n = 19) or 76 GyE/20 fractions (n = 19) protocol. The actual daily delivered dose distributions were estimated by forward calculation using the dCT sets, their corresponding treatment plans, and the recorded daily couch correction information. We then evaluated the daily changes of the dose indices D99% , V30GyE , and Dmax for the tumor volumes, non-tumorous liver, and other OARs, that is, stomach, esophagus, duodenum, colon, respectively. Contours were created for all dCT sets. We validated the efficacy of the dCT-based tumor registrations (hereafter, "tumor registration") by comparing them with the bone registration and diaphragm registration as a simulation of the treatment based on the positioning using the conventional kV X-ray imaging. The dose distributions and the indices of three registrations were obtained by simulation using the same dCT sets. RESULTS: In the 66 GyE/10 fractions, the daily D99% value in both the tumor and diaphragm registrations agreed with the planned value with 3%-6% (SD), and the V30GyE value for the liver agreed within ±3%; the indices in the bone registration showed greater deterioration. Nevertheless, tumor-dose deterioration occurred in all registration methods for two cases due to daily changes of body shape and respiratory condition. In the 76 GyE/20 fractions, in particular for such a treatment that the dose constraints for the OARs have to be cared in the original planning, the daily D99% in the tumor registration was superior to that in the other registration (p < 0.001), indicating the effectiveness of the tumor registration. The dose constraints, set in the plan as the maximum dose for OARs (i.e., duodenum, stomach, colon, and esophagus) were maintained for 16 patients including seven treated with re-planning. For three patients, the daily Dmax increased gradually or changed randomly, resulting in an inter-fractional averaged Dmax higher than the constraints. The dose distribution would have been improved if re-planning had been conducted. The results of these retrospective analyses indicate the importance of daily dose monitoring followed by adaptive re-planning when needed. CONCLUSIONS: The tumor registration in proton treatment for HCC was effective to maintain the daily dose to the tumor and the dose constraints of OARs, particularly in the treatment where the maintenance for the dose constraints needs to be considered throughout the treatment. Nevertheless daily proton dose monitoring with daily CT imaging is important for more reliable and safer treatment.

Multicenter retrospective study of Stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma
Yoshiko Doi, Yasushi Nagata, Yasuo Matsumoto, Kazushi Numata, Ryu Sasaki, Takashi Yamada, Hiroshi Igaki, Toshiyuki Imagumbai, Norio Katoh, Tadamasa Yoshitake, Takuya Shimizuguchi, Den Fujioka, Minoru Inoue, Yutaro Koide, Tomoki Kimura, Yoshinori Ito
Hepatology Research, Wiley, 2023年04月10日, ［査読有り］
研究論文（学術雑誌）

Evaluation of short-term gastrointestinal motion and its impact on dosimetric parameters in stereotactic body radiation therapy for pancreatic cancer
Yusuke Uchinami, Takahiro Kanehira, Yoshihiro Fujita, Naoki Miyamoto, Kohei Yokokawa, Fuki Koizumi, Motoyasu Shido, Shuhei Takahashi, Manami Otsuka, Koichi Yasuda, Hiroshi Taguchi, Keiji Nakazato, Keiji Kobashi, Norio Katoh, Hidefumi Aoyama
Clinical and Translational Radiation Oncology, 39, 100576, 100576, Elsevier BV, 2023年03月, ［査読有り］, ［責任著者］
研究論文（学術雑誌）

Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.
Hajime Higaki, Kentaro Nishioka, Manami Otsuka, Noboru Nishikawa, Motoyasu Shido, Hideki Minatogawa, Yukiko Nishikawa, Rikiya Takashina, Takayuki Hashimoto, Norio Katoh, Hiroshi Taguchi, Rumiko Kinoshita, Koichi Yasuda, Takashi Mori, Yusuke Uchinami, Fuki Koizumi, Yoshihiro Fujita, Shuhei Takahashi, Takahiro Hattori, Noriaki Nishiyama, Hidefumi Aoyama
Radiation oncology (London, England), 18, 1, 25, 25, 2023年02月07日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: The Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA) has not been validated for use with Japanese non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) and the factors impacting survival need to be assessed. METHODS: We retrospectively analyzed 294 NSCLC patients who were newly diagnosed with BM between 2013 and 2020 and had received radiotherapy for BM initially at the Hokkaido Cancer Center. We evaluated the effect on the prognosis of Lung-molGPA items, the expression of PD-L1 (classified as high, low, and no expression), and the treatment history. The main outcome was the survival measured from the day of the diagnosis of BM, and log-rank tests were performed to evaluate the results. RESULTS: The median overall survival (OS) times for adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, 2.5‒3.0, and 3.5‒4.0) were 5.5, 14.8, 28.3, and 39.0 months (p < 0.0001), respectively. The median survival times for non-adenocarcinoma by groups of GPA scores (0‒1.0, 1.5‒2.0, and 2.5‒3.0) were 3.2, 11.0, and 16.0 months (p = 0.0011), respectively. In adenocarcinoma patients with gene mutations, osimertinib significantly improved the outcome (median OS: 34.2 and 17.6 months with and without osimertinib, respectively (p = 0.0164)). There was no significant difference in the OS between patients who were initially treated with tyrosine-kinase inhibitor for BM and those who initially received radiotherapy (p = 0.5337). In patients tested for PD-L1 expression, the median survival times after the diagnosis of BM were 5.6, 22.5, and 9.3 months for the high-, low- and no-expression groups (p = 0.2198), respectively. Also, in patients with high PD-L1 expressions, those with ICI had survival (median OS, 8.6 months) than those without (median OS, 3.6 months). CONCLUSIONS: We confirmed that Lung-molGPA successfully classified Japanese NSCLC patients with BM by the prognosis. Osimertinib prolonged survival of EGFR-positive NSCLC patients with BM, and ICI was effective in patients with high PD-L1 expressions.

Study of hepatic toxicity in small liver tumors after photon or proton therapy based on factors predicting the benefits of proton.
Yusuke Uchinami, Norio Katoh, Daisuke Abo, Ryo Morita, Hiroshi Taguchi, Yoshihiro Fujita, Takahiro Kanehira, Ryusuke Suzuki, Naoki Miyamoto, Seishin Takao, Taeko Matsuura, Takuya Sho, Koji Ogawa, Tatsuya Orimo, Tatsuhiko Kakisaka, Keiji Kobashi, Hidefumi Aoyama
The British journal of radiology, 96, 1144, 20220720, 20220720, 2023年01月12日, ［査読有り］, ［責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, OBJECTIVES: In a previous study of hepatic toxicity, the following three factors were identified to predict the benefits of proton beam therapy (PBT) for hepatocellular carcinomas (HCC) with a maximum diameter of ≤5 cm and Child-pugh grade A (CP-A): number of tumors (one vs ≥2), the location of tumors (hepatic hilum or others), and the sum of the diameters of lesions. The aim of this study is to analyze the association between these three factors and hepatic toxicity. METHODS: We retrospectively reviewed patients of CP-A treated with PBT or photon stereotactic body radiotherapy (X-ray radiotherapy, XRT) for HCC ≤5 cm. For normal liver dose, the V5, V10, V20 (volumes receiving 5, 10, and 20 Gy at least), and the mean dose was evaluated. The albumin-bilirubin (ALBI) and CP score changes from the baseline were evaluated at 3 and 6 months after treatment. RESULTS: In 89 patients (XRT: 48, PBT: 41), those with two or three (2-3) predictive factors were higher normal liver doses than with zero or one (0-1) factor. In the PBT group, the ALBI score worsened more in patients with 2-3 factors than those with 0-1 factor, at 3 months (median 0.26 vs 0.02, p = 0.032) and at 6 months (median: 0.35 vs 0.10, p = 0.009). The ALBI score change in the XRT group and CP score change in either modality were not significantly different in the number of predictive factors. CONCLUSIONS: The predictive factor numbers predicted the ALBI score change in PBT but not in XRT. ADVANCES IN KNOWLEDGE: This study suggest that the number of predictive factors previously identified (0-1 vs 2-3) were significantly associated with dosimetric parameters of the normal liver in both modalities. In the proton group, the number of predictive factors was associated with a worsening ALBI score at 3 and 6 months, but these associations were not found in the photon SBRT group.

Income and Employment of Patients at the Start of and During Follow-up After Palliative Radiation Therapy for Bone Metastasis.
Hiroki Shirato, Hideyuki Harada, Yukako Iwasaki, Akifumi Notsu, Kazunari Yamada, Haruka Uezono, Yutaro Koide, Hitoshi Wada, Hikaru Kubota, Naoto Shikama, Takuya Yamazaki, Kei Ito, Joichi Heianna, Yukinori Okada, Ayako Tonari, Shigeo Takahashi, Takashi Kosugi, Yasuo Ejima, Norio Katoh, Kayo Yoshida, Takafumi Komiyama, Nobue Uchida, Misako Miwa, Miho Watanabe, Hisayasu Nagakura, Tetsuo Saito, Hiroko Ikeda, Isao Asakawa, Tateishi Seiichiro, Takeo Takahashi, Naoyuki Shigematsu
Advances in radiation oncology, 8, 4, 101205, 101205, 2023年, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: The aim of this study was to understand the income and employment status of patients at the start of and during follow-up after palliative radiation therapy for bone metastasis. METHODS AND MATERIALS: From December 2020 to March 2021, a prospective multi-institutional observational study was conducted to investigate income and employment of patients at the start of administration of radiation therapy for bone metastasis and at 2 and 6 months after treatment. Of 333 patients referred to radiation therapy for bone metastasis, 101 were not registered, mainly because of their poor general condition, and another 8 were excluded from the follow-up analysis owing to ineligibility. RESULTS: In 224 patients analyzed, 108 had retired for reasons unrelated to cancer, 43 had retired for reasons related to cancer, 31 were taking leave, and 2 had lost their jobs at the time of registration. The number of patients who were in the working group was 40 (30 with no change in income and 10 with decreased income) at registration, 35 at 2 months, and 24 at 6 months. Younger patients (P = 0), patients with better performance status (P = 0), patients who were ambulatory (P = .008), and patients with lower scores on a numerical rating scale of pain (P = 0) were significantly more likely to be in the working group at registration. There were 9 patients who experienced improvements in their working status or income at least once in the follow-up after radiation therapy. CONCLUSIONS: The majority of patients with bone metastasis were not working at the start of or after radiation therapy, but the number of patients who were working was not negligible. Radiation oncologists should be aware of the working status of patients and provide appropriate support for each patient. The benefit of radiation therapy to support patients continuing their work and returning to work should be investigated further in prospective studies.

Technical Note: Performance evaluation of volumetric imaging based on motion modeling by principal component analysis
Suzuka Asano, Keishi Oseki, Seishin Takao, Koichi Miyazaki, Kohei Yokokawa, Taeko Matsuura, Hiroshi Taguchi, Norio Katoh, Hidefumi Aoyama, Kikuo Umegaki, Naoki Miyamoto
Medical Physics, Wiley, 2022年12月03日, ［査読有り］
研究論文（学術雑誌）

Particle Beam Therapy for Intrahepatic and Extrahepatic Biliary Duct Carcinoma: A Multi-Institutional Retrospective Data Analysis.
Hideya Yamazaki, Takuya Kimoto, Motohisa Suzuki, Masao Murakami, Osamu Suzuki, Masaru Takagi, Norio Katoh, Takeshi Arimura, Takashi Ogino, Hiroyuki Ogino
Cancers, 14, 23, 2022年11月28日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, To examine the efficacy and toxicity of particle beam therapy (PT) for biliary duct carcinoma (BDC) and compare the outcomes between extrahepatic BDC (eBDC) and intrahepatic BDC (iBDC). We analyzed multi-institutional data from May 2009 to December 2019. The primary endpoint was overall survival (OS), and the secondary endpoints were local control (LC), progression-free survival (PFS) and toxicity. We included 150 patients with unresectable BDC treated with PT using a median prescribed dose of 70.2 GyRBE (range, 44-77 GyRBE) in 25 fractions (range, 10-38 fractions). With a median follow-up of 13.0 months, median survival time (MST) was 21 months, and 2-year OS was 44.8%. For eBDC and iBDC, the MSTs were 20 and 23 months, respectively. Two-year PFS and LC rates were 20.6% and 66.5%, respectively. Vascular invasion, prescribed dose and serum tumor marker level (carcinoembryonic antigen: CEA) were identified as poor prognostic factors for OS. A higher radiation dose EQD2 ≥ 67 Gy showed superior OS, with a hazard ratio of 0.341. The radiation dose of PT is an important predisposing factor for overall survival. The MST for patients with eBDC given a higher radiation dose was 25 months, compared to 15 months for those given the lower dose and 23 months for patients with iBDC (all iBDC given higher doses). iBDC and eBDC duct carcinomas showed equivalent outcomes with PT, especially when treated with a high radiation dose. In detailed analysis, baseline CEA level in iBDC, and radiation dose and GTV in eBDC were statistically significant predicators for OS. Acute and late toxicity grade ≥3 occurred in 2.2% and 2.7% of patients, respectively, including two late grade-5 toxicities. In conclusion, PT showed good efficacy for BDC, both eBDC and iBDC, with a low incidence of severe toxicity.

Detailed analysis of failure patterns using deformable image registration in hypopharyngeal cancer patients treated with sequential boost intensity-modulated radiotherapy.
Manami Otsuka, Koichi Yasuda, Yusuke Uchinami, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Ryusuke Suzuki, Naoki Miyamoto, Hideki Minatogawa, Yasuhiro Dekura, Takashi Mori, Kentaro Nishioka, Jun Taguchi, Yasushi Shimizu, Norio Katoh, Akihiro Homma, Hidefumi Aoyama
Journal of medical imaging and radiation oncology, 67, 1, 98, 110, 2022年11月14日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, INTRODUCTION: Sequential boost intensity-modulated radiotherapy (SQB-IMRT) uses two different planning CTs (pCTs) and treatment plans. SQB-IMRT is a form of adaptive radiotherapy that allows for responses to changes in the shape of the tumour and organs at risk (OAR). On the other hand, dose accumulation with the two plans can be difficult to evaluate. The purpose of this study was to analyse patterns of loco-regional failure using deformable image registration (DIR) in hypopharyngeal cancer patients treated with SQB-IMRT. METHODS: Between 2013 and 2019, 102 patients with hypopharyngeal cancer were treated with definitive SQB-IMRT at our institution. Dose accumulation with the 1st and 2nd plans was performed, and the dose to the loco-regional recurrent tumour volume was calculated using the DIR workflow. Failure was classified as follows: (i) in-field (≥95% of the recurrent tumour volume received 95% of the prescribed dose); (ii) marginal (20-95%); or (iii) out-of-field (<20%). RESULTS: After a median follow-up period of 25 months, loco-regional failure occurred in 34 patients. Dose-volume histogram analysis showed that all loco-regional failures occurred in the field within 95% of the prescribed dose, with no marginal or out-of-field recurrences observed. CONCLUSION: The dosimetric analysis using DIR showed that all loco-regional failures were within the high-dose region. More aggressive treatment may be required for gross tumours.

A study on predicting cases that would benefit from proton beam therapy in primary liver tumors of less than or equal to 5 cm based on the estimated incidence of hepatic toxicity
Yusuke Uchinami, Norio Katoh, Ryusuke Suzuki, Takahiro Kanehira, Masaya Tamura, Seishin Takao, Taeko Matsuura, Naoki Miyamoto, Yoshihiro Fujita, Fuki Koizumi, Hiroshi Taguchi, Koichi Yasuda, Kentaro Nishioka, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama
Clinical and Translational Radiation Oncology, 35, 70, 75, Elsevier BV, 2022年07月, ［査読有り］, ［責任著者］
英語, 研究論文（学術雑誌）, 32372005

Real-time CT image generation based on voxel-by-voxel modeling of internal deformation by utilizing the displacement of fiducial markers.
Risa Hayashi, Koichi Miyazaki, Seishin Takao, Kohei Yokokawa, Sodai Tanaka, Taeko Matsuura, Hiroshi Taguchi, Norio Katoh, Shinichi Shimizu, Kikuo Umegaki, Naoki Miyamoto
Medical physics, 48, 9, 5311, 5326, 2021年09月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: To show the feasibility of real-time CT image generation technique utilizing internal fiducial markers that facilitate the evaluation of internal deformation. METHODS: In the proposed method, a linear regression model that can derive internal deformation from the displacement of fiducial markers is built for each voxel in the training process before the treatment session. Marker displacement and internal deformation are derived from the four-dimensional computed tomography (4DCT) dataset. In the treatment session, the three-dimensional deformation vector field is derived according to the marker displacement, which is monitored by the real-time imaging system. The whole CT image can be synthesized by deforming the reference CT image with a deformation vector field in real-time. To show the feasibility of the technique, image synthesis accuracy and tumor localization accuracy were evaluated using the dataset generated by extended NURBS-Based Cardiac-Torso (XCAT) phantom and clinical 4DCT datasets from six patients, containing 10 CT datasets each. In the validation with XCAT phantom, motion range of the tumor in training data and validation data were about 10 and 15 mm, respectively, so as to simulate motion variation between 4DCT acquisition and treatment session. In the validation with patient 4DCT dataset, eight CT datasets from the 4DCT dataset were used in the training process. Two excluded inhale CT datasets can be regarded as the datasets with large deformations more than training dataset. CT images were generated for each respiratory phase using the corresponding marker displacement. Root mean squared error (RMSE), normalized RMSE (NRMSE), and structural similarity index measure (SSIM) between the original CT images and the synthesized CT images were evaluated as the quantitative indices of the accuracy of image synthesis. The accuracy of tumor localization was also evaluated. RESULTS: In the validation with XCAT phantom, the mean NRMSE, SSIM, and three-dimensional tumor localization error were 7.5 ± 1.1%, 0.95 ± 0.02, and 0.4 ± 0.3 mm, respectively. In the validation with patient 4DCT dataset, the mean RMSE, NRMSE, SSIM, and three-dimensional tumor localization error in six patients were 73.7 ± 19.6 HU, 9.2 ± 2.6%, 0.88 ± 0.04, and 0.8 ± 0.6 mm, respectively. These results suggest that the accuracy of the proposed technique is adequate when the respiratory motion is within the range of the training dataset. In the evaluation with a marker displacement larger than that of the training dataset, the mean RMSE, NRMSE, and tumor localization error were about 100 HU, 13%, and <2.0 mm, respectively, except for one case having large motion variation. The performance of the proposed method was similar to those of previous studies. Processing time to generate the volumetric image was <100 ms. CONCLUSION: We have shown the feasibility of the real-time CT image generation technique for volumetric imaging.

Validation of dose distribution for liver tumors treated with real-time-image gated spot-scanning proton therapy by log data based dose reconstruction.
Takahiro Yamada, Seishin Takao, Hidenori Koyano, Hideaki Nihongi, Yusuke Fujii, Shusuke Hirayama, Naoki Miyamoto, Taeko Matsuura, Kikuo Umegaki, Norio Katoh, Isao Yokota, Hiroki Shirato, Shinichi Shimizu
Journal of radiation research, 62, 4, 626, 633, 2021年07月10日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, In spot scanning proton therapy (SSPT), the spot position relative to the target may fluctuate through tumor motion even when gating the radiation by utilizing a fiducial marker. We have established a procedure that evaluates the delivered dose distribution by utilizing log data on tumor motion and spot information. The purpose of this study is to show the reliability of the dose distributions for liver tumors treated with real-time-image gated SSPT (RGPT). In the evaluation procedure, the delivered spot information and the marker position are synchronized on the basis of log data on the timing of the spot irradiation and fluoroscopic X-ray irradiation. Then a treatment planning system reconstructs the delivered dose distribution. Dose distributions accumulated for all fractions were reconstructed for eight liver cases. The log data were acquired in all 168 fractions for all eight cases. The evaluation was performed for the values of maximum dose, minimum dose, D99, and D5-D95 for the clinical target volumes (CTVs) and mean liver dose (MLD) scaled by the prescribed dose. These dosimetric parameters were statistically compared between the planned dose distribution and the reconstructed dose distribution. The mean difference of the maximum dose was 1.3% (95% confidence interval [CI]: 0.6%-2.1%). Regarding the minimum dose, the mean difference was 0.1% (95% CI: -0.5%-0.7%). The mean differences of D99, D5-D95 and MLD were below 1%. The reliability of dose distributions for liver tumors treated with RGPT-SSPT was shown by the evaluation of the accumulated dose distributions.

Treatment Outcomes of Stereotactic Body Radiation Therapy Using Real-time Tumor-tracking Radiotherapy System for Hepatocellular Carcinomas.
Yusuke Uchinami, Norio Katoh, Daisuke Abo, Hiroshi Taguchi, Koichi Yasuda, Kentaro Nishioka, Takeshi Soyama, Ryo Morita, Naoki Miyamoto, Ryusuke Suzuki, Takuya Sho, Masato Nakai, Koji Ogawa, Tatsuhiko Kakisaka, Tatsuya Orimo, Toshiya Kamiyama, Shinichi Shimizu, Hidefumi Aoyama
Hepatology research : the official journal of the Japan Society of Hepatology, 51, 8, 870, 879, 2021年04月24日, ［査読有り］, ［責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, AIM: To report the outcomes of stereotactic body radiotherapy (SBRT) using a real-time tumor-tracking radiotherapy (RTRT) system for hepatocellular carcinoma (HCC) patients. METHODS: From January 2005 to July 2018, 63 patients with 74 lesions with a maximum diameter ≤52 mm were treated by SBRT using the RTRT system. No patient with a Child-Pugh Score ≥9 was included and 85.6% had a score of 5 or 6. Using the biological effective dose (BED) with α/β ratio of 10 (BED10 ), the median dose in BED10 at the reference point was 76.8 Gy (range: 60-122.5). Overall survival (OS) and local control (LC) rates were assessed using the Kaplan-Meier method. RESULTS: With a median follow up period of 24.6 months (range: 0.9-118.4), the 1-year and 2-year OS rates were 86.8% (95% confidence interval [95% CI]; 75.8-93.3) and 71.1% (57.8-81.6), respectively. The 2-year OS was 89.6% in patients with the baseline modified albumin-bilirubin (mALBI) grade =1 and 61.7% in patients with grade ≥2a. In the multivariate analysis, the mALBI grade (=1 vs ≥2a) was a significant factor for OS (p=0.028, 95%CI: 1.11-6.18). The 1-year and 2-year LC rates were 100% (100-100) and 92.0% (77.5-97.5). The LC rates were significantly higher in the BED10 ≥100 Gy group than in the BED10 <100 Gy (2-year 100% vs 86.5%, p=0.049) at the reference point. CONCLUSION: This retrospective study of SBRT using RTRT for HCC showed favorable outcomes with lower incidence of toxicities, especially in patients treated with BED10 ≥100 Gy to the reference point. This article is protected by copyright. All rights reserved., 32372005

Assessment of the confidence interval in the multivariable normal tissue complication probability model for predicting radiation-induced liver disease in primary liver cancer.
Anussara Prayongrat, Natchalee Srimaneekarn, Sira Sriswasdi, Yoichi M Ito, Norio Katoh, Masaya Tamura, Yasuhiro Dekura, Chie Toramatsu, Chonlakiet Khorprasert, Napapat Amornwichet, Petch Alisanant, Yuichi Hirata, Anthony Hayter, Hiroki Shirato, Shinichi Shimizu, Keiji Kobashi
Journal of radiation research, 62, 3, 483, 493, 2021年04月24日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, We developed a confidence interval-(CI) assessing model in multivariable normal tissue complication probability (NTCP) modeling for predicting radiation-induced liver disease (RILD) in primary liver cancer patients using clinical and dosimetric data. Both the mean NTCP and difference in the mean NTCP (ΔNTCP) between two treatment plans of different radiotherapy modalities were further evaluated and their CIs were assessed. Clinical data were retrospectively reviewed in 322 patients with hepatocellular carcinoma (n = 215) and intrahepatic cholangiocarcinoma (n = 107) treated with photon therapy. Dose-volume histograms of normal liver were reduced to mean liver dose (MLD) based on the fraction size-adjusted equivalent uniform dose. The most predictive variables were used to build the model based on multivariable logistic regression analysis with bootstrapping. Internal validation was performed using the cross-validation leave-one-out method. Both the mean NTCP and the mean ΔNTCP with 95% CIs were calculated from computationally generated multivariate random sets of NTCP model parameters using variance-covariance matrix information. RILD occurred in 108/322 patients (33.5%). The NTCP model with three clinical and one dosimetric parameter (tumor type, Child-Pugh class, hepatitis infection status and MLD) was most predictive, with an area under the receiver operative characteristics curve (AUC) of 0.79 (95% CI 0.74-0.84). In eight clinical subgroups based on the three clinical parameters, both the mean NTCP and the mean ΔNTCP with 95% CIs were able to be estimated computationally. The multivariable NTCP model with the assessment of 95% CIs has potential to improve the reliability of the NTCP model-based approach to select the appropriate radiotherapy modality for each patient.

Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study.
Tomoki Kimura, Atsuya Takeda, Naoko Sanuki, Keisuke Ariyoshi, Takuhiro Yamaguchi, Toshiyuki Imagumbai, Norio Katoh, Takahisa Eriguchi, Yohei Oku, Shuichi Ozawa, Yuichiro Tsurugai, Masaki Kokubo, Shinichi Shimizu, Satoshi Ishikura
Hepatology research : the official journal of the Japan Society of Hepatology, 51, 4, 461, 471, 2021年04月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, AIM: To prospectively evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for patients with previously untreated solitary primary hepatocellular carcinoma (HCC). METHODS: The main eligibility criteria included the following: (1) primary solitary HCC; (2) no prior treatment for HCC; (3) Child-Turcotte-Pugh score of seven or less; and (4) unsuitability for or refusal of surgery and radiofrequency ablation (RFA). The prescribed dose of SBRT was 40 Gy in five fractions. The primary endpoint was 3-year overall survival (OS); the secondary endpoints included local progression-free survival (LPFS), local control (LC), and adverse events. The accrual target was 60 patients, expecting a 3-year OS of 70% with a 50% threshold. RESULTS: Between 2014 and 2018, 36 patients were enrolled; enrollment was closed early because of slow accrual. The median tumor size was 2.3 cm. The median follow-up at the time of evaluation was 20.8 months. The 3-year OS was 78% (95% confidence interval [CI]: 53%-90%). The 3-year LPFS and LC proportion were 73% (95% CI: 48%-87%) and 90% (95% CI: 65%-97%), respectively. Grade 3 or higher SBRT-related toxicities were observed in four patients (11%), and grade five toxicities were not observed. CONCLUSIONS: This study showed acceptably low incidence of SBRT-related toxicities. LC and OS after SBRT were comparable for previously untreated solitary HCC for patients unfit for resection and RFA. Although a definitive conclusion cannot be drawn by this study, the promising results indicate that SBRT may be an alternative option in the management of early HCC.

Analysis of acute-phase toxicities of intensity-modulated proton therapy using a model-based approach in pharyngeal cancer patients.
Koichi Yasuda, Hideki Minatogawa, Yasuhiro Dekura, Seishin Takao, Masaya Tamura, Nayuta Tsushima, Takayoshi Suzuki, Satoshi Kano, Takatsugu Mizumachi, Takashi Mori, Kentaro Nishioka, Motoyasu Shido, Norio Katoh, Hiroshi Taguchi, Noriyuki Fujima, Rikiya Onimaru, Isao Yokota, Keiji Kobashi, Shinichi Shimizu, Akihiro Homma, Hiroki Shirato, Hidefumi Aoyama
Journal of radiation research, 62, 2, 329, 337, 2021年03月10日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Pharyngeal cancer patients treated with intensity-modulated proton therapy (IMPT) using a model-based approach were retrospectively reviewed, and acute toxicities were analyzed. From June 2016 to March 2019, 15 pharyngeal (7 naso-, 5 oro- and 3 hypo-pharyngeal) cancer patients received IMPT with robust optimization. Simulation plans for IMPT and intensity-modulated X-ray therapy (IMXT) were generated before treatment. We also reviewed 127 pharyngeal cancer patients with IMXT in the same treatment period. In the simulation planning comparison, all of the normal-tissue complication probability values for dysphagia, dysgeusia, tube-feeding dependence and xerostomia were lower for IMPT than for IMXT in the 15 patients. After completing IMPT, 13 patients completed the evaluation, and 12 of these patients had a complete response. The proportions of patients who experienced grade 2 or worse acute toxicities in the IMPT and IMXT cohorts were 21.4 and 56.5% for dysphagia (P < 0.05), 46.7 and 76.3% for dysgeusia (P < 0.05), 73.3 and 62.8% for xerostomia (P = 0.43), 73.3 and 90.6% for mucositis (P = 0.08) and 66.7 and 76.4% for dermatitis (P = 0.42), respectively. Multivariate analysis revealed that IMPT was independently associated with a lower rate of grade 2 or worse dysphagia and dysgeusia. After propensity score matching, 12 pairs of IMPT and IMXT patients were selected. Dysphagia was also statistically lower in IMPT than in IMXT (P < 0.05). IMPT using a model-based approach may have clinical benefits for acute dysphagia.

Are simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy?
Kentaro Nishioka, Kento Gotoh, Takayuki Hashimoto, Takashige Abe, Takahiro Osawa, Ryuji Matsumoto, Isao Yokota, Norio Katoh, Rumiko Kinoshita, Koichi Yasuda, Toshiaki Yakabe, Takaaki Yoshimura, Seishin Takao, Nobuo Shinohara, Hidefumi Aoyama, Shinichi Shimizu, Hiroki Shirato
BJR|Open, 3, 1, British Institute of Radiology, 2021年01月, ［査読有り］
研究論文（学術雑誌）, The purpose of this study is to investigate whether verbal instructions are sufficient for bladder volume (BV) control not to deteriorate prostate position reproducibility in image-guided spot scanning proton therapy (SSPT) for localized prostate cancer.

A total of 268 treatment sessions in 12 consecutive prostate cancer patients who were treated with image-guided SSPT with fiducial markers were retrospectively analyzed. In addition to strict rectal volume control procedures, simple verbal instructions to void urine one hour before the treatment were used here. The BV was measured by a Bladder Scan just before the treatment, and the prostate motion was measured by intraprostatic fiducial markers and two sets of X-ray fluoroscopy images. The correlation between the BV change and prostate motion was assessed by linear mixed-effects models and systematic and random errors according to the reproducibility of the BV.

The mean absolute BV change during treatment was from −98.7 to 86.3 ml (median 7.1 ml). The mean absolute prostate motion of the patients in the left-right direction was −1.46 to 1.85 mm; in the cranial-caudal direction it was −6.10 to 3.65 mm, and in the anteroposterior direction −1.90 to 5.23 mm. There was no significant relationship between the BV change and prostate motion during SSPT. The early and late genitourinary and gastrointestinal toxicity was minimal with a minimum follow up of 4.57 years.

Simple verbal instructions about urination was suggested to be sufficient to control the BV not to impact on the prostate motion and clinical outcomes in image-guided SSPT. Careful attention to BV change is still needed when the seminal vesicle is to be treated.

Our data demonstrated that there was no apparent relationship between BV changes and prostate position reproducibility and simple verbal instruction about urination could be sufficient for image-guided SSPT.

Quantitative analysis of treatments using real-time image gated spot-scanning with synchrotron-based proton beam therapy system log data.
Takaaki Yoshimura, Shinichi Shimizu, Takayuki Hashimoto, Kentaro Nishioka, Norio Katoh, Hiroshi Taguchi, Koichi Yasuda, Taeko Matsuura, Seishin Takao, Masaya Tamura, Sodai Tanaka, Yoichi M Ito, Yuto Matsuo, Hiroshi Tamura, Kenji Horita, Kikuo Umegaki, Hiroki Shirato
Journal of applied clinical medical physics, 21, 12, 10, 19, 2020年12月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, A synchrotron-based real-time image gated spot-scanning proton beam therapy (RGPT) system with inserted fiducial markers can irradiate a moving tumor with high accuracy. As gated treatments increase the beam delivery time, this study aimed to investigate the frequency of intra-field adjustments corresponding to the baseline shift or drift and the beam delivery efficiency of a synchrotron-based RGPT system. Data from 118 patients corresponding to 127 treatment plans and 2810 sessions between October 2016 and March 2019 were collected. We quantitatively analyzed the proton beam delivery time, the difference between the ideal beam delivery time based on a simulated synchrotron magnetic excitation pattern and the actual treatment beam delivery time, frequency corresponding to the baseline shift or drift, and the gating efficiency of the synchrotron-based RGPT system according to the proton beam delivery machine log data. The mean actual beam delivery time was 7.1 min, and the simulated beam delivery time in an ideal environment with the same treatment plan was 2.9 min. The average difference between the actual and simulated beam delivery time per session was 4.3 min. The average frequency of intra-field adjustments corresponding to baseline shift or drift and beam delivery efficiency were 21.7% and 61.8%, respectively. Based on our clinical experience with a synchrotron-based RGPT system, we determined the frequency corresponding to baseline shift or drift and the beam delivery efficiency using the beam delivery machine log data. To maintain treatment accuracy within ± 2.0 mm, intra-field adjustments corresponding to baseline shift or drift were required in approximately 20% of cases. Further improvements in beam delivery efficiency may be realized by shortening the beam delivery time.

Analysis of treatment process time for real-time-image gated-spot-scanning proton-beam therapy (RGPT) system.
Takaaki Yoshimura, Shinichi Shimizu, Takayuki Hashimoto, Kentaro Nishioka, Norio Katoh, Tetsuya Inoue, Hiroshi Taguchi, Koichi Yasuda, Taeko Matsuura, Seishin Takao, Masaya Tamura, Yoichi M Ito, Yuto Matsuo, Hiroshi Tamura, Kenji Horita, Kikuo Umegaki, Hiroki Shirato
Journal of applied clinical medical physics, 21, 2, 38, 49, 2020年02月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, We developed a synchrotron-based real-time-image gated-spot-scanning proton-beam therapy (RGPT) system and utilized it to clinically operate on moving tumors in the liver, pancreas, lung, and prostate. When the spot-scanning technique is linked to gating, the beam delivery time with gating can increase, compared to that without gating. We aim to clarify whether the total treatment process can be performed within approximately 30 min (the general time per session in several proton therapy facilities), even for gated-spot-scanning proton-beam delivery with implanted fiducial markers. Data from 152 patients, corresponding to 201 treatment plans and 3577 sessions executed from October 2016 to June 2018, were included in this study. To estimate the treatment process time, we utilized data from proton beam delivery logs during the treatment for each patient. We retrieved data, such as the disease site, total target volume, field size at the isocenter, and the number of layers and spots for each field, from the treatment plans. We quantitatively analyzed the treatment process, which includes the patient load (or setup), bone matching, marker matching, beam delivery, patient unload, and equipment setup, using the data obtained from the log data. Among all the cases, 90 patients used the RGPT system (liver: n = 34; pancreas: n = 5; lung: n = 4; and prostate: n = 47). The mean and standard deviation (SD) of the total treatment process time for the RGPT system was 30.3 ± 7.4 min, while it was 25.9 ± 7.5 min for those without gating treatment, excluding craniospinal irradiation (CSI; head and neck: n = 16, pediatric: n = 31, others: n = 15); for CSI (n = 11) with two or three isocenters, the process time was 59.9 ± 13.9 min. Our results demonstrate that spot-scanning proton therapy with a gating function can be achieved in approximately 30-min time slots.

Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy.
Shiro Watanabe, Tetsuya Inoue, Shozo Okamoto, Keiichi Magota, Ayumi Takayanagi, Jun Sakakibara-Konishi, Norio Katoh, Kenji Hirata, Osamu Manabe, Takuya Toyonaga, Yuji Kuge, Hiroki Shirato, Nagara Tamaki, Tohru Shiga
EJNMMI research, 9, 1, 104, 104, 2019年12月04日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: We investigated the prognostic predictive value of the combination of fluorodeoxyglucose (FDG)- and fluoromisonidazole (FMISO)-PET in patients with non-small cell lung carcinoma (NSCLC) treated with stereotactic body radiation therapy (SBRT). PATIENTS AND METHODS: We prospectively examined patients with pathologically proven NSCLC; all underwent FDG and FMISO PET/CT scans before SBRT. PET images were acquired using a whole-body time-of-flight PET-CT scanner with respiratory gating. We classified them into recurrent and non-recurrent groups based on their clinical follow-ups and compared the groups' tumor diameters and PET parameters (i.e., maximum of the standardized uptake value (SUVmax), metabolic tumor volume, tumor-to-muscle ratio, and tumor-to-blood ratio). We performed univariate analysis to evaluate the impact of the PET variables on the patients' progression-free survival (PFS). We divided the patients by thresholds of FDG SUVmax and FMISO SUVmax obtained from receiver operating characteristic analysis for assessment of recurrence rate and PFS. RESULTS: Thirty-two NSCLC patients (19 male and 13 females; median age, 83 years) were enrolled. All received SBRT. At the study endpoint, 23 patients (71.9%) were non-recurrent and nine patients (28.1%) had recurrent disease. Significant between-group differences were observed in tumor diameter and all the PET parameters, demonstrating that those were significant predictors of the recurrence in all patients. In the 22 patients with tumors > 2 cm, tumor diameter and FDG SUVmax were not significant predictors. Thirty-two patients were divided into three patterns from the thresholds of FDG SUVmax (6.81) and FMISO SUVmax (1.89); A, low FDG and low FMISO (n = 14); B, high FDG and low FMISO (n = 8); C, high FDG and high FMISO (n = 10). No pattern A patient experienced tumor recurrence, whereas two pattern B patients (25%) and seven pattern C patients (70%) exhibited recurrence. A Kaplan-Meier analysis of all patients revealed a significant difference in PFS between patterns A and B (p = 0.013) and between patterns A and C (p < 0.001). In the tumors > 2 cm patients, significant differences in PFS were demonstrated between pattern A and C patients (p = 0.002). CONCLUSION: The combination of FDG- and FMISO-PET can identify patients with a baseline risk of recurrence and indicate whether additional therapy might be performed to improve survival.

Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T, Nakamura T, Kimura Y, Yoshida M, Someya M, Kawakami H, Sakuhara Y, Katoh N, Takahashi K, Ambo Y, Miura K, Motoya M, Tanaka E, Murakawa K, Yamabuki T, Yamazaki H, Katanuma A, Hirano S, Hokkaido Pancreatic, Study Group
International journal of radiation oncology, biology, physics, 105, 3, 606, 617, 2019年11月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: Preoperative treatment is recommended for borderline resectable pancreatic ductal adenocarcinoma. However, the standard treatment has not yet been determined. We conducted a multicenter phase 2 study to investigate the efficacy of neoadjuvant treatment of sequential chemoradiation followed by chemotherapy. METHODS AND MATERIALS: All enrolled patients were treated by preoperative chemoradiation (a total dose of 50.4 Gy in 28 fractions and orally administered S-1 at 80 mg/m2 on the day of irradiation) followed by chemotherapy (administration of gemcitabine at 1000 mg/m2/dose on days 1, 8, and 15 in 3 cycles of 4 weeks) and attempted curative resection. The primary outcome was an R0 resection rate among patients who completed preoperative treatment and pancreatectomy. The threshold of the R0 resection rate was defined as 74% based on a previous study of up-front surgery. RESULTS: Forty-five patients were included. Twenty-one patients could not undergo pancreatectomy because of progressive diseases (n = 14), adverse events (n = 5), or consent withdrawal (n = 2), and 4 patients underwent additional resection after dropping out. The resection rates were 53.3% and 62.2% in the per-protocol set (PPS) and full analysis set (FAS) populations, respectively. The R0 resection rates were 95.8% (95% confidence interval, 78.9%-99.9%) and 96.4% (81.7%-99.9%) in the PPS and FAS populations, respectively. The median overall survival and progression-free survival of all the included patients were 17.3 and 10.5 months, respectively. The median survival time of the patients with pancreatectomy was significantly longer than that of the patients without pancreatectomy in the PPS (27.9 vs 12.3 months; P = .001) and FAS populations (32.2 vs 11.8 months; P < .001). CONCLUSIONS: This study revealed that a long duration of preoperative treatment of sequential chemoradiation followed by systemic chemotherapy provides a high rate of R0 resection and sufficient survival time in patients undergoing pancreatectomy.

Percutaneous insertion of hepatic fiducial true-spherical markers for real-time adaptive radiotherapy.
Ryo Morita, Daisuke Abo, Yusuke Sakuhara, Takeshi Soyama, Norio Katoh, Naoki Miyamoto, Yuusuke Uchinami, Shinichi Shimizu, Hiroki Shirato, Kohsuke Kudo
Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy, 29, 6, 1, 10, 2019年09月13日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Purpose: This study evaluated the success rate and complications of percutaneous implantation of hepatic fiducial true-spherical gold markers for real-time adaptive radiotherapy (RAR), which constitutes real-time image-guided radiotherapy with gating. Material and methods: We retrospectively evaluated 100 patients who underwent 116 percutaneous intrahepatic implantations of 2-mm-diameter, spherical, gold fiducial markers before RAR from 1999 to 2016, with Seldinger's method. We defined technical success as marker placement at the intended liver parenchyma, without mispositioning, and clinical success as successful tracking of the gold marker and completion of planned RAR. Complications related to marker placement were assessed. Results: The technical success rate for true-spherical gold marker implantation was 92.2% (107/116). Nine of 116 markers migrated (intra-procedurally in seven patients, delayed in two patients). Migration out of the liver (n = 4) or intrahepatic vessels (n = 5) occurred without complications; these markers were not retrieved. The clinical success rate was 100.0% (115/115). Abdominal pain occurred in 16 patients, fever and hemorrhage in seven patients each, and pneumothorax and nausea in one patient each. No major complications were encountered. Conclusions: Percutaneous transhepatic implantation of true-spherical gold markers for RAR is feasible and can be conducted with a high success rate and low complication rate.

Quantitative evaluation of image recognition performance of fiducial markers in real-time tumor-tracking radiation therapy.
Miyamoto N, Maeda K, Abo D, Morita R, Takao S, Matsuura T, Katoh N, Umegaki K, Shimizu S, Shirato H
Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB), 65, 33, 39, 2019年09月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: To quantitatively evaluate and compare the image recognition performance of multiple fiducial markers available in real-time tumor-tracking radiation therapy (RTRT). METHODS: Clinically available markers including sphere shape, coil shape, cylinder shape, line shape, and ball shape (folded line shape) were evaluated in liver and lung models of RTRT. Maximum thickness of the polymethyl metacrylate (PMMA) phantom that could automatically recognize the marker was determined by template-pattern matching. Image registration accuracy of the fiducial marker was determined using liver RTRT model. Lung RTRT was mimicked with an anthropomorphic chest phantom and a one-dimensional motion stage in order to simulate marker motion in heterogeneous fluoroscopic images. The success or failure of marker tracking and image registration accuracy for the lung model were evaluated in the same manner as that for the liver model. RESULTS: All fiducial markers except for line shape and coil shape of thinner diameter were recognized by the PMMA phantom, which is assumed to have the typical thickness of an abdomen, with two-dimensional image registration accuracy of <2 pixels. Three-dimensional calculation error with the use of real-time stereoscopic fluoroscopy in RTRT was thought to be within 1 mm. In the evaluation using the lung model, the fiducial markers were recognized stably with sufficient accuracy for clinical application. The same was true for the evaluation using the liver model. CONCLUSIONS: The image recognition performance of fiducial markers was quantified and compared. The results presented here may be useful for the selection of fiducial markers.

Impact of organ motion on volumetric and dosimetric parameters in stomach lymphomas treated with intensity-modulated radiotherapy.
Uchinami Y, Suzuki R, Katoh N, Taguchi H, Yasuda K, Miyamoto N, Ito YM, Shimizu S, Shirato H
Journal of applied clinical medical physics, 20, 8, 78, 86, 2019年08月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: Interplay effects may influence dose distributions to a moving target when using dynamic delivery techniques such as intensity-modulated radiotherapy (IMRT). The aim of this study was to evaluate the impact of organ motion on volumetric and dosimetric parameters in stomach lymphomas treated with IMRT. METHODS: Ten patients who had been treated with IMRT for stomach lymphomas were enrolled. The clinical target volume (CTV) was contoured as the whole stomach. Considering interfractional uncertainty, the internal target volume (ITV) margin was uniformly 1.5 cm to the CTV and then modified based on the 4DCT images in case of the large respiratory motion. The planning target volume (PTV) was created by adding 5 mm to the ITV. The impact of organ motion on the volumetric and dosimetric parameters was evaluated retrospectively (4D simulation). The organ motion was reproduced by shifting the isocenter on the radiation treatment planning system. Several simulation plans were created to test the influence of the beam-on timing in the respiration cycle on the dose distribution. The homogeneity index (HI), volume percentage of stomach covered by the prescribed dose (Vp ), and D99 of the CTV were evaluated. RESULTS: The organ motion was the largest in the superior-inferior direction (10.1 ± 4.5 mm [average ± SD]). Stomach volume in each respiratory phase compared to the mean volume varied approximately within a ± 5% range in most of the patients. The PTV margin was sufficiently large to cover the CTV during the IMRT. There was a significant reduction in Vp and D99 but not in HI in the 4D simulation in free-breathing and multiple fractions compared to the clinically-used plan (P < 0.05) suggesting that interplay effects deteriorate the dose distribution. The absolute difference of D99 was less than 1% of the prescribed dose. CONCLUSIONS: There were significant interplay effects affecting the dose distribution in stomach IMRT. The magnitude of the dose reduction was small when patients were treated on free-breathing and multiple fractions.

The normal tissue complication probability model-based approach considering uncertainties for the selective use of radiation modality in primary liver cancer patients.
Prayongrat A, Kobashi K, Ito YM, Katoh N, Tamura M, Dekura Y, Toramatsu C, Khorprasert C, Amornwichet N, Alisanant P, Shirato H, Shimizu S
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 135, 100, 106, 2019年06月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: To predict the probability of radiation-induced liver toxicity (RILT) and implement the normal tissue complication probability (NTCP) model-based approach considering confidence intervals (CIs) to select patients for new treatment techniques, such as proton beam therapy, based on a certain NTCP reduction (ΔNTCP) threshold for primary liver cancer patients. METHODS AND MATERIALS: Common Toxicity Criteria for Adverse Events (CTCAE) grade ≥2 RILT was scored. The Lyman NTCP models predicting the probability of CTCAE grade ≥2 RILT as a function of the fraction-size adjusted mean liver dose (MLD), using reference fraction size = 2 Gy/fraction and α/β ratio = 2 Gy, were fitted using the maximum likelihood method. At certain combinations of MLDs, ΔNTCP with a CI was evaluated by the delta method. RESULTS: Of the 239 patients, the incidence of CTCAE grade ≥2 RILT was 55% (46% in the Child-Pugh (CP)-A vs. 81% in the CP-B/C, p < 0.001). Among 180 CP-A patients, 40% who had viral hepatitis infections experienced toxicity vs. 32% in the nonhepatitis subgroup. The MLD was 18 Gy in the toxicity group vs. 16.1 Gy in the nontoxicity group (p = 0.002). The estimated NTCP model parameters specific to the patient subgroups and the ΔNTCP with CI assuming a particular CP classification and viral hepatitis infection status were considerably different which possible changed treatment decision. CONCLUSIONS: Patients with CP-A and viral hepatitis infection or CP-B/C cirrhosis had greater susceptibility to CTCAE grade ≥2 RILT. The estimated NTCP and ΔNTCP for individual patients along with a consideration of uncertainties improve the reliability of the NTCP model-based approach.

Real-Time Tumor-Tracking Radiotherapy and General Stereotactic Body Radiotherapy for Adrenal Metastasis in Patients With Oligometastasis.
Katoh N, Onishi H, Uchinami Y, Inoue T, Kuriyama K, Nishioka K, Shimizu S, Komiyama T, Miyamoto N, Shirato H
Technology in cancer research & treatment, 17, 1533033818809983, 1533033818809983, 2018年10月, ［査読有り］, ［筆頭著者, 責任著者］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Precise local radiotherapy for adrenal metastasis can prolong the useful life of patients with oligometastasis. The aim of this retrospective, 2-center study was to establish the safety and effectiveness of real-time tumor-tracking radiotherapy and general stereotactic body radiotherapy in treating patients with adrenal metastatic tumors. MATERIALS AND METHODS: Thirteen lesions in 12 patients were treated with real-time tumor-tracking radiotherapy (48 Gy in 8 fractions over 2 weeks) and 8 lesions in 8 patients were treated with general stereotactic body radiotherapy (40-50 Gy in 5-8 fractions over 2 weeks or 60-70 Gy in 10 fractions over 2 weeks). Overall survival rates, local control rates, and adverse effects were analyzed. RESULTS: The actuarial overall survival rates for all patients at 1 and 2 years were 78.5% and 45.8%, respectively, with a median follow-up of 17.5 months, and the actuarial local control rates for all tumors at 1 and 2 years were 91.7% and 53.0%, respectively, with a median follow-up of 9 months. A complete local tumor response was obtained in 3 tumors treated by real-time tumor-tracking radiotherapy (lung adenocarcinomas with diameters of 35, 40, and 60 mm). There was a statistically significant difference in the local control between the groups treated by real-time tumor-tracking radiotherapy (100% at 1 year) and general stereotactic body radiotherapy (50% at 1 year; P < .001). No late adverse reactions at Grade 2 or higher were reported for either treatment group. CONCLUSIONS: This study showed that although both treatments are safe and effective, the real-time tumor-tracking radiotherapy is more effective than general stereotactic body radiotherapy in local control for adrenal metastasis.

R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy.
Kamachi H, Tsuruga Y, Orimo T, Wakayama K, Shimada S, Nagatsu A, Yokoo H, Kamiyama T, Katoh N, Taketomi A
In vivo (Athens, Greece), 32, 5, 1183, 1191, 2018年09月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Local antitumor efficacy and the outcome of neoadjuvant chemoradiotherapy (NACRT) with low-dose gemcitabine and wide irradiation area for borderline resectable and unresectable pancreatic cancer were evaluated. PATIENTS AND METHODS: Thirty-four cases of borderline resectable and unresectable pancreatic cancer were recruited. Three-dimensional conformal radiotherapy to the pancreatic bed and the region scheduled for lymph node dissection was performed to a total dose of 50.4 Gy28 fractions with gemcitabine at a dose of 150 mg/m2 weekly. Clinical and pathological results were examined. RESULTS: Twenty-seven patients (79.4%) completed the protocol. Grade 3/4 leucopenia (n=10), and grade 3 anorexia (n=1) occurred. Seven cases were excluded (two refused treatment; five had progressive disease), 20 underwent laparotomy, and 16 resected (47.1%) cases achieved R0 resection. Median survival time, and 3-year and 5-year survival rates were 39.0 months, and 56.3% and 28.1% in resected cases, respectively. CONCLUSION: NACRT with low-dose gemcitabine and wide irradiation area achieved 100% R0 resection and acceptable prognosis.

Stereotactic body radiotherapy to treat small lung lesions clinically diagnosed as primary lung cancer by radiological examination: A prospective observational study
Tetsuya Inoue, Norio Katoh, Yoichi M Ito, Tomoki Kimura, Yasushi Nagata, Kengo Kuriyama, Hiroshi Onishi, Tadamasa Yoshitake, Yoshiyuki Shioyama, Yusuke Iizuka, Koji Inaba, Koji Konishi, Masaki Kokubo, Katsuyuki Karasawa, Takuyo Kozuka, Kensuke Tanaka, Jun Sakakibara-Konishi, Ichiro Kinoshita, Hiroki Shirato
Lung Cancer, 122, 107, 112, Elsevier Ireland Ltd, 2018年08月01日, ［査読有り］
英語, 研究論文（学術雑誌）

Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma.
Takahiro Einama, Hirofumi Kamachi, Yosuke Tsuruga, Toshihiro Sakata, Kazuaki Shibuya, Yuzuru Sakamoto, Shingo Shimada, Kenji Wakayama, Tatsuya Orimo, Hideki Yokoo, Toshiya Kamiyama, Norio Katoh, Yusuke Uchinami, Tomoko Mitsuhashi, Akinobu Taketomi
Medicine, 97, 31, e11309, 2018年08月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Recently, several reports demonstrated the efficacy of neoadjuvant chemotherapy (NAC) or chemoradiotherapy (NACRT) for patients with borderline resectable (BRPC) and locally advanced unresectable pancreatic carcinoma (LAPC). The aim of this study was to evaluate the treatment response after NACRT, especially for nerve plexuses, and the optimal resection area for superior mesenteric artery nerve plexuses in BRPC and LAPC patients after NACRT.A total of 17 patients with BRPC and LAPC received preoperative gemcitabine-based NACRT. The numbers of BRPC and LAPC patients were 13 and 4, respectively. We evaluated nerve plexus invasion by CT before and after NACRT, decided on the resection area of plexus invasion in SMA before NACRT, and compared the preoperative evaluation and clinicopathological findings.In the plexus of the supra-mesenteric artery (pl-SMA), arterial nerve plexus invasion, in cases <90°, all patients showed the absence of residual cancer in the resected specimen after NACRT. In cases between 90° and 180°, 1 of 2 patients (50%) showed nerve plexus invasion. In cases over 180°, all patients showed nerve plexus invasion. We could perform R0 resection in all 10 cases, and pl-SMA invasion disappeared in 6 of 7 BRPC patients.We demonstrated the relationship between the angle of nerve plexus tumor invasion and treatment effect after NACRT. We could perform R0 resection in all pl-SMA invasion cases, deciding on the resection area of pl-SMA based on CT before NACRT.

Assessing the uncertainty in a normal tissue complication probability difference (∆NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy.
Kobashi K, Prayongrat A, Kimoto T, Toramatsu C, Dekura Y, Katoh N, Shimizu S, Ito YM, Shirato H
Journal of radiation research, 59, suppl_1, i50, i57, Oxford University Press, 2018年03月01日, ［査読有り］
英語, 研究論文（学術雑誌）

Prospective study to evaluate the safety of the world-first spot-scanning dedicated, small 360-degree gantry, synchrotron-based proton beam therapy system
Kentaro Nishioka, Anussara Prayongrat, Kota Ono, Shunsuke Onodera, Takayuki Hashimoto, Norio Katoh, Tetsuya Inoue, Rumiko Kinoshita, Koichi Yasuda, Takashi Mori, Rikiya Onimaru, Hiroki Shirato, Shinichi Shimizu
Journal of Radiation Research, 59, suppl_1, i63, i71, 2018年03月01日, ［査読有り］
研究論文（国際会議プロシーディングス）

Analysis of inter- and intra fractional partial bladder wall movement using implanted fiducial markers
Kentaro Nishioka, Shinichi Shimizu, Nobuo Shinohara, Yoichi M. Ito, Takashige Abe, Satoru Maruyama, Norio Katoh, Rumiko Kinoshita, Takayuki Hashimoto, Naoki Miyamoto, Rikiya Onimaru, Hiroki Shirato
RADIATION ONCOLOGY, 12, 1, 44, 2017年03月, ［査読有り］
英語, 研究論文（学術雑誌）

Impact of Real-Time Image Gating on Spot Scanning Proton Therapy for Lung Tumors: A Simulation Study.
Kanehira T, Matsuura T, Takao S, Matsuzaki Y, Fujii Y, Fujii T, Ito YM, Miyamoto N, Inoue T, Katoh N, Shimizu S, Umegaki K, Shirato H
International journal of radiation oncology, biology, physics, 97, 1, 173, 181, 2017年01月, ［査読有り］
英語, 研究論文（学術雑誌）

Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system
Norio Katoh, Itaru Soda, Hiroyasu Tamamura, Shotaro Takahashi, Yusuke Uchinami, Hiromichi Ishiyama, Kiyotaka Ota, Tetsuya Inoue, Rikiya Onimaru, Keiko Shibuya, Kazushige Hayakawa, Hiroki Shirato
RADIATION ONCOLOGY, 12, 1, 3, 2017年01月, ［査読有り］, ［筆頭著者, 責任著者］
英語, 研究論文（学術雑誌）

Evaluation of the motion of lung tumors during stereotactic body radiation therapy (SBRT) with four-dimensional computed tomography (4DCT) using real-time tumor-tracking radiotherapy system (RTRT)
Keiichi Harada, Norio Katoh, Ryusuke Suzuki, Yoichi M. Ito, Shinichi Shimizu, Rikiya Onimaru, Tetsuya Inoue, Naoki Miyamoto, Hiroki Shirato
PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 32, 2, 305, 311, 2016年02月, ［査読有り］, ［責任著者］
英語, 研究論文（学術雑誌）, 32372006

Intrafractional Baseline Shift or Drift of Lung Tumor Motion During Gated Radiation Therapy With a Real-Time Tumor-Tracking System
Seishin Takao, Naoki Miyamoto, Taeko Matsuura, Rikiya Onimaru, Norio Katoh, Tetsuya Inoue, Kenneth Lee Sutherland, Ryusuke Suzuki, Hiroki Shirato, Shinichi Shimizu
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 94, 1, 172, 180, 2016年01月, ［査読有り］
英語, 研究論文（学術雑誌）

Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial
Hidefumi Aoyama, Masao Tago, Hiroki Shirato
JAMA ONCOLOGY, 1, 4, 457, 464, 2015年07月, ［査読有り］
英語, 研究論文（学術雑誌）

Influence of respiration on dose calculation in stereotactic body radiotherapy of the lung
Rie Yamazaki, Rikiya Onimaru, Norio Katoh, Tetsuya Inoue, Takeshi Nishioka, Hiroki Shirato, Hiroyuki Date
Radiological Physics and Technology, 7, 2, 284, 289, 2014年07月, ［査読有り］
研究論文（学術雑誌）

Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) system
Shinichi Shimizu, Kentaro Nishioka, Ryusuke Suzuki, Nobuo Shinohara, Satoru Maruyama, Takashige Abe, Rumiko Kinoshita, Norio Katoh, Rikiya Onimaru, Hiroki Shirato
RADIATION ONCOLOGY, 9, 118, 2014年05月, ［査読有り］
英語, 研究論文（学術雑誌）

Stereotactic body radiotherapy using gated radiotherapy with real-time tumor-tracking for stage I non-small cell lung cancer
Tetsuya Inoue, Norio Katoh, Rikiya Onimaru, Shinichi Shimizu, Kazuhiko Tsuchiya, Ryusuke Suzuki, Jun Sakakibara-Konishi, Naofumi Shinagawa, Satoshi Oizumi, Hiroki Shirato
Radiation Oncology, 8, 1, 69, 2013年03月21日, ［査読有り］
研究論文（学術雑誌）

What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-modulated radiation therapy
Chie Toramatsu, Norio Katoh, Shinichi Shimizu, Hideaki Nihongi, Taeko Matsuura, Seishin Takao, Naoki Miyamoto, Ryusuke Suzuki, Kenneth Sutherland, Rumiko Kinoshita, Rikiya Onimaru, Masayori Ishikawa, Kikuo Umegaki, Hiroki Shirato
RADIATION ONCOLOGY, 8, 48, 2013年03月, ［査読有り］, ［責任著者］
英語, 研究論文（学術雑誌）

[F-18]fluoromisonidazole and a New PET System With Semiconductor Detectors and a Depth of Interaction System for Intensity Modulated Radiation Therapy for Nasopharyngeal Cancer
Koichi Yasuda, Rikiya Onimaru, Shozo Okamoto, Tohru Shiga, Norio Katoh, Kazuhiko Tsuchiya, Ryusuke Suzuki, Wataru Takeuchi, Yuji Kuge, Nagara Tamaki, Hiroki Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 85, 1, 142, 147, 2013年01月, ［査読有り］
英語, 研究論文（学術雑誌）

A New Brain Positron Emission Tomography Scanner With Semiconductor Detectors for Target Volume Delineation and Radiotherapy Treatment Planning in Patients With Nasopharyngeal Carcinoma
Norio Katoh, Koichi Yasuda, Tohru Shiga, Masakazu Hasegawa, Rikiya Onimaru, Shinichi Shimizu, Gerard Bengua, Masayori Ishikawa, Nagara Tamaki, Hiroki Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82, 4, E671, E676, 2012年03月, ［査読有り］, ［筆頭著者, 責任著者］
英語, 研究論文（学術雑誌）

Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence
Tetsuya Inoue, Norio Katoh, Rikiya Onimaru, Hiroki Shirato
Pulmonary Medicine, 2012, 369820, 2012年, ［査読有り］
研究論文（学術雑誌）

Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer
Jun Sakakibara-Konishi, Satoshi Oizumi, Ichiro Kinoshita, Naofumi Shinagawa, Junko Kikuchi, Mototsugu Kato, Tetsuya Inoue, Norio Katoh, Rikiya Onimaru, Hiroki Shirato, Hirotoshi Dosaka-Akita, Masaharu Nishimura
LUNG CANCER, 74, 2, 248, 252, 2011年11月, ［査読有り］
英語, 研究論文（学術雑誌）

Long-term Outcomes of Fractionated Stereotactic Radiotherapy for Intracranial Skull Base Benign Meningiomas in Single Institution
Shunsuke Onodera, Hidefumi Aoyama, Norio Katoh, Hiroshi Taguchi, Kouichi Yasuda, Daisuke Yoshida, Ken Surtherland, Ryusuke Suzuki, Masayori Ishikawa, Bengua Gerard, Shunsuke Terasaka, Hiroki Shirato
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 41, 4, 462, 468, 2011年04月, ［査読有り］
英語, 研究論文（学術雑誌）

Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions
Shozo Okamoto, Tohru Shiga, Naoya Hattori, Naoki Kubo, Toshiki Takei, Norio Katoh, Yutaka Sawamura, Kenichi Nishijima, Yuji Kuge, Nagara Tamaki
ANNALS OF NUCLEAR MEDICINE, 25, 3, 213, 220, 2011年04月, ［査読有り］
英語, 研究論文（学術雑誌）

EVALUATION OF THE EFFECTIVENESS OF THE STEREOTACTIC BODY FRAME IN REDUCING RESPIRATORY INTRAFRACTIONAL ORGAN MOTION USING THE REAL-TIME TUMOR-TRACKING RADIOTHERAPY SYSTEM
Gerard Bengua, Masayori Ishikawa, Kenneth Sutherland, Kenji Horita, Rie Yamazaki, Katsuhisa Fujita, Rikiya Onimaru, Noriwo Katoh, Tetsuya Inoue, Shunsuke Onodera, Hiroki Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77, 2, 630, 636, 2010年06月, ［査読有り］
英語, 研究論文（学術雑誌）

Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions
Tetsuya Inoue, Norio Katoh, Hidefumi Aoyama, Rikiya Onimaru, Hiroshi Taguchi, Shunsuke Onodera, Satoshi Yamaguchi, Hiroki Shirato
Japanese Journal of Clinical Oncology, 40, 8, 788, 794, 8, 2010年04月, ［査読有り］
研究論文（学術雑誌）

High Dose Three-Dimensional Conformal Boost Using the Real-Time Tumor Tracking Radiotherapy System in Cervical Cancer Patients Unable to Receive Intracavitary Brachytherapy
Hee Chul Park, Shinichi Shimizu, Akio Yonesaka, Kazuhiko Tsuchiya, Yasuhiko Ebina, Hiroshi Taguchi, Norio Katoh, Rumiko Kinoshita, Masayori Ishikawa, Noriaki Sakuragi, Hiroki Shirato
YONSEI MEDICAL JOURNAL, 51, 1, 93, 99, 2010年01月, ［査読有り］
英語, 研究論文（学術雑誌）

A feasibility study of novel plastic scintillation dosimetry with pulse-counting mode
M. Ishikawa, G. Bengua, K. L. Sutherland, J. Hiratsuka, N. Katoh, S. Shimizu, H. Aoyama, K. Fujita, R. Yamazaki, K. Horita, H. Shirato
PHYSICS IN MEDICINE AND BIOLOGY, 54, 7, 2079, 2092, 2009年04月, ［査読有り］
英語, 研究論文（学術雑誌）

A New PET Scanner with Semiconductor Detectors Enables Better Identification of Intratumoral Inhomogeneity
Tohru Shiga, Yuichi Morimoto, Naoki Kubo, Norio Katoh, Chietsugu Katoh, Wataru Takeuchi, Reiko Usui, Kenji Hirata, Shinichi Kojima, Kikuo Umegaki, Hiroki Shirato, Nagara Tamaki
JOURNAL OF NUCLEAR MEDICINE, 50, 1, 148, 155, 2009年01月, ［査読有り］
英語, 研究論文（学術雑誌）

Real-time tumor-tracking radiotherapy for adrenal tumors
Norio Katoh, Rikiya Onimaru, Yusuke Sakuhara, Daisuke Abo, Shinichi Shimizu, Hiroshi Taguchi, Yoshiaki Watanabe, Nobuo Shinohara, Masayori Ishikawa, Hiroki Shirato
RADIOTHERAPY AND ONCOLOGY, 87, 3, 418, 424, 2008年06月, ［査読有り］
英語, 研究論文（学術雑誌）

Three-dimensional intrafractional motion of breast during tangential breast irradiation monitored with high-sampling frequency using a real-time tumor-tracking radiotherapy system
Rumiko Kinoshita, Shinichi Shimizu, Hiroshi Taguchi, Norio Katoh, Masaharu Fujino, Rikiya Onimaru, Hidefumi Aoyama, Fumi Katoh, Tokuhiko Omatsu, Masayori Ishikawa, Hiroki Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70, 3, 931, 934, 2008年03月, ［査読有り］
英語, 研究論文（学術雑誌）

Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy
Rikiya Onimaru, Masaharu Fujino, Koichi Yamazaki, Yuya Onodera, Hiroshi Taguchi, Norio Katoh, Fumihiro Hommura, Satoshi Oizumi, Masaharu Nishimura, Hiroki Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 70, 2, 374, 381, 2008年02月, ［査読有り］
英語, 研究論文（学術雑誌）

Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone
Hidefumi Aoyama, Masao Tago, Norio Kato, Tatsuya Toyoda, Masahiro Kenjyo, Saeko Hirota, Hiroki Shioura, Taisuke Inomata, Etsuo Kunieda, Kazushige Hayakawa, Keiichi Nakagawa, Gen Kobashi, Hiroki Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 68, 5, 1388, 1395, 2007年08月, ［査読有り］
英語, 研究論文（学術雑誌）

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial
H Aoyama, H Shirato, M Tago, K Nakagawa, T Toyoda, K Hatano, M Kenjyo, N Oya, S Hirota, H Shioura, E Kunieda, T Inomata, K Hayakawa, N Katoh, G Kobashi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 295, 21, 2483, 2491, 2006年06月, ［査読有り］
英語, 研究論文（学術雑誌）

Hypofractionated radiotherapy boost for dose escalation as a treatment option for high-grade spinal cord astrocytic tumor
N Katoh, H Shirato, H Aoyama, R Onimaru, K Suzuki, K Hida, K Miyasaka, Y Iwasaki
JOURNAL OF NEURO-ONCOLOGY, 78, 1, 63, 69, 2006年05月, ［査読有り］, ［筆頭著者, 責任著者］
英語, 研究論文（学術雑誌）

Speed and amplitude of lung tumor motion precisely detected in four-dimensional setup and in real-time tumor-tracking radiotherapy
H Shirato, K Suzuki, GC Sharp, K Fujita, R Onimaru, M Fujino, N Kato, Y Osaka, R Kinoshita, H Taguchi, S Onodera, K Miyasaka
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 64, 4, 1229, 1236, 2006年03月, ［査読有り］
英語, 研究論文（学術雑誌）

放射線治療効果の向上を目指した新手法開発とその臨床応用 動体追跡照射装置を用いた放射線治療
鬼丸 力也, 白土 博樹, 藤野 賢治, 田口 大志, 加藤 徳雄, 大坂 康博, 清水 伸一, 青山 英史, 鈴木 恵士郎
日本放射線影響学会大会講演要旨集, 48回, 75, 75, (一社)日本放射線影響学会, 2005年11月
英語

Comparison of imaging modalities for the accurate delineation of arteriovenous malformation, with reference to stereotactic radiosurgery
H Aoyama, H Shirato, N Katoh, K Kudo, T Asano, S Kuroda, T Ishikawa, K Miyasaka
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 62, 4, 1232, 1238, 2005年07月, ［査読有り］
英語, 研究論文（学術雑誌）

Stereotactic irradiation for intracranial arteriovenous malformation using stereotactic radiosurgery or hypofractionated stereotactic radiotherapy
TC Chang, H Shirato, H Aoyama, S Ushikoshi, N Kato, S Kuroda, T Ishikawa, K Houkin, Y Iwasaki, K Miyasaka
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 60, 3, 861, 870, 2004年11月, ［査読有り］
英語, 研究論文（学術雑誌）

Three-dimensional conformal setup (3D-CSU) of patients using the coordinate system provided by three internal fiducial markers and two orthogonal diagnostic X-ray systems in the treatment room
H Shirato, M Oita, K Fujita, S Shimizu, R Onimaru, S Uegaki, Y Watanabe, N Kato, K Miyasaka
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 60, 2, 607, 612, 2004年10月, ［査読有り］
英語, 研究論文（学術雑誌）

Impact of margin for target volume in low-dose involved field radiotherapy after induction chemotherapy for intracranial germinoma
H Shirato, H Aoyama, J Ikeda, K Fujieda, N Kato, N Ishi, K Miyasaka, Y Iwasaki, Y Sawamura
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 60, 1, 214, 217, 2004年09月, ［査読有り］
英語, 研究論文（学術雑誌）

A case of intravascular lymphoma with increased regional cerebral blood flow in I-123 IMP single-photon emission CT
C Miyazaki, M Mukai, Y Kawaai, M Takeda, N Katoh, S Nagano, K Kubo, M Kohno
AMERICAN JOURNAL OF NEURORADIOLOGY, 25, 4, 565, 570, 2004年04月, ［査読有り］
英語, 研究論文（学術雑誌）

体内の動きが膵癌SBRTにおける呼気止め分割CBCT画像に与える影響の評価
温品あい莉, 山田亮太, 吉村高明, 吉村高明, 吉村高明, 金平孝博, 加藤徳雄, 橋本孝之, 青山英史, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 38th, 2025年

Comparing predictors of radiation-induced lymphopenia in various timeframes in NSCLC radiotherapy
Takahiro Kanehira, Hiroshi Taguchi, Jun Sakakibara-Konishi, Norio Katoh, Yusuke Uchinami, Keiji Kobashi, Takayuki Hashimoto, Hidefumi Aoyama, RADIOTHERAPY AND ONCOLOGY, 194, S5012, S5015, 2024年05月
英語, 研究発表ペーパー・要旨（国際会議）

膵癌に対する動体追跡放射線治療用の経皮的あるいは経動脈的マーカー留置術の検討　　　　　　　　　　　　　　　
加藤 大祐, 阿保 大介, 森田 亮, 打浪 雄介, 加藤 徳雄, 山田 亮太, 木野田 直也, 藤井 宝顕, 山崎 康之, 高柳 歩, 青山 英史, 工藤 與亮, 日本インターベンショナルラジオロジー学会雑誌, 39, Suppl., 191, 191, 2024年04月
(一社)日本インターベンショナルラジオロジー学会, 日本語

同時放射線化学療法で治療の膵癌患者における胃腸毒性の予測
KOIZUMI Fuki, KATOH Norio, KANEHIRA Takahiro, KAWAMOTO Yasuyuki, NAKAMURA Toru, KAKISAKA Tatsuhiko, UCHINAMI Yusuke, YOKOTA Isao, KOBASHI Keiji, AOYAMA Hidefumi, 日本医学放射線学会総会抄録集, 83rd, 2024年

体幹部領域の呼吸同期VMATにおける照射時間に対する患者因子の影響
山田亮太, 吉村高明, 吉村高明, 吉村高明, 田村弘詞, 一宇佑太, 横川航平, 加藤徳雄, 日本診療放射線技師会誌, 71, 10, 2024年

PO-2122 Effect of early fractional lymphocyte loss on lymphopenia probability models for NSCLC
T. Kanehira, H. Taguchi, N. Katoh, Y. Uchinami, T. Yoshimura, M. Tamura, R. Suzuki, T. Hashimoto, H. Aoyama, Radiotherapy and Oncology, 182, S1909, S1911, 2023年05月, ［査読有り］, ［国際誌］
Elsevier BV, 英語, 研究発表ペーパー・要旨（国際会議）

体幹部定位放射線治療時の呼気止め分割CBCTにおける呼吸再現性と輪郭の評価　　　　　　　　　　　　　　　
山田 亮太, 吉村 高明, 一宇 佑太, 若林 倭, 松尾 勇斗, 孫田 惠一, 加藤 徳雄, 日本放射線技術学会総会学術大会予稿集, 79回, 190, 190, 2023年03月
(公社)日本放射線技術学会, 日本語

適応陽子線治療における日々の線量分布の迅速評価システムの開発
小橋啓司, 小橋啓司, 西岡健太郎, 西岡健太郎, 橋本孝之, 橋本孝之, 田村弘詞, 中里慧二, 田口大志, 安田耕一, 安田耕一, 打浪雄介, 打浪雄介, 加藤徳雄, 加藤徳雄, 青山英史, 青山英史, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 36th, 2023年

転移性肝腫瘍のシステマチックレビューと統一治療方針による粒子線レジストリの解析　　　　　　　　　　　　　　　
福光 延吉, 柴 慎太郎, 渋谷 圭, 岡崎 祥平, 宮坂 勇平, 山口 久志, 沼尻 晴子, 若月 優, 辻 比呂志, 加藤 徳雄, 手良向 聡, 藤川 桂, 万代 昌紀, 吉野 孝之, 日本癌治療学会学術集会抄録集, 60回, OF, 6, 2022年10月
(一社)日本癌治療学会, 英語

内科・外科による消化器病共同診療の現況と展望 当科における切除可能境界膵癌に対する術前治療の現状　　　　　　　　　　　　　　　
原田 一顕, 中村 赳晶, 渡辺 亮介, 山村 貴洋, 川本 泰之, 結城 敏志, 桑谷 将城, 田口 大志, 加藤 徳雄, 浅野 賢道, 中村 透, 平野 聡, 小松 嘉人, 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 28, 28, 2022年09月
日本消化器病学会-北海道支部, 日本語

汎用リニアックを用いた膵定位放射線治療における呼気止め分割CBCT　　　　　　　　　　　　　　　
一宇 佑太, 山田 亮太, 安渡 大輔, 田村 弘詞, 若林 倭, 加藤 徳雄, 青山 英史, 日本放射線技術学会雑誌, 78, 9, 1057, 1057, 2022年09月
(公社)日本放射線技術学会, 日本語

Propensity scoreを用いた解析によるvp3、4肝細胞癌の門脈腫瘍栓に対する術前放射線治療の有効性の検討　　　　　　　　　　　　　　　
柿坂 達彦, 神山 俊哉, 折茂 達也, 長津 明久, 旭 よう, 坂本 譲, 蒲池 浩文, 加藤 徳雄, 畑中 佳奈子, 武冨 紹信, 日本外科学会定期学術集会抄録集, 121回, SF, 3, 2021年04月
(一社)日本外科学会, 日本語

尿量の経日変化および前立腺体積が放射線治療時の前立腺の位置に与える影響(The Impact of Daily Urinary Volume Variations and Prostate Volume on Prostate Position During Radiotherapy)　　　　　　　　　　　　　　　
Nishioka Kentaro, Hashimoto Takayuki, Yokota Isao, Katoh Norio, Kinoshita Rumiko, Yasuda Koichi, Takao Seishin, Yoshimura Takaaki, Aoyama Hidefumi, Shimizu Shinichi, 日本医学放射線学会学術集会抄録集, 80回, S193, S194, 2021年03月
(公社)日本医学放射線学会, 英語

SMARCB1欠損篩骨洞癌に対する強度変調陽子線治療:症例報告と文献レビュー
宮崎智彦, 安田耕一, 志藤元泰, 小泉富基, 藤田祥博, 高橋周平, 湊川英樹, 大塚愛美, 加藤徳雄, 清水伸一, 青山英史, 北海道放射線医学雑誌, 1, 2021年

小児がんに対する陽子線再照射
橋本孝之, 森崇, 西岡健太郎, 打浪雄介, 安田耕一, 木下留美子, 田口大志, 加藤徳雄, 清水伸一, 青山英史, 日本小児血液・がん学会雑誌(Web), 58, 2, 2021年

肝細胞癌陽子線治療前MRIにおけるばらつきの小さいADC値指標の検討:治療効果予測に向けた前段階の研究
藤田祥博, 加藤徳雄, 田口大志, 打浪雄介, 西岡健太郎, 森崇, 湊川英樹, 安田耕一, 清水伸一, 青山英史, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 34th, 2021年

動体追跡陽子線照射における気管支内視鏡的放射線治療用マーカー留置術の検討
伊藤 祥太郎, 品川 尚文, 高島 雄太, 國崎 守, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純, 加藤 徳雄, 田口 大志, 青山 英史, 今野 哲, 気管支学, 42, 6, 576, 576, 2020年11月
(NPO)日本呼吸器内視鏡学会, 日本語

膵癌に対するS-1併用術前化学放射線療法(S-1併用NACRT)の治療成績
小泉 富基, 加藤 徳雄, 中村 透, 川本 泰之, 田口 大志, 打浪 雄介, 清水 伸一, 青山 英史, 日本医学放射線学会秋季臨床大会抄録集, 56回, S103, S103, 2020年10月
(公社)日本医学放射線学会, 日本語

画像誘導治療の今後について 画像誘導陽子線治療の将来展望　　　　　　　　　　　　　　　
田口 大志, 橋本 孝之, 加藤 徳雄, 木下 留美子, 安田 耕一, 西岡 健太郎, 森 崇, 打浪 雄介, 宮本 直樹, 高尾 聖心, 清水 伸一, 青山 英史, 日本癌治療学会学術集会抄録集, 58回, SY14, 3, 2020年10月
(一社)日本癌治療学会, 英語

動体追跡陽子線照射における気管支内視鏡的放射線治療用マーカー留置術の検討
伊藤 祥太郎, 品川 尚文, 高島 雄太, 國崎 守, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純, 加藤 徳雄, 田口 大志, 青山 英史, 今野 哲, 気管支学, 42, Suppl., S277, S277, 2020年06月
(NPO)日本呼吸器内視鏡学会, 日本語

画像誘導陽子線治療の将来展望
田口大志, 橋本孝之, 橋本孝之, 加藤徳雄, 木下留美子, 安田耕一, 西岡健太郎, 西岡健太郎, 森崇, 打浪雄介, 宮本直樹, 高尾聖心, 清水伸一, 清水伸一, 青山英史, 日本癌治療学会学術集会(Web), 58th, 2020年

局所進行食道癌に対してspot scanning法による根治的化学陽子線療法を施行した一例　　　　　　　　　　　　　　　
宮崎 智彦, 打浪 雄介, 田口 大志, 加藤 徳雄, 清水 伸一, 白土 博樹, 中積 宏之, 中野 真太郎, 坂本 直哉, 高尾 聖心, 田村 昌也, 松浦 妙子, 日本医学放射線学会秋季臨床大会抄録集, 55回, S520, S520, 2019年09月
(公社)日本医学放射線学会, 日本語

Initial Clinical Outcomes of Real-Time-Image Gated Spot-Scanning Proton Beam Therapy for Hepatocellular Carcinomas
N. Katoh, Y. Uchinami, D. Abo, S. Takao, T. Inoue, H. Taguchi, R. Morita, T. Soyama, T. Hashimoto, R. Onimaru, A. Prayongrat, M. Tamura, T. Matsuura, S. Shimizu, H. Shirato, International Journal of Radiation Oncology*Biology*Physics, 105, 1, E222, E223, 2019年09月
Elsevier BV

局所進行食道癌に対してspot scanning法による根治的化学陽子線療法を施行した一例　　　　　　　　　　　　　　　
宮崎 智彦, 打浪 雄介, 田口 大志, 加藤 徳雄, 清水 伸一, 白土 博樹, 中積 宏之, 中野 真太郎, 坂本 直哉, 高尾 聖心, 田村 昌也, 松浦 妙子, 日本医学放射線学会秋季臨床大会抄録集, 55回, S520, S520, 2019年09月
(公社)日本医学放射線学会, 日本語

Big Data Analysis of Treatment Process Time for the Real-Time-Image Gated-Spot-Scanning Proton-Beam Therapy (RGPT) System
T. Yoshimura, S. Shimizu, T. Hashimoto, N. Katoh, T. Inoue, K. Nishioka, T. Matsuura, S. Takao, M. Tamura, H. Tamura, K. Horita, K. Umegaki, H. Shirato, International Journal of Radiation Oncology*Biology*Physics, 102, 3, e501, e502, 2018年11月
Elsevier BV

Uncertainties of Normal Tissue Complication Probability (NTCP) and NTCP Difference between Radiation Treatment Modalities for Radiation-Induced Liver Toxicity in Child-Pugh A Primary Liver Cancer Patients
A. Prayongrat, K. Kobashi, Y. Ito, N. Katoh, Y. Dekura, N. Amornwichet, S. Shimizu, H. Shirato, International Journal of Radiation Oncology*Biology*Physics, 102, 3, e65, e66, 2018年11月
Elsevier BV

Analysis of Beam Delivery Times and Dose Rates for the Treatment of Mobile Tumors Using Real Time Image Gated Spot-Scanning Proton Beam Therapy
S. Shimizu, T. Yoshimura, N. Katoh, T. Inoue, T. Hashimoto, K. Nishioka, S. Takao, T. Matsuura, N. Miyamoto, Y.M. Ito, K. Umegaki, H. Shirato, International Journal of Radiation Oncology*Biology*Physics, 102, 3, S182, S183, 2018年11月
Elsevier BV

乳癌眼窩尖部転移により視力低下をきたし,放射線治療により著明な改善を認めた1例
湊川英樹, 安田耕一, 打浪雄介, 白土博樹, 土屋和彦, 加藤徳雄, 木下留美子, 石田直子, 山下啓子, 石嶋漢, Japanese Journal of Radiology, 36, Supplement, 11, 11, 2018年02月25日
(公社)日本医学放射線学会, 日本語

乳癌眼窩尖部転移により視力低下をきたし、放射線治療により著明な改善を認めた1例　　　　　　　　　　　　　　　
湊川 英樹, 安田 耕一, 打浪 雄介, 白土 博樹, 土屋 和彦, 加藤 徳雄, 木下 留美子, 石田 直子, 山下 啓子, 石嶋 漢, Japanese Journal of Radiology, 36, Suppl., 11, 11, 2018年02月
(公社)日本医学放射線学会, 日本語

放射線治療における数値指標の医学物理的利用
清水伸一, 小橋啓司, 伊藤陽一, PRAYONGRAT Anussara, 加藤徳雄, 安田耕一, 出倉康裕, 木元拓也, 白土博樹, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 31st (CD-ROM), 39, 2018年
日本語

An Organ Motion and Acute Toxicity Study of Image-Guided Spot-Scanning Proton Beam Therapy With An Internal Fiducial Marker for Pancreatic Cancers.
Y. Uchinami, N. Katoh, D. Abo, K. Harada, Y. Nishikawa, T. Inoue, T. Hashimoto, R. Onimaru, N. Miyamoto, Y. Sakuhara, S. Shimizu, H. Shirato, International Journal of Radiation Oncology*Biology*Physics, 99, 2, E194, E194, 2017年10月, ［査読有り］
英語

Analysis of Threshold Doses for Radiation Induced Liver Parenchymal Changes on MRI after Real Time–Image Gated Spot-Scanning Proton Beam Therapy of Hepatocellular Carcinomas
N. Katoh, Y. Uchinami, S. Takao, K. Yasuda, K. Harada, T. Inoue, T. Matsuura, T. Hashimoto, S. Shimizu, H. Shirato, International Journal of Radiation Oncology*Biology*Physics, 99, 2, E159, E160, 2017年10月, ［査読有り］, ［筆頭著者］
英語, 記事・総説・解説・論説等（学術雑誌）, 11887512

Can F-18-fluoromisonidazole PET/CT Predict the Clinical Outcome for Stage I Non-small Cell Lung Cancer Treated By Stereotactic Body Radiation Therapy?
T. Inoue, S. Watanabe, K. Harada, K. Yasuda, N. Katoh, S. Okamoto, T. Shiga, Y. Kuge, N. Tamaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99, 2, E466, E466, 2017年10月
英語, 研究発表ペーパー・要旨（国際会議）

肝腫瘍に対する動態追跡照射のための経皮的マーカ留置
森田亮, 曽山武士, 阿保大介, 作原祐介, 工藤與亮, 加藤徳雄, 白土博樹, IVR, 32, 2, 161, 161, 2017年07月10日
(一社)日本インターベンショナルラジオロジー学会, 日本語

【悪性脊椎脊髄腫瘍に対する治療】 原発性悪性脊椎脊髄腫瘍に対する放射線治療
鬼丸 力也, 森 崇, 加藤 徳雄, 関 俊隆, 白土 博樹, 脊椎脊髄ジャーナル, 30, 7, 673, 676, 2017年07月
(株)三輪書店, 日本語

肝腫瘍に対する動態追跡照射のための経皮的マーカ留置　　　　　　　　　　　　　　　
森田 亮, 曽山 武士, 阿保 大介, 作原 祐介, 工藤 與亮, 加藤 徳雄, 白土 博樹, IVR: Interventional Radiology, 32, 2, 161, 161, 2017年07月
(一社)日本インターベンショナルラジオロジー学会, 日本語

甲状腺癌分化癌の骨転移に対するIMRTを含めた外照射の治療成績　　　　　　　　　　　　　　　
安田 耕一, 加藤 徳雄, 岡本 祥三, 木下 留美子, 志賀 哲, 水町 貴諭, 畠山 博充, 本間 明宏, 田口 純, 清水 康, 森 崇, 土屋 和彦, 白土 博樹, 頭頸部癌, 43, 2, 221, 221, 2017年05月
(一社)日本頭頸部癌学会, 日本語

肝腫瘍に対する動態追跡照射のための経皮的マーカ留置(Percutaneous hepatic fiducial marker implantation for Real-time Tumor-tracking Radiotherapy(RTRT))　　　　　　　　　　　　　　　
森田 亮, 作原 祐介, 曽山 武士, 阿保 大介, 加藤 徳雄, 工藤 與亮, 白土 博樹, IVR: Interventional Radiology, 32, Suppl., 173, 173, 2017年04月
(一社)日本インターベンショナルラジオロジー学会, 英語

Analysis of Durations and Dose Rates for Treatment of Moving Liver Tumors Using Real-Time Image Gated Spot Scanning Proton Beam Therapy
S. Shimizu, N. Katoh, T. Hashimoto, K. Nishioka, T. Yoshimura, S. Takao, T. Matsuura, N. Miyamoto, K. Umegaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 96, 2, S211, S212, 2016年10月
英語, 研究発表ペーパー・要旨（国際会議）

Stereotactic Body Radiation Therapy Using a Real-time Tumor-Tracking Radiation Therapy System for Hepatocellular Carcinomas
Y. Uchinami, N. Katoh, D. Abo, K. Harada, T. Inoue, H. Taguchi, R. Onimaru, S. Shimizu, Y. Sakuhara, K. Ogawa, T. Kamiyama, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 96, 2, E155, E155, 2016年10月
英語, 研究発表ペーパー・要旨（国際会議）

Simulation Study of Real-Time-Image Gating On Spot Scanning Proton Therapy for Lung Tumors
T. Kanehira, T. Matsuura, S. Takao, Y. Matsuzaki, Y. Fujii, T. Fujii, N. Miyamoto, T. Inoue, N. Katoh, S. Shimizu, K. Umegaki, H. Shirato, MEDICAL PHYSICS, 43, 6, 2016年06月
英語, 研究発表ペーパー・要旨（国際会議）

Dosimetric Comparison of Spot-Scanning Proton Therapy Techniques for Liver Tumors Close to the Skin Surface
S. Takao, T. Matsuura, Y. Matsuzaki, Y. Fujii, T. Fujii, N. Katoh, S. Shimizu, K. Umegaki, H. Shirato, MEDICAL PHYSICS, 43, 6, 3505, 3505, 2016年06月
英語, 研究発表ペーパー・要旨（国際会議）

Clinical application for molecular imaging(Therapy) 分子イメージングを用いた放射線治療　　　　　　　　　　　　　　　
安田 耕一, 岡本 祥三, 西川 由記子, 伊藤 陽一, 志賀 哲, 井上 哲也, 森 崇, 豊永 拓哉, 鬼丸 力也, 渡邊 史郎, 土屋 和彦, 竹内 渉, 加藤 徳雄, 久下 裕司, 玉木 長良, 白土 博樹, JSMI Report, 9, 2, 83, 83, 2016年04月
日本分子イメージング学会, 日本語

Treatment Time and Dose Rate Analysis for Respiratory Moving Liver Tumor Using Real-time-image Gated Spot Scanning Proton Beam Therapy System
SHIMIZU Shinichi, KATOH Norio, TAKAO Seishin, MATSUURA Taeko, MIYAMOTO Naoki, HASHIMOTO Takayuki, NISHIOKA Kentaro, YOSHIMURA Takaaki, UMEGAKI Kikuo, SHIRATO Hiroki, 日本医学放射線学会総会抄録集, 75th, S225, S225, 2016年02月29日
(公社)日本医学放射線学会, 英語

照射中と4DCT撮像時の肺内マーカー移動の比較
原田慶一, 加藤徳雄, 井上哲也, 鬼丸力也, 清水伸一, 白土博樹, 鈴木隆介, 宮本直樹, 石川正純, Japanese Journal of Radiology, 34, Supplement, 10, 10, 2016年02月25日
(公社)日本医学放射線学会, 日本語

呼吸性移動の複雑さと対策:最新の動体追跡放射線治療
宮本直樹, 高尾聖心, 原田慶一, 石川正純, 鈴木隆介, 松浦妙子, 牧永彩乃, 井上哲也, 加藤徳雄, 清水伸一, 鬼丸力也, 白土博樹, 日本放射線腫瘍学会高精度放射線外部照射部会学術大会プログラム・抄録集, 29th, 46, 2016年
日本語

食道癌術後/化学放射線療法後再発に対する化学放射線療法の成績
井上哲也, 原田慶一, 加藤徳雄, 清水伸一, 白土博樹, 中積宏之, 福島拓, 小松嘉人, 海老原裕磨, 七戸俊明, 北海道医学雑誌, 90, 2, 153‐154, 154, 2015年11月01日
北海道医学会, 日本語

The Voxel-based Analysis of FMISO-PET Image in Patients With Local Recurrence of Nasopharyngeal Carcinoma
Y. Nishikawa, K. Yasuda, S. Okamoto, Y. M. Ito, T. Mori, R. Onimaru, T. Shiga, K. Tsuchiya, S. Watanabe, W. Takeuchi, N. Katoh, Y. Kuge, N. Tamaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, E337, E337, 2015年11月
英語, 研究発表ペーパー・要旨（国際会議）

Respiration-gated F-18-fluoromisonidazole PET/CT for Stage I Non-Small Cell Lung Cancer Treated by Stereotactic Body Radiation Therapy
T. Inoue, S. Okamoto, S. Watanabe, K. Yasuda, N. Katoh, K. Harada, R. Onimaru, T. Shiga, N. Tamaki, Y. Kuge, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, E390, E391, 2015年11月
英語, 研究発表ペーパー・要旨（国際会議）

Target Residual Motion During Beam Delivery in Gated Irradiation Using Real Time Tumor Tracking Radiation Therapy System: Analysis of Simultaneous Motion of Multiple Internal Fiducial Markers
N. Miyamoto, M. Ishikawa, R. Suzuki, A. Makinaga, T. Matsuura, S. Takao, Y. Matsuzaki, T. Inoue, N. Katoh, S. Shimizu, R. Onimaru, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, E554, E554, 2015年11月
英語, 研究発表ペーパー・要旨（国際会議）

Development of a Real-Time Image Gated Proton Beam Therapy (RGPT) System and Its Initial Clinical Application to Respiratory Moving Liver Tumors
S. Shimizu, N. Katoh, S. Takao, T. Matsuura, N. Miyamoto, T. Hashimoto, K. Nishioka, T. Yoshimura, Y. Matsuzaki, R. Kinoshita, Y. Nishikawa, R. Onimaru, K. Umegaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93, 3, S42, S42, 2015年11月
英語, 研究発表ペーパー・要旨（国際会議）

当院における悪性胸膜中皮腫27例の検討
菊池 創, 朝比奈 肇, 榊原 純, 品川 尚文, 大泉 聡史, 樋田 泰浩, 加賀基 知三, 井上 哲也, 加藤 徳雄, 西村 正治, 肺癌, 55, 1, 2, 8, 2015年02月20日
The Japan Lung Cancer Society, 日本語

4DCTを用いた肺内マーカー移動の解析　　　　　　　　　　　　　　　
加藤 徳雄, 原田 慶一, 鈴木 隆介, 井上 哲也, 鬼丸 力也, 清水 伸一, 宮本 直樹, 白土 博樹, Japanese Journal of Radiology, 33, Suppl., 5, 5, 2015年02月
(公社)日本医学放射線学会, 日本語

局所進行食道癌に対する強度変調放射線治療を用いた放射線化学療法の経験
井上哲也, 加藤徳雄, 清水伸一, 白土博樹, 鈴木隆介, 佐々木尚英, 福島拓, 小松嘉人, 北海道外科雑誌, 59, 2, 206, 206, 2014年12月20日
北海道外科学会, 日本語

Japanese Multi-institutional Study of Stereotactic Body Radiation Therapy For Renal and Adrenal Tumors
N. Katoh, H. Onishi, H. Matsushita, T. Nomiya, K. Nakata, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S467, S467, 2014年09月
英語, 研究発表ペーパー・要旨（国際会議）

放射線治療に関する名称付けルール
安田耕一, 土屋和彦, 井上哲也, 西岡健太郎, 原田慶一, 西川由記子, 鬼丸力也, 清水伸一, 加藤徳雄, 木下留美子, 小野寺俊介, 白土博樹, 鈴木隆介, 藤田勝久, 辻真太郎, 山崎理衣, Jpn J Radiol, 32, Supplement, 7, 7, 2014年02月25日
(公社)日本医学放射線学会, 日本語

局所進行食道癌に対する通常照射と強度変調放射線治療を組み合わせた放射線化学療法
井上哲也, 加藤徳雄, 清水伸一, 白土博樹, 鈴木隆介, 佐々木尚英, 福島拓, 小松嘉人, 北海道外科雑誌, 58, 2, 112, 216, 2013年12月20日
北海道外科学会, 日本語

当院における悪性胸膜中皮腫27例の検討　　　　　　　　　　　　　　　
菊池 創, 朝比奈 肇, 北井 秀典, 池澤 靖元, 高階 太一, 品川 尚文, 榊原 純, 大泉 聡史, 西村 正治, 樋田 泰浩, 加賀 基知三, 井上 哲也, 加藤 徳雄, 肺癌, 53, 7, 918, 918, 2013年12月
(NPO)日本肺癌学会, 日本語

当院における悪性胸膜中皮腫27例の検討
菊池創, 朝比奈肇, 北井秀典, 池澤靖元, 高階太一, 品川尚文, 榊原純, 大泉聡史, 西村正治, 樋田泰浩, 加賀基知三, 井上哲也, 加藤徳雄, 肺癌(Web), 53, 7, 918(J-STAGE), 918, 2013年12月
(NPO)日本肺癌学会, 日本語

A Retrospective Multicenter Study of Stereotactic Body Radiation Therapy Using a Real-Time Tumor-Tracking Radiation Therapy System for Stage I Non-Small Cell Lung Cancer
N. Katoh, I. Soda, H. Tamamura, S. Takahashi, T. Inoue, R. Onimaru, K. Shibuya, K. Hayakawa, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87, 2, S507, S507, 2013年10月
英語, 研究発表ペーパー・要旨（国際会議）

悪性胸膜中皮腫に対する病理診断と治療戦略 当院における悪性胸膜中皮腫27例の検討
菊池 創, 朝比奈 肇, 北井 秀典, 池澤 靖元, 高階 太一, 品川 尚文, 榊原 純, 大泉 聡史, 樋田 泰浩, 加賀 基知三, 井上 哲也, 加藤 徳雄, 西村 正治, 肺癌, 53, 5, 382, 382, 2013年10月
(NPO)日本肺癌学会, 日本語

Safety, Stability, and Location of Implantation of Multiple Gold Markers Into the Soft Bladder Wall by Rigid Cystoscopy
K. Nishioka, S. Shimizu, R. Onimaru, R. Kinoshita, N. Kato, K. Harada, T. Abe, S. Maruyama, N. Shinohara, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87, 2, S397, S397, 2013年10月, ［査読有り］
英語, 研究発表ペーパー・要旨（国際会議）

SU‐E‐J‐57: A Feasibility Study On Molecular‐Imaging‐Based Real‐Time Tumor Tracking for Gated Radiotherapy
M. Ishikawa, S. Tanabe, S. Yamaguchi, N. Ukon, T. Yamanaka, K. Sutherland, N. Miyamoto, R. Suzuki, N. Katoh, K. Yasuda, H. Shirato, Medical Physics, 40, 6, 162, 2013年06月

北海道大学病院における上咽頭癌の治療 10年間(2000〜2010)のまとめ
土屋 和彦, 安田 耕一, 西川 由記子, 木下 留美子, 鬼丸 力也, 原田 慶一, 井上 哲也, 加藤 徳雄, 清水 伸一, 白土 博樹, 西岡 健, 鈴木 恵士郎, 田口 大志, 長谷川 雅一, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 福田 諭, 竹内 啓, 田口 純, 耳鼻咽喉科展望, 56, 補冊2, 174, 175, 2013年05月
耳鼻咽喉科展望会, 日本語

原発性肺癌に対する動体追跡照射を用いた体幹部定位放射線治療
井上哲也, 加藤徳雄, 鬼丸力也, 榊原純, 品川尚文, 大泉聡史, 鈴木隆介, 白土博樹, 日本医学放射線学会総会抄録集, 72nd, S271, S271, 2013年02月28日
(公社)日本医学放射線学会, 日本語

照射前FMISO‐PETの集積部位と照射後再発の位置関係
安田耕一, 土屋和彦, 岡本祥三, 鬼丸力也, 志賀哲, 加藤徳雄, 原田慶一, 久下裕司, 玉木長良, 白土博樹, 日本医学放射線学会総会抄録集, 72nd, S381-S382, S382, 2013年02月28日
(公社)日本医学放射線学会, 日本語

肝臓への放射線治療用病変識別マーカー留置　　　　　　　　　　　　　　　
作原 祐介, 阿保 大介, 加藤 徳雄, 田口 大志, 曽山 武士, 白土 博樹, 日本医学放射線学会学術集会抄録集, 72回, S310, S310, 2013年02月
(公社)日本医学放射線学会, 日本語

Stereotactic Body Radiation Therapy Using Gated Radiation Therapy With Real-time Tumor-tracking for Stage I Non-small Cell Lung Cancer
T. Inoue, N. Katoh, R. Onimaru, R. Suzuki, J. Sakakibara-Konishi, N. Shinagawa, S. Oizumi, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84, 3, S559, S559, 2012年11月
英語, 研究発表ペーパー・要旨（国際会議）

低酸素イメージングと放射線治療(Hypoxia imaging and Radiation therapy)　　　　　　　　　　　　　　　
安田 耕一, 鬼丸 力也, 岡本 祥三, 志賀 哲, 加藤 徳雄, 玉木 長良, 白土 博樹, 日本癌学会総会記事, 71回, 84, 85, 2012年08月
日本癌学会, 英語

リンフォーマの画像診断と新規治療のプラクティス 皮膚悪性リンパ腫に対する放射線治療　　　　　　　　　　　　　　　
鬼丸 力也, 清水 伸一, 土屋 和彦, 加藤 徳雄, 木下 留美子, 井上 哲也, 小野寺 俊輔, 安田 耕一, 西岡 健太郎, 白土 博樹, 日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 28回, 82, 82, 2012年06月
日本皮膚悪性腫瘍学会, 日本語

末梢肺におけるディスポーザブルゴールドマーカーによる金球留置の成績
小倉粋, 品川尚文, 池澤靖元, 高階太一, 水柿秀紀, 山田範幸, 朝比奈肇, 榊原純, 井上哲也, 加藤徳雄, 鬼丸力也, 白戸博樹, 大泉聡史, 大泉聡史, 西村正治, 気管支学, 34, S199, 2012年05月20日
特定非営利活動法人 日本呼吸器内視鏡学会, 日本語

先進的放射線治療におけるPETの役割
加藤徳雄, 鬼丸力也, 安田耕一, 志賀哲, 土屋和彦, 岡本祥三, 玉木長良, 白土博樹, 日本薬学会年会要旨集, 132nd, 1, 118, 118, 2012年03月05日
(公社)日本薬学会, 日本語

胃MALTリンパ腫に対する動体追跡照射の経験
米山理奈, 安田耕一, 加藤徳雄, 鬼丸力也, 白土博樹, Jpn J Radiol, 30, Supplement 1, 5, 5, 2012年02月25日
(公社)日本医学放射線学会, 日本語

当院における緩和的放射線治療の適応と効果
照井健, 小池和彦, 平山泰生, 日下部俊朗, 中島信久, 鬼丸力也, 井上哲也, 加藤徳雄, 石谷邦彦, 日本臨床腫瘍学会学術集会プログラム・抄録集, 10th, 312-313, 2012年
日本語

乳房温存療法後局所再発症例の検討
木下留美子, 清水伸一, 土屋和彦, 加藤徳雄, 田口大志, 高橋將人, 高橋弘昌, 白土博樹, 臨床放射線, 56, 13, 1813-1818, 1818, 2011年12月10日
金原出版, 日本語

Development of a 3D Brain PET Scanner Using CdTe Semiconductor Detectors and Its First Clinical Application
Y. Morimoto, Y. Ueno, W. Takeuchi, S. Kojima, K. Matsuzaki, T. Ishitsu, K. Umegaki, Y. Kiyanagi, N. Kubo, C. Katoh, T. Shiga, H. Shirato, N. Tamaki, IEEE TRANSACTIONS ON NUCLEAR SCIENCE, 58, 5, 2181, 2189, 2011年10月
英語

当院における緩和的放射線治療の実際
照井健, 平山泰生, 小池和彦, 日下部俊朗, 中島信久, 鬼丸力也, 井上哲也, 加藤徳雄, 石谷邦彦, 日本癌治療学会誌, 46, 2, 738, 2011年09月13日
日本語

EBUS‐GS併用経気管支鏡下生検にて診断し動体追跡放射線照射にて治療した末梢小型肺癌の検討
竹内裕, 品川尚文, 池澤靖元, 高階太一, 小倉粋, 水柿秀紀, 山田範幸, 朝比奈肇, 榊原純, 加藤徳雄, 鬼丸力也, 白土博樹, 大泉聡史, 西村正治, 気管支学, 33, S174, 2011年05月20日
特定非営利活動法人 日本呼吸器内視鏡学会, 日本語

Prospective Study on the Effect of High Resolution Semiconductor PET in Fluoromisonidazole (FMISO)-Guided Intensity Modulated Radiation Therapy (IMRT) Dose-escalation Simulation Planning in Patients with Nasopharyngeal Carcinoma (NPC)
K. Yasuda, S. Okamoto, R. Onimaru, T. Shiga, M. Hasegawa, N. Katoh, Y. Kuge, K. Umegaki, N. Tamaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81, 2, S506, S507, 2011年
英語, 研究発表ペーパー・要旨（国際会議）

Utilization of positron emission tomography (PET) for radiotherapy
Rikiya Onimaru, Koichi Yasuda, Norio Katoh, Hiroki Shirato, Tohru Shiga, Shozo Okamoto, Nagara Tamaki, Akihiro Homma, Nobuhiko Oridate, Satoshi Fukuda, Japanese Journal of Head and Neck Cancer, 37, 3, 376, 380, 2011年

乳房温存療法後局所再発症例の検討　　　　　　　　　　　　　　　
木下 留美子, 清水 伸一, 土屋 和彦, 加藤 徳雄, 田口 大志, 高橋 将人, 高橋 弘昌, 白土 博樹, 日本医学放射線学会秋季臨床大会抄録集, 46回, S506, S506, 2010年08月
(公社)日本医学放射線学会, 日本語

口唇癌の放射線治療のretrospective study
香泉和寿, 安田耕一, 長谷川雅一, 鬼丸力也, 清水伸一, 木下留美子, 井上哲也, 加藤徳雄, 小野寺俊輔, 田口大志, 溝口史樹, 青山英史, 白土博樹, 西岡健, 武島嗣英, Jpn J Radiol, 28, Supplement 1, 7, 7, 2010年07月25日
(公社)日本医学放射線学会, 日本語

H&N癌のための18F‐フルオロミソニダゾールPETの影響とIMRTへの適用
安田耕一, 長谷川雅一, 鬼丸力也, 木下留美子, 加藤徳雄, 田口大志, 清水伸一, 井上哲也, 小野寺俊輔, 溝口史樹, 青山英史, 白土博樹, 志賀哲, 岡本祥三, 玉木長良, 石川正純, SUTHERLAND Kenneth, BENGUA Gerard, 宮本直樹, 鈴木隆介, Jpn J Radiol, 28, Supplement 1, 14, 14, 2010年07月25日
(公社)日本医学放射線学会, 日本語

鼻腔・副鼻腔癌に対する超選択的動注を併用した根治的化学放射線療法
長谷川雅一, 安田耕一, 吉田大介, 加藤徳雄, 鬼丸力也, 浅野剛, 白土博樹, 本間明宏, 折舘伸彦, 福田諭, 石川正純, BENGUA Gerard, SUTHERLAND Kenneth, 宮本直樹, 鈴木隆介, Jpn J Radiol, 28, Supplement 1, 7, 7, 2010年07月25日
(公社)日本医学放射線学会, 日本語

Oligometastases症例に対する定位放射線治療の有用性についての検討
井上哲也, 加藤徳雄, 青山英史, 鬼丸力也, 石川正純, 田口大志, 白土博樹, 日本医学放射線学会総会抄録集, 69th, S193-S194, S194, 2010年02月28日
(公社)日本医学放射線学会, 日本語

2.動体追跡放射線照射(RTRT)における金球標識(金マーカー)留置キットの使用経験(第31回 日本呼吸器内視鏡学会北海道支部会)
竹内 裕, 品川 尚文, 小倉 粋, 河井 康孝, 伊藤 健一郎, 水柿 秀紀, 山田 範幸, 菊地 英毅, 菊地 順子, 小西 純, 大泉 聡史, 西村 正治, 井上 哲也, 加藤 徳雄, 鬼丸 力也, 白土 博樹, 気管支学 : 日本気管支研究会雑誌, 32, 1, 80, 80, 2010年01月25日
日本呼吸器内視鏡学会, 日本語

Conceptual Design of PET-linac System for Molecular-guided Radiotherapy
M. Ishikawa, S. Yamaguchi, S. Tanabe, G. Bengua, K. Sutherland, R. Suzuki, N. Miyamoto, K. Nishijima, N. Katoh, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78, 3, S674, S674, 2010年
英語, 研究発表ペーパー・要旨（国際会議）

Feasibility Study on Molecular-imaging Based Tracking System for Lung Cancer Treatment
S. Tanabe, M. Ishikawa, S. Yamaguchi, G. Bengua, K. Sutherland, R. Suzuki, N. Miyamoto, N. Katoh, R. Onimaru, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78, 3, S749, S749, 2010年
英語, 研究発表ペーパー・要旨（国際会議）

Oligometastases症例に対する定位放射線治療の有用性についての検討
井上哲也, 加藤徳雄, 青山英史, 鬼丸力也, 石川正純, 田口大志, 白土博樹, 日本放射線腫よう学会誌, 21, Supplement 1, 159, 2009年08月19日
日本語

OR16-6 動体追跡放射線照射(RTRT)における金球標識(金マーカー)留置キットの使用経験(診断・他,一般口演16,第32回日本呼吸器内視鏡学会学術集会)
竹内 裕, 品川 尚文, 小倉 粋, 河井 康孝, 伊藤 健一郎, 水柿 秀紀, 山田 範幸, 菊地 英毅, 菊地 順子, 小西 純, 井上 哲也, 加藤 徳雄, 鬼丸 力也, 白土 博樹, 大泉 聡史, 西村 正治, 気管支学 : 日本気管支研究会雑誌, 31, 0, S118, 2009年05月20日
日本呼吸器内視鏡学会, 日本語

放射線治療におけるFDG‐PETでのSUVと正確な標的体積設定への影響因子
藤野賢治, 田口大志, 加藤徳雄, 木下留美子, 鬼丸力也, 長谷川雅一, 溝口史樹, 青山英史, 白土博樹, 志賀哲, 玉木長良, 加藤千恵次, 梶智人, Radiat Med, 27, Supplement 1, 6, 2009年04月25日
日本語

放射線治療におけるFDG-PETでのSUVと正確な標的体積設定への影響因子　　　　　　　　　　　　　　　
藤野 賢治, 田口 大志, 加藤 徳雄, 木下 留美子, 鬼丸 力也, 長谷川 雅一, 溝口 史樹, 青山 英史, 白土 博樹, 志賀 哲, 玉木 長良, 加藤 千恵次, 梶 智人, Japanese Journal of Radiology, 27, Suppl., 6, 6, 2009年04月
(公社)日本医学放射線学会, 日本語

上咽頭癌における半導体PET画像を用いた放射線治療計画
加藤徳雄, 志賀哲, 長谷川雅一, 鬼丸力也, 安田耕一, 清水伸一, ベングア ジェラード, 石川正純, 玉木長良, 白土博樹, 日本医学放射線学会総会抄録集, 68th, S307-S308, S308, 2009年02月28日
(公社)日本医学放射線学会, 日本語

¹⁸F‐FMISO PETを用いたIMRT dose painting planの試み
安田耕一, 白土博樹, 岡本祥三, 志賀哲, SUTHERLAND Ken, 加藤徳雄, 長谷川雅一, 鬼丸力也, BENGUA Gerard, 石川正純, 日本医学放射線学会総会抄録集, 68th, S267, S267, 2009年02月28日
(公社)日本医学放射線学会, 日本語

Can the Real-time Tumor-tracking Radiotherapy Give the Planned Dose to the Tumor? DVH Analysis Based on Measured Real-time Tracking Data
M. Ishikawa, K. L. Sutherland, G. Bengua, R. Suzuki, N. Miyamoto, N. Katoh, S. Shimizu, R. Onimaru, H. Aoyama, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 75, 3, S590, S591, 2009年
英語, 研究発表ペーパー・要旨（国際会議）

Skull base MeningiomaにおけるIMRTの利用—当院治療成績を踏まえて—
小野寺俊輔, 白土博樹, 青山英史, 田口大志, 加藤徳雄, 木下留美子, 鬼丸力也, 清水伸一, 井上哲也, 安田耕一, 日本医学放射線学会秋季臨床大会抄録集, 44th, S521, S521, 2008年09月24日
(公社)日本医学放射線学会, 日本語

鼻腔/副鼻腔癌に対する超選択的動注を併用した根治的化学放射線療法の治療成績
長谷川雅一, 安田耕一, 吉田大介, 加藤徳雄, 鬼丸力也, 浅野剛, 白土博樹, 本間明宏, 折館伸彦, 福田諭, 日本放射線腫よう学会誌, 20, Supplement 1, 223, 2008年09月22日
日本語

当院における遠隔放射線治療の現状について
鈴木恵士郎, 木下留美子, 鬼丸力也, 安田耕一, 小野寺俊介, 加藤徳雄, 田口大志, 藤野賢治, 青山英史, 白上博樹, 宮坂和男, Radiat Med, 26, Suppl.I, 3, 3, 2008年04月25日
(公社)日本医学放射線学会, 日本語

北海道大学における非小細胞肺癌に対する体幹部定位放射線治療の治療成績
鬼丸力也, 加藤徳雄, 井上哲也, 田口大志, 清水伸一, 長谷川雅一*, 安田耕一, 小野寺俊輔, 木下留美子, 青山英史, 白土博樹, 日本放射線腫よう学会誌, 20, Supplement 1, 2008年

A new positron emission tomography with semiconductor detectors for target volume delineation and radiotherapy treatment planning in patients with nasopharyngeal carcinoma
N. Katoh, T. Shiga, M. Hasegawa, R. Onimaru, K. Yasuda, S. Shimizu, G. Bengua, M. Ishikawa, N. Tamaki, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72, 1, S589, S590, 2008年
英語, 研究発表ペーパー・要旨（国際会議）

定位放射線治療による予後改善に関する研究 T2N0M0非小細胞肺癌の体幹部放射線治療の線量増加試験に関する研究
白土博樹, 鬼丸力也, 田口大志, 加藤徳雄, 石川正純, 定位放射線治療による予後改善に関する研究 平成19年度 総括研究報告書, 9-10, 2008年
日本語

当院におけるMU値検証システムについて
鈴木恵士郎, 白土博樹, 青山英史, 鬼丸力也, 加藤徳雄, 田口大志, 藤野賢治, 吉田有里, 宮坂和男, 熊谷まなみ, 藤田勝久, Radiat Med, 25, Suppl.I, 8, 8, 2007年04月25日
(公社)日本医学放射線学会, 日本語

頭頸部癌のDOC併用放射線療法 副作用軽減を目的としたステロイド使用について　　　　　　　　　　　　　　　
小野寺 俊輔, 木下 留美子, 藤野 賢治, 加藤 徳雄, 田口 大志, 鬼丸 力也, 大阪 康博, 清水 伸一, 鈴木 恵士郎, 西岡 健, 白土 博樹, Radiation Medicine, 25, Suppl.I, 15, 15, 2007年04月
(公社)日本医学放射線学会, 日本語

腎・副腎腫瘍に対する動体追跡照射 技術的検討について　　　　　　　　　　　　　　　
加藤 徳雄, 芹澤 慈子, 白土 博樹, 鬼丸 力也, 大坂 康博, 鈴木 恵士郎, 渡辺 佳明, 阿保 大介, 清水 匡, 宮坂 和男, 清水 伸一, Radiation Medicine, 25, Suppl.I, 17, 17, 2007年04月
(公社)日本医学放射線学会, 日本語

動体追跡装置を用いた前立腺癌の放射線治療のPSA再発及び副作用発生率
大坂康博, 青山英史, 田口大志, 加藤徳雄, 木下留美子, 藤野賢治, 鬼丸力也, 鈴木恵士郎, 白土博樹, 日本医学放射線学会学術集会抄録集, 66th, S247, S247, 2007年02月28日
(公社)日本医学放射線学会, 日本語

多発肺腫瘍に対する3ケ月以内の連続した定位照射の安全性と有効性の検討
鬼丸力也, 藤野賢治, 田口大志, 加藤徳雄, 木下留美子, 安田耕一, 鈴木恵士郎, 白土博樹, 宮坂和男, 日本医学放射線学会学術集会抄録集, 66th, S233, S233, 2007年02月28日
(公社)日本医学放射線学会, 日本語

脳動静脈奇形定位照射におけるMR‐perfusionを用いた治療前後の血流動態の検討
芹澤慈子, THA Khin K, 青山英史, 工藤與亮, 加藤徳雄, 寺江聡, 白土博樹, 日本医学放射線学会学術集会抄録集, 66th, S225, S225, 2007年02月28日
(公社)日本医学放射線学会, 日本語

Feasibility study of real-time tumor-tracking radiotherapy for adrenal tumors: Three-dimensional movement of internal fiducial gold markers measured in supine and prone patient positions
N. Katoh, R. Onimaru, S. Shimizu, D. Abo, Y. Sakuhara, H. Taguchi, Y. Osaka, B. Gerard, M. Ishikawa, H. Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 69, 3, S675, S675, 2007年
英語, 研究発表ペーパー・要旨（国際会議）

CT FDG‐PET fusion imageの肺癌放射線治療計画への利用
藤野賢治, 田口大志, 加藤徳雄, 青山英史, 鈴木恵士郎, 鬼丸力也, 木下留美子, 安田耕一, 白土博樹, 加藤知恵次, 志賀哲, 玉木長良, 小野寺俊輔, 臨床放射線, 52, 1, 137, 144, 2007年
日本語

画像誘導放射線治療と強度変調放射線治療 (特集 Image-guided Radiotherapy--現状と将来)
鬼丸 力也, 藤野 賢治, 加藤 徳雄, 臨床放射線, 52, 8, 961, 966, 2007年
金原出版, 日本語, 書評論文,書評,文献紹介等

手術不能Stage I非小細胞肺癌に対する動体追跡照射のマージンと効果の探索的検討
鬼丸力也, 白土博樹, 藤野賢治, 田口大志, 加藤徳雄, 木下留美子, 鈴木恵士郎, 青山英史, 宮坂和男, 日本放射線腫よう学会誌, 18, Supplement 1, 217, 2006年10月25日
日本語

プラスチックシンチレーションファイバー検出器の応答特性に関する基礎的検討
笈田将皇, 石川正純, 藤野賢治, 加藤徳雄, 田口大志, 白土博樹, 渡辺良晴, 日本放射線腫よう学会誌, 18, Supplement 1, 199, 2006年10月25日
日本語

極微小プラスチックシンチレータを用いた水吸収線量測定法の開発
石川正純, 笈田将皇, 加藤徳雄, 藤野賢治, 大坂康博, 白土博樹, 日本放射線腫よう学会誌, 18, Supplement 1, 199, 2006年10月25日
日本語

膵癌に対する4次元強度変調放射線治療(4D‐IMRT)に向けての基礎的研究
安田耕一, 加藤徳雄, 青山英史, 田口大志, 藤野賢治, 木下留美子, 鬼丸力也, 鈴木恵士朗, 白土博樹, 宮坂和男, 日本放射線腫よう学会誌, 18, Supplement 1, 170, 2006年10月25日
日本語

【体幹部定位放射線治療】 動体追跡照射装置を用いた腹部臓器への迎撃照射　　　　　　　　　　　　　　　
鬼丸 力也, 田口 大志, 加藤 徳雄, 作原 祐介, 阿保 大介, 白土 博樹, 宮坂 和男, 臨床放射線, 51, 10, 1165, 1170, 2006年10月
金原出版(株), 日本語

前立腺癌における動体追跡装置を用いた尿道線量低減強度変調放射線治療の検討
大坂康博, 青山英史, 田口大志, 加藤徳雄, 木下留美子, 藤野賢治, 鬼丸力也, 鈴木恵士郎, 白土博樹, 宮坂和男, 日本医学放射線学会学術集会抄録集, 65th, S211, S211, 2006年02月25日
(公社)日本医学放射線学会, 日本語

Prediction of four-dimensional (4D) tumor response using finite element method (FEM) and radiobiological model for adaptive radiotherapy
H. Taguchi, S. Takao, Y. Kogure, H. Shirato, S. Tadano, K. Suzuki, R. Onimaru, N. Katoh, R. Kinoshita, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66, 3, S596, S596, 2006年
英語, 研究発表ペーパー・要旨（国際会議）

Challenges in the use of breath-hold (18)F-fluorodeoxyglucose positron emission tomography in real-time tumor-tracking radiotherapy in patients with lung cancer without atelectasis
M. Fujino, C. Katoh, T. Kaji, N. Kubo, N. Kato, S. Onodera, T. Shiga, H. Aoyama, H. Shirato, N. Tamaki, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 66, 3, S617, S618, 2006年
英語, 研究発表ペーパー・要旨（国際会議）

Intercepting irradiation for abdominal organ tumor using real time tracking radiation therapy (RTRT) system
Rikiya Onimaru, H. Taguchi, N. Katoh, Y. Sakuhara, D. Abo, H. Shirato, K. Miyasaka, Japanese Journal of Clinical Radiology, 51, 10, 1165, 1170, 2006年

放射線治療計画用分子イメージングシステムの肺癌放射線治療計画への初期利用経験
小野寺俊輔, 藤野賢治, 加藤徳雄, 青山英史, 西岡健, 白土博樹, 宮坂和男, 加藤千恵次, 志賀哲, 玉木長良, 日本放射線腫よう学会誌, 17, Supplement 1, 164, 164, 2005年10月25日
(公社)日本放射線腫瘍学会, 日本語

動体追跡照射装置を用いた迎撃照射
鬼丸力也, 藤野賢治, 田口大志, 加藤徳雄, 木下留美子, 鈴木恵士郎, 青山英史, 白土博樹, 日本放射線腫よう学会誌, 17, Supplement 1, 61, 61, 2005年10月25日
(公社)日本放射線腫瘍学会, 日本語

放射線治療計画用分子イメージングシステムの開発
藤野賢治, 加藤徳雄, 青山英史, 西岡健, 白土博樹, 加藤千恵次, 志賀哲, 玉木長良, 田口太志, 鬼丸力也, 日本放射線腫よう学会誌, 17, Supplement 1, 102, 102, 2005年10月25日
(公社)日本放射線腫瘍学会, 日本語

Estimation of dose distribution from the fluoroscopy in real-time tumor tracking radiotherapy (RTRT) for stereotactic body radiotherapy (SBRT)
M Oita, R Onimaru, K Suzuki, H Aoyama, M Fujino, N Kato, R Kinoshita, K Fujita, H Shirato, K Miyasaka, RADIOTHERAPY AND ONCOLOGY, 76, S147, S147, 2005年09月
英語, 研究発表ペーパー・要旨（国際会議）

聴神経腫瘍に対する定位分割照射の治療成績　　　　　　　　　　　　　　　
坂本 徹, 白土 博樹, 澤村 豊, 鈴木 恵士郎, 青山 英史, 加藤 徳雄, 定位的放射線治療, 9, 37, 44, 2005年08月
定位分割照射を行った聴神経腫瘍165例(男62例・女103例,中央値54歳)の成績を報告した.平均腫瘍径は照射前17.0mm,平均観察期間42ヵ月後13.9mmであった.2〜7年の累積腫瘍制御率は91.8%で,腫瘍増大を9例に認め,うち3例に手術,2例に追加照射を行った.累積腫瘍縮小率は3年で54%,7年で61.6%であった.腫瘍径25mm以上の31例では7年の累積腫瘍制御率90.5%,縮小率78.1%であった.腫瘍の性状別にみると,cystic typeは腫瘍制御率100%,縮小率88.6%で,solid typeは各々86.8%,56.6%と,縮小率に有意差を認めた.聴力検査の結果は,照射前が平均48.7dBで,照射1年後に10dB,5年で20.1dBの低下を認め,7年の累積聴力温存率は71.5%,保存率は56.3%であった.腫瘍縮小群は非縮小群に比較して聴力温存率が高い傾向であった.合併障害は三叉神経障害,めまいが9%,顔面神経麻痺が3%にみられたがいずれも一過性で,照射後にシャント手術を必要としたのは18例であった, 日本定位放射線治療学会, 日本語

定位放射線照射と4次元放射線治療
白土博樹, 加藤徳雄, 藤野賢治, 鬼丸力也, 宮坂和男, 画像診断, 25, 5, 640-646, 2005年04月25日
日本語

肺腫ようの胸部単純写真での存在部位から推定する通常の放射線治療でのinternal margin
鬼丸力也, 藤野賢治, 白土博樹, 鈴木恵士郎, 田口大志, 加藤徳雄, 木下留美子, 宮坂和男, 日本医学放射線学会学術集会抄録集, 64th, S344, 2005年02月25日
日本語

Long-term outcome of fractionated small-field irradiation (FSR) for vestibular schwannoma in patients followed for more than five years
N Katoh, T Sakamoto, H Aoyama, W Sakai, H Taguchi, K Suzuki, K Tsuchiya, S Fukuda, H Shirato, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63, 2, S264, S265, 2005年
英語, 研究発表ペーパー・要旨（国際会議）

Estimation of fluoroscopic dose in real-time tumor tracking radiotherapy (RTRT) using a commercial based radiotherapy planning system　　　　　　　　　　　　　　　
M.Oita, R Onimaru, K Suzuki, H Aoyama, M Fujino, N Kato, R Kinoshita, K Fujita, H Shirato, K Miyasaka, Radiotherapy and Oncology, 76, S2, 147, 147, 2005年

前立腺癌の動体追跡装置を用いた尿道線量低減強度変調放射線治療
大坂康博, 青山英史, 鬼丸力也, 田口大志, 木下留美子, 加藤徳雄, 鈴木恵士郎, 白土博樹, 宮坂和男, 日本放射線腫よう学会誌, 16, Supplement 1, 91, 2004年11月
日本語

脊髄原発gliomaに対する放射線治療
加藤徳雄, 白土博樹, 青山英史, 鬼丸力也, 飛騨一利, 岩崎喜信, 宮坂和男, 日本放射線腫よう学会誌, 16, Supplement 1, 106, 2004年11月
日本語

Methionine PET in differentiating recurrent brain tumor from radiation necrosis following cranial radiation
N Katoh, K Nakada, T Takei, H Aoyama, H Shirato, C Katoh, Y Kuge, E Tsukamoto, N Tamaki, PET AND MOLECULAR IMAGING: STATE OF THE ART AND FUTURE PERSPECTIVES, 1264, 217, 221, 2004年
英語

Methionine PET in differentiating recurrent brain tumor from radiation necrosis following cranial radiation therapy.
K Nakada, N Katoh, N Takei, H Aoyama, H Shirato, C Katoh, Y Kuge, F Yamamoto, E Tsukamoto, N Tamaki, JOURNAL OF NUCLEAR MEDICINE, 44, 5, 244P, 245P, 2003年05月
英語, 研究発表ペーパー・要旨（国際会議）

肺非小細胞癌における肺腫瘍・脳転移に対する定位放射線照射(第46回肺癌学会北海道支部会 北海道支部 支部活動)
加藤 徳雄, 青山 英史, 鬼丸 力也, 白土 博樹, 宮坂 和男, 原田 敏之, 木下 一郎, 山崎 浩一, 西村 正治, 秋田 弘俊, 肺癌, 43, 1, 72, 73, 2003年02月20日
日本肺癌学会, 日本語

心肺停止に陥った冠攣縮性狭心症症例の蘇生後I-123 metaiodobenzylguanidine(MIBG)心筋シンチグラフィーの検討
大山 徳子, 大山 尚貢, 尾崎 威文, 高木 千佳, 岡田 斉, 佐藤 勝彦, 加藤 法喜, 林 俊之, 加藤 徳雄, 阿保 大介, 久保 公三, 宮崎 知保子, 市立札幌病院医誌, 60, 2, 165, 168, 2000年12月
心肺停止後蘇生され,心肺停止の原因が心原性と考えられ,かつ急性冠症候群と診断した11例を,急性心筋梗塞群(5例)と冠攣縮性狭心症群(6例)に分類し,MIBG心筋シンチグラフィー所見を比較検討した.MIBGは15分後(初期)像において左心部(H)と上縦隔(M)に関心領域を設定し,H/M比をMIBG取り込みの指標とした.冠攣縮性狭心症群の平均H/M比は2.217±0.306,急性心筋梗塞群の平均H/M比は1.590±0.299で冠攣縮性狭心症群で有意に取り込みが多かった, 市立札幌病院, 日本語

Stereotactic Body Radiation Therapy　　　　　　　　　　　　　　　
Editor Yasushi Nagata, Chapter 17 Real-Time Tumor-Tracking Radiotherapy (RTRT), SyncTraX
Springer Singapore, 2023年10月, 9789819939787, ［分担執筆］

免疫チェックポイント阻害薬と放射線治療—Clinical evidences for the combination of immune checkpoint inhibitor and radiation therapy—特集 がん免疫療法の展望 : 免疫チェックポイント阻害薬の併用療法に中心に ; 免疫チェックポイント阻害薬の併用療法のエビデンス
安田 耕一, 志藤 元泰, 小泉 富基, 高橋 周平, 藤田 祥博, 大塚 愛美, 宮﨑 智彦, 西川 昇, 打浪 雄介, 森 崇, 西岡 健太郎, 木下 留美子, 田口 大志, 加藤 徳雄, 橋本 孝之, 青山 英史
2022年07月, 日本語

再照射 小児がんに対する陽子線再照射
橋本 孝之, 森 崇, 西岡 健太郎, 打浪 雄介, 安田 耕一, 木下 留美子, 田口 大志, 加藤 徳雄, 清水 伸一, 青山 英史
(一社)日本小児血液・がん学会, 2021年08月, 日本語

SMARCB1欠損篩骨洞癌に対する強度変調陽子線治療 症例報告と文献レビュー　　　　　　　　　　　　　　　
宮崎 智彦, 安田 耕一, 志藤 元泰, 小泉 富基, 藤田 祥博, 高橋 周平, 湊川 英樹, 大塚 愛美, 加藤 徳雄, 清水 伸一, 青山 英史
(NPO)メディカルイメージラボ, 2021年03月, 日本語

S-1併用陽子線治療後conversion surgeryを行った切除不能局所進行膵癌の1例:症例報告と文献レビュー　　　　　　　　　　　　　　　
小泉富基, 加藤徳雄, 中村透, 川本泰之, 高尾聖心, 阿保大介, 清水伸一, 清水伸一, 青山英史
2021年, 日本語, ［査読有り］

肝細胞癌の陽子線治療
加藤徳雄
2017年06月30日, 日本語

肝癌に対する定位放射線治療と陽子線治療 (特集 放射線科診療における肝臓がんの最新の画像診断と治療)
加藤 徳雄
金原出版, 2017年04月, 日本語

【呼吸性移動対策の今後-光子線治療から粒子線治療まで-】 次世代型動体追跡放射線治療システムの臨床応用と今後の展望
宮本 直樹, 石川 正純, 井上 哲也, 加藤 徳雄, 清水 伸一, 鬼丸 力也, 白土 博樹
金原出版(株), 2016年02月, 日本語

放射線治療のいま : 各がん腫におけるエビデンスと標準治療(5)体幹部定位放射線治療
加藤 徳雄
ヴァン・メディカル, 2015年, 日本語

【放射線治療活用BOOK 2014】 (DIVISION-3)これからの放射線治療の展望 最新の動体追跡放射線治療装置　　　　　　　　　　　　　　　
宮本 直樹, 石川 正純, 松浦 妙子, 井上 哲也, 加藤 徳雄, 清水 伸一, 鬼丸 力也, 梅垣 菊男, 白土 博樹
(株)メディカルアイ, 2014年12月, 日本語

【高精度放射線治療における呼吸性移動対策のコツとピットフォール】 RTRTによる呼吸性移動対策 有用性と今後の展望　　　　　　　　　　　　　　　
宮本 直樹, 石川 正純, 井上 哲也, 加藤 徳雄, 清水 伸一, 鬼丸 力也, 白土 博樹
(株)メディカルアイ, 2014年02月, 日本語

臨床 動体追跡放射線治療10年の経験 (特集 放射線治療の現在)
加藤 徳雄, 鬼丸 力也, 田口 大志
産業開発機構, 2009年11月, 日本語

[非小細胞肺癌]画像誘導放射線治療と強度変調放射線治療
白土博樹, 鬼丸力也, 石川正純, 田口大志, 加藤徳雄, 清水伸一
2008年03月31日, 日本語

放射線治療効果の向上を目指した新手法開発とその臨床応用 動体追跡照射装置を用いた放射線治療
鬼丸 力也, 白土 博樹, 藤野 賢治, 田口 大志, 加藤 徳雄, 大坂 康博, 清水 伸一, 青山 英史, 鈴木 恵士郎
(一社)日本放射線影響学会, 2005年11月, 英語

大腸癌肝転移の粒子線レジストリ解析とシステマチックレビュー　　　　　　　　　　　　　　　
福光 延吉, 柴 慎太郎, 渋谷 圭, 小林 大二郎, 宮坂 勇平, 山口 久志, 沼尻 晴子, 若月 優, 辻 比呂志, 荻野 浩幸, 加藤 徳雄, 手良向 聡, 中田 美津子, 万代 昌紀, 吉野 孝之
日本癌治療学会学術集会抄録集, 2024年10月, (一社)日本癌治療学会, 英語
2024年10月 - 2024年10月

当院における仙骨脊索腫に対する陽子線治療の後方視的検討　　　　　　　　　　　　　　　
檜垣 朔, 田口 大志, 宮崎 智彦, 森 崇, 西岡 健太郎, 加藤 徳雄, 橋本 孝之, 田村 昌也, 高尾 聖心, 松浦 妙子, 青山 英史
日本医学放射線学会秋季臨床大会抄録集, 2024年09月, (公社)日本医学放射線学会, 日本語
2024年09月 - 2024年09月

持続可能な膵がん教室にするための現状と課題
田辺 睦子, 中村 透, 寺澤 孝男, 伊藤 元, 白岩 剛, 川本 泰之, 桑谷 将城, 加藤 徳雄, 浅野 賢道, 山田 眞佐美, 池澤 賢治, 安保 義恭, 潟沼 朗生, 平手 大輔
膵臓, 2024年07月, (一社)日本膵臓学会, 日本語
2024年07月 - 2024年07月

膵癌に対する動体追跡放射線治療用の経皮的あるいは経動脈的マーカー留置術の検討　　　　　　　　　　　　　　　
加藤 大祐, 阿保 大介, 森田 亮, 打浪 雄介, 加藤 徳雄, 山田 亮太, 木野田 直也, 藤井 宝顕, 山崎 康之, 高柳 歩, 青山 英史, 工藤 與亮
日本インターベンショナルラジオロジー学会雑誌, 2024年04月, (一社)日本インターベンショナルラジオロジー学会, 日本語
2024年04月 - 2024年04月

胸部食道がん化学放射線療法における重症放射線食道炎に関する後方視的研究
原田 一顕, 中村 赳晶, 渡辺 亮介, 山村 貴洋, 結城 敏志, 坂本 直哉, 川本 泰之, 小松 嘉人, 打浪 雄介, 田口 大志, 加藤 徳雄, 青山 英史
北海道医学雑誌, 2023年11月, 北海道医学会, 日本語
2023年11月 - 2023年11月

体幹部定位放射線治療時の呼気止め分割CBCTにおける呼吸再現性と輪郭の評価　　　　　　　　　　　　　　　
山田 亮太, 吉村 高明, 一宇 佑太, 若林 倭, 松尾 勇斗, 孫田 惠一, 加藤 徳雄
日本放射線技術学会総会学術大会予稿集, 2023年03月, (公社)日本放射線技術学会, 日本語
2023年03月 - 2023年03月

肝細胞癌陽子線治療効果予測におけるADC値指標の検討　　　　　　　　　　　　　　　
藤田 祥博, 加藤 徳雄, 打浪 雄介, 田口 大志, 西岡 健太郎, 森 崇, 安田 耕一, 小泉 富基, 大塚 愛美, 高尾 聖心, 田村 昌也, Sutherland Kenneth, Khin Khin Tha, 伊藤 陽一, 青山 英史
Japanese Journal of Radiology, 2023年02月, (公社)日本医学放射線学会, 日本語
2023年02月 - 2023年02月

内科・外科による消化器病共同診療の現況と展望 当科における切除可能境界膵癌に対する術前治療の現状　　　　　　　　　　　　　　　
原田 一顕, 中村 赳晶, 渡辺 亮介, 山村 貴洋, 川本 泰之, 結城 敏志, 桑谷 将城, 田口 大志, 加藤 徳雄, 浅野 賢道, 中村 透, 平野 聡, 小松 嘉人, 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2022年09月, 日本消化器病学会-北海道支部, 日本語
2022年09月 - 2022年09月

根治的化学放射線療法を施行した非小細胞肺癌症例の検討　　　　　　　　　　　　　　　
高階 力也, 田口 大志, 打浪 雄介, 加藤 徳雄, 青山 英史
Japanese Journal of Radiology, 2022年02月, (公社)日本医学放射線学会, 日本語
2022年02月 - 2022年02月

S-1併用陽子線治療後conversion surgeryを行った切除不能局所進行膵癌の1例　　　　　　　　　　　　　　　
小泉 富基, 加藤 徳雄, 打浪 雄介, 田口 大志, 青山 英史, 清水 伸一, 中村 透, 川本 泰之, 高尾 聖心, 田村 昌也, 松浦 妙子, 清水 伸一
Japanese Journal of Radiology, 2022年02月, (公社)日本医学放射線学会, 日本語
2022年02月 - 2022年02月

尿量の経日変化および前立腺体積が放射線治療時の前立腺の位置に与える影響(The Impact of Daily Urinary Volume Variations and Prostate Volume on Prostate Position During Radiotherapy)　　　　　　　　　　　　　　　
Nishioka Kentaro, Hashimoto Takayuki, Yokota Isao, Katoh Norio, Kinoshita Rumiko, Yasuda Koichi, Takao Seishin, Yoshimura Takaaki, Aoyama Hidefumi, Shimizu Shinichi
日本医学放射線学会学術集会抄録集, 2021年03月, (公社)日本医学放射線学会, 英語
2021年03月 - 2021年03月

The Impact of Daily Urinary Volume Variations and Prostate Volume on Prostate Position During Radiotherapy(和訳中)　　　　　　　　　　　　　　　
Nishioka Kentaro, Hashimoto Takayuki, Yokota Isao, Katoh Norio, Kinoshita Rumiko, Yasuda Koichi, Takao Seishin, Yoshimura Takaaki, Aoyama Hidefumi, Shimizu Shinichi
日本医学放射線学会学術集会抄録集, 2021年03月, (公社)日本医学放射線学会, 英語
2021年03月 - 2021年03月

動体追跡陽子線照射における気管支内視鏡的放射線治療用マーカー留置術の検討
伊藤 祥太郎, 品川 尚文, 高島 雄太, 國崎 守, 古田 恵, 水柿 秀紀, 朝比奈 肇, 菊地 英毅, 菊地 順子, 榊原 純, 加藤 徳雄, 田口 大志, 青山 英史, 今野 哲
気管支学, 2020年11月, (NPO)日本呼吸器内視鏡学会, 日本語
2020年11月 - 2020年11月

Automatic Bladder Delineation on MR Images Using a Convolution Neural Network for Online Image-Guided Radiotherapy
K. Nishioka, Y. Nomura, T. Hashimoto, R. Kinoshita, N. Katoh, H. Taguchi, K. Yasuda, T. Mori, Y. Uchinami, M. Otsuka, T. Matsuura, S. Takao, R. Suzuki, S. Tanaka, T. Yoshimura, H. Aoyama, S. Shimizu
International Journal of Radiation Oncology*Biology*Physics, 2020年11月, Elsevier BV
2020年11月 - 2020年11月

局所進行食道癌に対してspot scanning法による根治的化学陽子線療法を施行した一例　　　　　　　　　　　　　　　
宮崎 智彦, 打浪 雄介, 田口 大志, 加藤 徳雄, 清水 伸一, 白土 博樹, 中積 宏之, 中野 真太郎, 坂本 直哉, 高尾 聖心, 田村 昌也, 松浦 妙子
日本医学放射線学会秋季臨床大会抄録集, 2019年09月, (公社)日本医学放射線学会, 日本語
2019年09月 - 2019年09月

Prognosis after Local Recurrence or Metastases in Medically Operable Stage I Non-Small Cell Lung Cancer Patients Treated By Stereotactic Body Radiotherapy
H. Onishi, Y. Shioyama, Y. Matsuo, K. Takayama, A. Miyakawa, H. Yamashita, T. Nomiya, Y. Matsumo, H. Matsushita, T. Kimura, N. Murakami, H. Ishiyama, T. Uno, T. Takanaka, N. Katoh, A. Takeda, K. Nakata, K. Ogawa, K. Nihei, M. Aoki, K. Kuriyama, T. Komiyama, K. Marino, M. Araya, S. Aoki, R. Saito, Y. Maehata, R. Tominaga, H. Nonaka, M. Oguri, M. Matsuda, T. Yamada, T. Akita, M. Hiraoka
International Journal of Radiation Oncology*Biology*Physics, 2019年09月, Elsevier BV, 英語
2019年09月 - 2019年09月

Multicenter Prospective Study of Stereotactic Body Radiotherapy for Untreated Solitary Primary Hepatocellular Carcinoma: The STRSPH Study
T. Kimura, A. Takeda, S. Ishikura, K. Ariyoshi, T. Yamaguchi, T. Imagumbai, N. Katoh, T. Eriguchi, Y. Oku, S. Ozawa, Y. Tsurugai, M. Kokubo, S. Shimizu
International Journal of Radiation Oncology*Biology*Physics, 2019年09月, Elsevier BV, 英語
2019年09月 - 2019年09月

Initial Clinical Outcomes of Real-Time-Image Gated Spot-Scanning Proton Beam Therapy for Hepatocellular Carcinomas
N. Katoh, Y. Uchinami, D. Abo, S. Takao, T. Inoue, H. Taguchi, R. Morita, T. Soyama, T. Hashimoto, R. Onimaru, A. Prayongrat, M. Tamura, T. Matsuura, S. Shimizu, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 2019年09月, Elsevier BV, 英語
2019年09月 - 2019年09月

Big Data Analysis of Treatment Process Time for the Real-Time-Image Gated-Spot-Scanning Proton-Beam Therapy (RGPT) System
T. Yoshimura, S. Shimizu, T. Hashimoto, N. Katoh, T. Inoue, K. Nishioka, T. Matsuura, S. Takao, M. Tamura, H. Tamura, K. Horita, K. Umegaki, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 2018年11月, Elsevier BV, 英語
2018年11月 - 2018年11月

Uncertainties of Normal Tissue Complication Probability (NTCP) and NTCP Difference between Radiation Treatment Modalities for Radiation-Induced Liver Toxicity in Child-Pugh A Primary Liver Cancer Patients
A. Prayongrat, K. Kobashi, Y. Ito, N. Katoh, Y. Dekura, N. Amornwichet, S. Shimizu, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 2018年11月, Elsevier BV, 英語
2018年11月 - 2018年11月

Analysis of Beam Delivery Times and Dose Rates for the Treatment of Mobile Tumors Using Real Time Image Gated Spot-Scanning Proton Beam Therapy
S. Shimizu, T. Yoshimura, N. Katoh, T. Inoue, T. Hashimoto, K. Nishioka, S. Takao, T. Matsuura, N. Miyamoto, Y.M. Ito, K. Umegaki, H. Shirato
International Journal of Radiation Oncology*Biology*Physics, 2018年11月, Elsevier BV, 英語
2018年11月 - 2018年11月

肝腫瘍に対する動態追跡照射のための経皮的マーカ留置　　　　　　　　　　　　　　　
森田 亮, 曽山 武士, 阿保 大介, 作原 祐介, 工藤 與亮, 加藤 徳雄, 白土 博樹
IVR: Interventional Radiology, 2017年07月, 日本語

甲状腺癌分化癌の骨転移に対するIMRTを含めた外照射の治療成績　　　　　　　　　　　　　　　
安田 耕一, 加藤 徳雄, 岡本 祥三, 木下 留美子, 志賀 哲, 水町 貴諭, 畠山 博充, 本間 明宏, 田口 純, 清水 康, 森 崇, 土屋 和彦, 白土 博樹
頭頸部癌, 2017年05月, 日本語

肝腫瘍に対する動態追跡照射のための経皮的マーカ留置(Percutaneous hepatic fiducial marker implantation for Real-time Tumor-tracking Radiotherapy(RTRT))　　　　　　　　　　　　　　　
森田 亮, 作原 祐介, 曽山 武士, 阿保 大介, 加藤 徳雄, 工藤 與亮, 白土 博樹
IVR: Interventional Radiology, 2017年04月, 英語

Clinical application for molecular imaging(Therapy) 分子イメージングを用いた放射線治療　　　　　　　　　　　　　　　
安田 耕一, 岡本 祥三, 西川 由記子, 伊藤 陽一, 志賀 哲, 井上 哲也, 森 崇, 豊永 拓哉, 鬼丸 力也, 渡邊 史郎, 土屋 和彦, 竹内 渉, 加藤 徳雄, 久下 裕司, 玉木 長良, 白土 博樹
JSMI Report, 2016年04月, 日本語

Treatment Time and Dose Rate Analysis for Respiratory Moving Liver Tumor Using Real-time-image Gated Spot Scanning Proton Beam Therapy System
SHIMIZU Shinichi, KATOH Norio, TAKAO Seishin, MATSUURA Taeko, MIYAMOTO Naoki, HASHIMOTO Takayuki, NISHIOKA Kentaro, YOSHIMURA Takaaki, UMEGAKI Kikuo, SHIRATO Hiroki
日本医学放射線学会総会抄録集, 2016年02月29日, 英語

18F-fluoromisonidazole PET/CT for Stage I Non-Small Cell Lung Cancer Treated by Stereotactic Body Radiotherapy
INOUE Tetsuya, OKAMOTO Shozo, WATANABE Shiro, YASUDA Koichi, KATOH Norio, HARADA Keiichi, SHIGA Toru, TAMAKI Nagara, KUGE Yuji, SHIRATO Hiroki
日本医学放射線学会総会抄録集, 2016年02月29日, 英語

Spot-scanning proton beam therapy (SSPT) with or without the use of a real-time tumor-tracking function: Clinical Experience
KATOH Norio, SHIMIZU Shinichi, NISHIOKA Kentaro, HASHIMOTO Takayuki, INOUE Tetsuya, MATSUURA Taeko, SEISHIN Takao, ONIMARU Rikiya, UMEGAKI Kikuo, SHIRATO Hiroki
日本医学放射線学会総会抄録集, 2016年02月29日, 英語

Stereotactic Body Radiation Therapy and Proton Beam Therapy for Hepatocellular Carcinoma
KATOH Norio
日本医学放射線学会総会抄録集, 2016年02月29日, 英語

照射中と4DCT撮像時の肺内マーカー移動の比較　　　　　　　　　　　　　　　
原田 慶一, 加藤 徳雄, 井上 哲也, 鬼丸 力也, 清水 伸一, 白土 博樹, 鈴木 隆介, 宮本 直樹, 石川 正純
Japanese Journal of Radiology, 2016年02月, 日本語

椎体IMRTとその精度に関する研究　　　　　　　　　　　　　　　
安田 耕一, 清水 伸一, 橋本 孝之, Sutherland Ken, 白土 博樹, 土屋 和彦, 加藤 徳雄, 鬼丸 力也, 木下 留美子, 井上 哲也, 西岡 健太郎, 西川 由記子, 森 崇, 原田 慶一, 原田 八重, 鈴木 隆介, 寅松 千枝, 松浦 妙子, 高尾 聖心, 宮本 直樹, 伊藤 陽一
Japanese Journal of Radiology, 2016年02月, 日本語

Real-time-image gated proton beam therapy (RGPT) for cancer
SHIRATO Hiroki, SHIRATO Hiroki, SHIRATO Hiroki, SHIMIZU Shinichi, SHIMIZU Shinichi, SHIMIZU Shinichi, ONIMARU Rikiya, ONIMARU Rikiya, HASHIMOTO Takayuki, HASHIMOTO Takayuki, TSUCHIYA Kazuhiko, KATOH Norio, KATOH Norio, INOUE Tetsuya, INOUE Tetsuya
日本癌治療学会学術集会(Web), 2016年, 英語

食道癌術後/化学放射線療法後再発に対する化学放射線療法の成績　　　　　　　　　　　　　　　
井上 哲也, 原田 慶一, 加藤 徳雄, 清水 伸一, 白土 博樹, 中積 宏之, 福島 拓, 小松 嘉人, 海老原 裕磨, 七戸 俊明
北海道医学雑誌, 2015年11月, 日本語

当院における悪性胸膜中皮腫27例の検討
菊池 創, 朝比奈 肇, 榊原 純, 品川 尚文, 大泉 聡史, 樋田 泰浩, 加賀基 知三, 井上 哲也, 加藤 徳雄, 西村 正治
肺癌, 2015年02月20日, The Japan Lung Cancer Society, 日本語
2015年02月20日 - 2015年02月20日

4DCTを用いた肺内マーカー移動の解析　　　　　　　　　　　　　　　
加藤 徳雄, 原田 慶一, 鈴木 隆介, 井上 哲也, 鬼丸 力也, 清水 伸一, 宮本 直樹, 白土 博樹
Japanese Journal of Radiology, 2015年02月, 日本語

局所進行食道癌に対する強度変調放射線治療を用いた放射線化学療法の経験　　　　　　　　　　　　　　　
井上 哲也, 加藤 徳雄, 清水 伸一, 白土 博樹, 鈴木 隆介, 佐々木 尚英, 福島 拓, 小松 嘉人
北海道外科雑誌, 2014年12月, 日本語

肝臓への放射線治療用病変識別マーカー留置　　　　　　　　　　　　　　　
作原 祐介, 阿保 大介, 曽山 武士, 安井 太一, 寺江 聡, 加藤 徳雄, 白土 博樹
IVR: Interventional Radiology, 2014年12月, 日本語

Chemoradiation therapy using intensity-modulated radiation therapy for locally advanced esophageal carcinoma
INOUE Tetsuya, KATOH Norio, SHIMIZU Shinichi, SUZUKI Ryusuke, SASAKI Takahide, FUKUSHIMA Hiraku, KOMATSU Yoshito, SHIRATO Hiroki
日本医学放射線学会総会抄録集, 2014年02月28日, 英語

放射線治療に関する名称付けルール
安田耕一, 土屋和彦, 井上哲也, 西岡健太郎, 原田慶一, 西川由記子, 鬼丸力也, 清水伸一, 加藤徳雄, 木下留美子, 小野寺俊介, 白土博樹, 鈴木隆介, 藤田勝久, 辻真太郎, 山崎理衣
Jpn J Radiol, 2014年02月25日, (公社)日本医学放射線学会, 日本語
2014年02月25日 - 2014年02月25日

放射線療法に関する名付けルール(Naming rule for radiation therapy)　　　　　　　　　　　　　　　
安田 耕一, 土屋 和彦, 井上 哲也, 西岡 健太郎, 原田 慶一, 西川 由記子, 鬼丸 力也, 清水 伸一, 加藤 徳雄, 木下 留美子, 小野寺 俊介, 白土 博樹, 鈴木 隆介, 藤田 勝久, 辻 真太郎, 山崎 理衣
Japanese Journal of Radiology, 2014年02月, 日本語

北海道大学病院における髄膜腫に対する強度変調放射線治療(IMRT)の初期成績　　　　　　　　　　　　　　　
西川 由記子, 原田 慶一, 西岡 健太郎, 安田 耕一, 井上 哲也, 土屋 和彦, 小野寺 俊輔, 木下 留美子, 加藤 徳雄, 清水 伸一, 鬼丸 力也, 白土 博樹, 鈴木 隆介, 石川 正純
Japanese Journal of Radiology, 2014年02月, 日本語

当院における悪性胸膜中皮腫27例の検討　　　　　　　　　　　　　　　
菊池 創, 朝比奈 肇, 北井 秀典, 池澤 靖元, 高階 太一, 品川 尚文, 榊原 純, 大泉 聡史, 西村 正治, 樋田 泰浩, 加賀 基知三, 井上 哲也, 加藤 徳雄
肺癌, 2013年12月, (NPO)日本肺癌学会, 日本語
2013年12月 - 2013年12月

局所進行食道癌に対する通常照射と強度変調放射線治療を組み合わせた放射線化学療法　　　　　　　　　　　　　　　
井上 哲也, 加藤 徳雄, 清水 伸一, 白土 博樹, 鈴木 隆介, 佐々木 尚英, 福島 拓, 小松 嘉人
北海道外科雑誌, 2013年12月, 日本語

悪性胸膜中皮腫に対する病理診断と治療戦略 当院における悪性胸膜中皮腫27例の検討　　　　　　　　　　　　　　　
菊池 創, 朝比奈 肇, 北井 秀典, 池澤 靖元, 高階 太一, 品川 尚文, 榊原 純, 大泉 聡史, 樋田 泰浩, 加賀 基知三, 井上 哲也, 加藤 徳雄, 西村 正治
肺癌, 2013年10月, 日本語

照射前FMISO-PETの集積部位と照射後再発の位置関係　　　　　　　　　　　　　　　
安田 耕一, 土屋 和彦, 岡本 祥三, 鬼丸 力也, 志賀 哲, 加藤 徳雄, 原田 慶一, 久下 裕司, 玉木 長良, 白土 博樹
日本医学放射線学会学術集会抄録集, 2013年02月, 日本語

肝臓への放射線治療用病変識別マーカー留置　　　　　　　　　　　　　　　
作原 祐介, 阿保 大介, 加藤 徳雄, 田口 大志, 曽山 武士, 白土 博樹
日本医学放射線学会学術集会抄録集, 2013年02月, 日本語

原発性肺癌に対する動体追跡照射を用いた体幹部定位放射線治療　　　　　　　　　　　　　　　
井上 哲也, 加藤 徳雄, 鬼丸 力也, 榊原 純, 品川 尚文, 大泉 聡史, 鈴木 隆介, 白土 博樹
日本医学放射線学会学術集会抄録集, 2013年02月, 日本語

北海道大学病院における上咽頭癌の治療:―10年間 (2000～2010) のまとめ―
土屋 和彦, 安田 耕一, 西川 由記子, 木下 留美子, 鬼丸 力也, 原田 慶一, 井上 哲也, 加藤 徳雄, 清水 伸一, 白土 博樹, 西岡 健, 鈴木 恵士郎, 田口 大志, 長谷川 雅一, 折舘 伸彦, 本間 明宏, 鈴木 清護, 畠山 博充, 加納 里志, 水町 貴諭, 坂下 智博, 福田 諭, 竹内 啓, 田口 純
耳鼻咽喉科展望, 2013年, 日本語

Real-time Tumor-tracking Radiation Therapy for Lymphoma of the Stomach
N. Katoh, R. Suzuki, S. Shimizu, T. Inoue, K. Yasuda, R. Onimaru, R. Kimura, M. Kato, M. Ishikawa, H. Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012年11月, 英語
2012年11月 - 2012年11月

低酸素イメージングと放射線治療(Hypoxia imaging and Radiation therapy)　　　　　　　　　　　　　　　
安田 耕一, 鬼丸 力也, 岡本 祥三, 志賀 哲, 加藤 徳雄, 玉木 長良, 白土 博樹
日本癌学会総会記事, 2012年08月, 英語

リンフォーマの画像診断と新規治療のプラクティス 皮膚悪性リンパ腫に対する放射線治療　　　　　　　　　　　　　　　
鬼丸 力也, 清水 伸一, 土屋 和彦, 加藤 徳雄, 木下 留美子, 井上 哲也, 小野寺 俊輔, 安田 耕一, 西岡 健太郎, 白土 博樹
日本皮膚悪性腫瘍学会学術大会プログラム・抄録集, 2012年06月, 日本語

末梢肺におけるディスポーザブルゴールドマーカーによる金球留置の成績　　　　　　　　　　　　　　　
小倉 粋, 品川 尚文, 池澤 靖元, 高階 太一, 水柿 秀紀, 山田 範幸, 朝比奈 肇, 榊原 純, 井上 哲也, 加藤 徳雄, 鬼丸 力也, 白戸 博樹, 大泉 聡史, 西村 正治
気管支学, 2012年05月, 日本語

放射線を利用した画像診断・治療の最前線 先進的放射線治療におけるPETの役割　　　　　　　　　　　　　　　
加藤 徳雄, 鬼丸 力也, 安田 耕一, 志賀 哲, 土屋 和彦, 岡本 祥三, 玉木 長良, 白土 博樹
日本薬学会年会要旨集, 2012年03月, 日本語

胃MALTリンパ腫に対する動体追跡照射の経験　　　　　　　　　　　　　　　
米山 理奈, 安田 耕一, 加藤 徳雄, 鬼丸 力也, 白土 博樹
Japanese Journal of Radiology, 2012年02月, 日本語

北海道大学病院における乳房外Paget病の放射線治療経験　　　　　　　　　　　　　　　
原田 慶一, 木下 留美子, 加藤 徳雄, 西岡 健太郎, 清水 伸一, 鬼丸 力也, 白土 博樹
日本医学放射線学会学術集会抄録集, 2012年02月, 日本語

胃悪性リンパ腫に対する迎撃照射とマーカー移動の解析　　　　　　　　　　　　　　　
加藤 徳雄, 鈴木 隆介, 井上 哲也, 安田 耕一, 鬼丸 力也, 清水 伸一, 木村 理奈, 石川 正純, 白土 博樹
日本医学放射線学会学術集会抄録集, 2012年02月, 日本語

A new brain positron emission tomography scanner with semiconductor detectors for target volume delineation and radiotherapy treatment planning in patients with nasopharyngeal carcinoma
KATOH Norio, YASUDA Koichi, HASEGAWA Masakazu, ONIMARU Rikiya, SHIMIZU Shinichi, SHIRATO Hiroki, SHIGA Tohru, TAMAKI Nagara, BENGUA Gerard, ISHIKAWA Masayori
Int J Radiat Oncol Biol Phys, 2012年, 英語

食道癌IMRT(強度変調放射線治療)の初期経験　　　　　　　　　　　　　　　
原田 慶一, 井上 哲也, 安田 耕一, 加藤 徳雄, 清水 伸一, 白土 博樹, Bengua Gerard, 石川 正純, 中積 宏之, 結城 敏志, 小松 嘉人
北海道外科雑誌, 2011年12月, 日本語

当院における緩和的放射線治療の実際　　　　　　　　　　　　　　　
照井 健, 平山 泰生, 小池 和彦, 日下部 俊朗, 中島 信久, 鬼丸 力也, 井上 哲也, 加藤 徳雄, 石谷 邦彦
日本癌治療学会誌, 2011年09月, 日本語

O3-4 EBUS-GS併用経気管支鏡下生検にて診断し動体追跡放射線照射にて治療した末梢小型肺癌の検討(インターベンション/動体追跡照射,一般口演3,第34回日本呼吸器内視鏡学会学術集会)
竹内 裕, 品川 尚文, 池澤 靖元, 高階 太一, 小倉 粋, 水柿 秀紀, 山田 範幸, 朝比奈 肇, 榊原 純, 加藤 徳雄, 鬼丸 力也, 白土 博樹, 大泉 聡史, 西村 正治
気管支学 : 日本気管支研究会雑誌, 2011年05月20日, 日本語

EBUS-GS併用経気管支鏡下生検にて診断し動体追跡放射線照射にて治療した末梢小型肺癌の検討　　　　　　　　　　　　　　　
竹内 裕, 品川 尚文, 池澤 靖元, 高階 太一, 小倉 粋, 水柿 秀紀, 山田 範幸, 朝比奈 肇, 榊原 純, 加藤 徳雄, 鬼丸 力也, 白土 博樹, 大泉 聡史, 西村 正治
気管支学, 2011年05月, 日本語

乳房温存療法後局所再発症例の検討　　　　　　　　　　　　　　　
木下 留美子, 清水 伸一, 土屋 和彦, 加藤 徳雄, 田口 大志, 高橋 将人, 高橋 弘昌, 白土 博樹
日本医学放射線学会秋季臨床大会抄録集, 2010年08月, 日本語

口唇癌の放射線治療のretrospective study
香泉和寿, 安田耕一, 長谷川雅一, 鬼丸力也, 清水伸一, 木下留美子, 井上哲也, 加藤徳雄, 小野寺俊輔, 田口大志, 溝口史樹, 青山英史, 白土博樹, 西岡健, 武島嗣英
Jpn J Radiol, 2010年07月25日, (公社)日本医学放射線学会, 日本語
2010年07月25日 - 2010年07月25日

H&N癌のための18F‐フルオロミソニダゾールPETの影響とIMRTへの適用
安田耕一, 長谷川雅一, 鬼丸力也, 木下留美子, 加藤徳雄, 田口大志, 清水伸一, 井上哲也, 小野寺俊輔, 溝口史樹, 青山英史, 白土博樹, 志賀哲, 岡本祥三, 玉木長良, 石川正純, SUTHERLAND Kenneth, BENGUA Gerard, 宮本直樹, 鈴木隆介
Jpn J Radiol, 2010年07月25日, (公社)日本医学放射線学会, 日本語
2010年07月25日 - 2010年07月25日

2.動体追跡放射線照射(RTRT)における金球標識(金マーカー)留置キットの使用経験(第31回 日本呼吸器内視鏡学会北海道支部会)
竹内 裕, 品川 尚文, 小倉 粋, 河井 康孝, 伊藤 健一郎, 水柿 秀紀, 山田 範幸, 菊地 英毅, 菊地 順子, 小西 純, 大泉 聡史, 西村 正治, 井上 哲也, 加藤 徳雄, 鬼丸 力也, 白土 博樹
気管支学 : 日本気管支研究会雑誌, 2010年01月25日, 日本語

動体追跡装置を用いた肺定位照射時の投与線量解析—動体追跡データに基づくDVH解析—
石川正純, サザランド ケネス, ベングア ジェラード, 鈴木隆介, 宮本直樹, 加藤徳雄, 清水伸一, 鬼丸力也, 青山英史, 白土博樹
日本放射線腫よう学会誌, 2009年08月19日, 日本語
2009年08月19日 - 2009年08月19日

OR16-6 動体追跡放射線照射(RTRT)における金球標識(金マーカー)留置キットの使用経験(診断・他,一般口演16,第32回日本呼吸器内視鏡学会学術集会)
竹内 裕, 品川 尚文, 小倉 粋, 河井 康孝, 伊藤 健一郎, 水柿 秀紀, 山田 範幸, 菊地 英毅, 菊地 順子, 小西 純, 井上 哲也, 加藤 徳雄, 鬼丸 力也, 白土 博樹, 大泉 聡史, 西村 正治
気管支学 : 日本気管支研究会雑誌, 2009年05月20日, 日本語

転移性脳腫瘍への放射線治療後の認知機能の推移　　　　　　　　　　　　　　　
青山 英史, 加藤 徳雄, 白土 博樹
Japanese Journal of Radiology, 2009年04月, (公社)日本医学放射線学会, 日本語
2009年04月 - 2009年04月

対向型PET装置を用いた分子イメージング動体追跡装置の開発〜¹⁸F点線源を用いた追跡精度の検証〜
棚邊哲史, 石川正純, 山口哲, 武島嗣英, 鈴木隆介, 宮本直樹, 加藤徳雄, 清水伸一, 鬼丸力也, 白土博樹
医学物理 Supplement, 2009年04月, 日本語
2009年04月 - 2009年04月

上咽頭癌における半導体PET画像を用いた放射線治療計画
加藤徳雄, 志賀哲, 長谷川雅一, 鬼丸力也, 安田耕一, 清水伸一, ベングア ジェラード, 石川正純, 玉木長良, 白土博樹
日本医学放射線学会総会抄録集, 2009年02月28日, (公社)日本医学放射線学会, 日本語
2009年02月28日 - 2009年02月28日

Can the Real-time Tumor-tracking Radiotherapy Give the Planned Dose to the Tumor? DVH Analysis Based on Measured Real-time Tracking Data
M. Ishikawa, K. L. Sutherland, G. Bengua, R. Suzuki, N. Miyamoto, N. Katoh, S. Shimizu, R. Onimaru, H. Aoyama, H. Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009年, 英語
2009年 - 2009年

Skull base MeningiomaにおけるIMRTの利用—当院治療成績を踏まえて—
小野寺俊輔, 白土博樹, 青山英史, 田口大志, 加藤徳雄, 木下留美子, 鬼丸力也, 清水伸一, 井上哲也, 安田耕一
日本医学放射線学会秋季臨床大会抄録集, 2008年09月24日, (公社)日本医学放射線学会, 日本語
2008年09月24日 - 2008年09月24日

北海道大学における非小細胞肺癌に対する体幹部定位放射線治療の治療成績
鬼丸力也, 加藤徳雄, 井上哲也, 田口大志, 清水伸一, 長谷川雅一, 安田耕一, 小野寺俊輔, 木下留美子, 青山英史, 白土博樹
日本放射線腫よう学会誌, 2008年09月22日, 日本語
2008年09月22日 - 2008年09月22日

動体追跡装置を用い安全域3mmで行ったホルモン非併用の前立腺癌放射線治療
清水伸一, 大坂康博, 鬼丸力也, 長谷川雅一, 田口大志, 加藤徳雄, 木下留美子, 青山英史, 白土博樹
日本放射線腫よう学会誌, 2008年09月22日, 日本語
2008年09月22日 - 2008年09月22日

SOF線量計によるIr‐192高線量率密封小線源治療時のin‐vivoリアルタイム線量測定
石川正純, 平塚純一, 長瀬尚巳, GERARD Bengua, KENNETH Sutherland, 加藤徳雄, 清水伸一, 鬼丸力也, 青山英史, 白土博樹
日本放射線腫よう学会誌, 2008年09月22日, 日本語
2008年09月22日 - 2008年09月22日

分子イメージングを利用した患者位置確認のための対向型Open‐PET装置の製作と基礎検討
棚邊哲史, 石川正純, 山口哲, 武島嗣英, GERARD Bengua, KENNETH Sutherland, 加藤徳雄, 清水伸一, 鬼丸力也, 白土博樹
日本放射線腫よう学会誌, 2008年09月22日, 日本語
2008年09月22日 - 2008年09月22日

75歳以上の高齢者に対する子宮頚癌の放射線治療
木下留美子, 田口大志, 加藤徳雄, 清水伸一, 溝口史樹, 米坂祥朗, 北原利博, 白土博樹
日本放射線腫よう学会誌, 2008年09月22日, 日本語
2008年09月22日 - 2008年09月22日

A new positron emission tomography with semiconductor detectors for target volume delineation and radiotherapy treatment planning in patients with nasopharyngeal carcinoma
N. Katoh, T. Shiga, M. Hasegawa, R. Onimaru, K. Yasuda, S. Shimizu, G. Bengua, M. Ishikawa, N. Tamaki, H. Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008年, 英語
2008年 - 2008年

腎・副腎腫瘍に対する動体追跡照射;臨床的検討について
芹澤慈子, 加藤徳雄, 白土博樹, 鬼丸力也, 大坂康博, 鈴木恵士郎, 渡辺明, 澤田明徳, 清水匡, 宮坂和男, 清水伸一
Radiat Med, 2007年04月25日, 日本語
2007年04月25日 - 2007年04月25日

腎・副腎腫瘍に対する動体追跡照射;技術的検討について
加藤徳雄, 芹澤慈子, 白土博樹, 鬼丸力也, 大坂康博, 鈴木恵士郎, 渡辺佳明, 阿保大介, 清水匡, 宮坂和男, 清水伸一
Radiat Med, 2007年04月25日, (公社)日本医学放射線学会, 日本語
2007年04月25日 - 2007年04月25日

頭頚部癌のDOC併用放射線療法;副作用軽減を目的としたステロイド使用について
小野寺俊輔, 木下留美子, 藤野賢治, 加藤徳雄, 田口大志, 鬼丸力也, 大阪康博, 清水伸一, 鈴木恵士郎, 西岡健, 白土博樹
Radiat Med, 2007年04月25日, 日本語
2007年04月25日 - 2007年04月25日

動体追跡装置を用いた照射中の乳腺表面の動きの検討
木下留美子, 清水伸一, 加藤徳雄, 藤野賢治, 鬼丸力也, 白土博樹
日本医学放射線学会学術集会抄録集, 2007年02月28日, 日本語
2007年02月28日 - 2007年02月28日

Feasibility study of real-time tumor-tracking radiotherapy for adrenal tumors: Three-dimensional movement of internal fiducial gold markers measured in supine and prone patient positions
N. Katoh, R. Onimaru, S. Shimizu, D. Abo, Y. Sakuhara, H. Taguchi, Y. Osaka, B. Gerard, M. Ishikawa, H. Shirato
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007年, 英語
2007年 - 2007年

副腎領域における腹臥位と仰臥位でのマーカー移動と迎撃照射の有効性の検討
加藤徳雄, 白土博樹, 鬼丸力也, 大坂康博, 清水伸一, 阿保大介, 作原祐介, 宮坂和男
日本放射線腫よう学会誌, 2006年10月25日, 日本語
2006年10月25日 - 2006年10月25日

Real-time and precise monitoring of the breast motion during irradiation using real-time tumor-tracking radiotherapy (RTRT) system
R. Kinoshita, S. Shimizu, N. Katoh, R. Onimaru, H. Shirato, K. Miyasaka
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006年, 英語
2006年 - 2006年

放射線治療効果の向上を目指した新手法開発とその臨床応用 動体追跡照射装置を用いた放射線治療
鬼丸 力也, 白土 博樹, 藤野 賢治, 田口 大志, 加藤 徳雄, 大坂 康博, 清水 伸一, 青山 英史, 鈴木 恵士郎
日本放射線影響学会大会講演要旨集, 2005年11月, (一社)日本放射線影響学会, 英語
2005年11月 - 2005年11月

画像診断技術の進歩と放射線治療 脳動静脈奇形の定位照射を例として　　　　　　　　　　　　　　　
青山 英史, 加藤 徳雄, 土屋 和彦, 藤野 賢治, 白土 博樹, 宮坂 和男
日本医学放射線学会雑誌, 2004年11月, (公社)日本医学放射線学会, 日本語
2004年11月 - 2004年11月

画像診断の進歩と放射線治療 治療計画と効果判定にどのように役立っているか 放射線脳壊死と腫瘍再発の鑑別におけるL-[methyl-11C]-methionine PET(Met-PET)
加藤 徳雄, 中駄 邦博, 青山 英史, 竹井 俊樹, 白土 博樹, 玉木 長良, 宮坂 和男
断層映像研究会雑誌, 2003年09月, 断層映像研究会, 日本語
2003年09月 - 2003年09月

Could stereotactic irradiation (STI) for both lung tumor and metastatic brain tumors improve survival and functional status of patients with non-small cell lung cancer (NSCLC)?　　　　　　　　　　　　　　　
Katoh N, Aoyama H, Onimaru R, Shirato H, Miyasaka K
6th Internatinal Stereotactic Radisorugery Society Congress, 2003年06月, 英語, 口頭発表（一般）
［国際会議］

肺非小細胞癌における肺腫瘍・脳転移に対する定位放射線照射(第46回肺癌学会北海道支部会 北海道支部 支部活動)
加藤 徳雄, 青山 英史, 鬼丸 力也, 白土 博樹, 宮坂 和男, 原田 敏之, 木下 一郎, 山崎 浩一, 西村 正治, 秋田 弘俊
肺癌, 2003年02月20日, 日本語

放射線脳壊死と脳腫瘍の鑑別におけるL-[methyl-11C]-methionine PET(MET)　　　　　　　　　　　　　　　
加藤 徳雄, 中駄 邦博, 青山 英史, 竹井 俊樹, 白土 博樹, 玉木 長良, 宮坂 和男
日本医学放射線学会雑誌, 2003年02月, (公社)日本医学放射線学会, 日本語
2003年02月 - 2003年02月

肝損傷のIVR　　　　　　　　　　　　　　　
船窪 正勝, 久保 公三, 阿保 大介, 大山 徳子, 加藤 徳雄, 宮崎 知保子, 佐藤 朝之
IVR: Interventional Radiology, 2001年07月, (一社)日本インターベンショナルラジオロジー学会, 日本語
2001年07月 - 2001年07月

腎損傷のIVR　　　　　　　　　　　　　　　
久保 公三, 阿保 大介, 船窪 正勝, 大山 徳子, 加藤 徳雄, 宮崎 知保子, 佐藤 朝之
IVR: Interventional Radiology, 2001年07月, (一社)日本インターベンショナルラジオロジー学会, 日本語
2001年07月 - 2001年07月

脾損傷のIVR　　　　　　　　　　　　　　　
阿保 大介, 久保 公三, 船窪 正勝, 大山 徳子, 加藤 徳雄, 宮崎 知保子, 佐藤 朝之
IVR: Interventional Radiology, 2001年07月, (一社)日本インターベンショナルラジオロジー学会, 日本語
2001年07月 - 2001年07月

中枢神経サルコイドーシスの2例　　　　　　　　　　　　　　　
阿保 大介, 宮崎 知保子, 加藤 徳雄, 大山 徳子, 羽田 健一, 久保 公三
日本医学放射線学会雑誌, 2001年05月, (公社)日本医学放射線学会, 日本語
2001年05月 - 2001年05月

脳ノカルジア症の2例　　　　　　　　　　　　　　　
加藤 徳雄, 阿保 大介, 大山 徳子, 羽田 健一, 久保 公三, 宮崎 知保子, 寺江 聡
日本医学放射線学会雑誌, 2001年05月, (公社)日本医学放射線学会, 日本語
2001年05月 - 2001年05月

抗リン脂質抗体症候群を背景にして発症した腎梗塞の1例　　　　　　　　　　　　　　　
阿保 大介, 久保 公三, 大山 徳子, 松下 和裕, 加藤 徳雄, 宮崎 知保子
IVR: Interventional Radiology, 2001年01月, (一社)日本インターベンショナルラジオロジー学会, 日本語
2001年01月 - 2001年01月

十二指腸閉塞で発症した多発膵十二指腸動脈瘤の1例　　　　　　　　　　　　　　　
大山 徳子, 久保 公三, 阿保 大介, 松下 和裕, 加藤 徳雄, 宮崎 知保子
IVR: Interventional Radiology, 2001年01月, (一社)日本インターベンショナルラジオロジー学会, 日本語
2001年01月 - 2001年01月

現在
欧州放射線腫瘍学会　　　　　　　　　　　　　　　

現在
米国放射線腫瘍学会　　　　　　　　　　　　　　　

現在
日本肝癌研究会　　　　　　　　　　　　　　　

現在
日本膵臓学会　　　　　　　　　　　　　　　

現在
日本放射線腫瘍学会　　　　　　　　　　　　　　　

現在
日本医学放射線学会　　　　　　　　　　　　　　　

心臓の回避と腫瘍への高精度陽子線照射を両立するデュアルゲーティング照射法の開発
科学研究費助成事業
2025年04月 - 2029年03月
加藤 徳雄, 宮本 直樹
日本学術振興会, 基盤研究(C), 北海道大学, 25K10978

MR画像誘導陽子線治療システムおよび磁場下の治療計画・検証技法に関する基盤開発
科学研究費助成事業
2024年04月01日 - 2028年03月31日
松浦 妙子, 宮本 直樹, 打浪 雄介, 高尾 聖心, 陳 叶, 橋本 孝之, 栗山 靖敏, 加藤 徳雄
日本学術振興会, 基盤研究(B), 北海道大学, 24K02389

陽子線ピンポイントFLASH照射法とマトリックス型照射位置検出器の開発
科学研究費助成事業
2024年06月28日 - 2027年03月31日
松浦 妙子, 橘 英伸, 陳 叶, 栗山 靖敏, 横川 航平, 加藤 徳雄
日本学術振興会, 挑戦的研究(萌芽), 北海道大学, 24K22101

粒子線治療の費用対効果評価のための標準的な手法とデータに関する研究
科学研究費助成事業 基盤研究(B)
2017年04月01日 - 2022年03月31日
森脇 健介, 林 宏至, 奥村 敏之, 清水 伸一, 加藤 徳雄
本課題では、切除不能の肝細胞癌を事例とした陽子線治療の費用対効果評価の標準的手法の確立を目的とした研究活動を行っている。陽子線治療の臨床試験データを用いた費用効果分析の実施方針の作成は、おおむね完了しており、データの蓄積を待つ段階にあるため、本年度は標準的手法の確立に向けて、以下2点の取り組みを行った。1)近年のがん治療の費用効果分析方法のレビュー：イギリスのNICEが近年実施した癌治療の費用効果分析のレビューを行い、癌種、分析枠組、モデル、分析期間、外挿法、評価結果について記述・要約を行った。2018年1月～2020年1月に公表された技術評価ガイダンスは66件であり、うち41件（62%）が癌に関する事例であった。癌腫は41件中、15件（36.6%）の血液癌が最多であり、肺癌8件（19.5%）、乳癌6件（14.6%）がそれに続いた。なお、83.3%の事例でPartSA(Partitioned survival analysis)モデルが用いられた。また、血液癌では単群試験に基づく費用効果分析事例も確認され、陽子線の費用効果分析を進めるための参考事例と考えられた。2)がん治療の費用効果分析マニュアルの作成：PartSAモデルを用いた費用効果分析のための実践的なマニュアルの開発を行った。陽子線治療の事例はデータ収集中のため、切除不能な局所進行の非小細胞性肺癌における根治的化学放射線療法後の維持療法としてのデュルバルマブ治療の費用効果分析を事例として選定した。マニュアルでは、①カプランマイヤー曲線の画像から生存時間データを作成する方法、②パラメトリック関数のフィッティング法、③TreeAge Proを用いたPartSAモデルの構築・解析法を解説し、日本における癌治療の費用効果分析の推進を支援することが期待された。
日本学術振興会, 基盤研究(B), 17H04099

微小空間画像による極低侵襲・マーカーレス実時間画像誘導放射線治療技法の開発
科学研究費助成事業 基盤研究(B)
2018年04月01日 - 2021年03月31日
清水 伸一, 宮本 直樹, 高尾 聖心, 梅垣 菊男, 橋本 孝之, 木下 留美子, 吉村 高明, 西岡 健太郎, 加藤 徳雄, 田口 大志, 松浦 妙子
本研究は、陽子線治療ガントリー設置動体追跡装置の2軸X線透視装置を発展させ、現状より更に低侵襲で尚且つ腫瘍や体内臓器の空間的・時間的変動や呼吸性移動を考慮したがん治療が実現できる実時間画像誘導放射線治療システムを創造することを目的としている。
動体追跡装置では2方向X線透視画像から特徴点の3次元位置座標をリアルタイムに計算し、様々な呼吸位相から治療計画に用いたのものと同じ呼吸位相を時間的に演算によって切り出しゲーティング治療を実現している。透視X線は治療放射線を照射する時間以外にも待機的に用いられているため本来不要な被曝が生じており、特徴点の抽出・認識にマーカを使用する必要があるため、観血的手技が必要などの患者負担が生じている。
まず初年度の実績として、マーカを用いずにゲーティング治療を行う手法についての特許出願を行った(特願2019-056069, 2019)。この特許出願は本研究で想定している特徴点近傍に領域を絞って情報を得て判断を行う画像認識手法を用いており、実際に治療を行う際に必須の物となる。正常組織の線量負荷を低減することの臨床的意義を検証する研究を実施した。
次に次年度の研究活動として、実時間画像誘導放射線治療をダイナミックMRI画像を用いて行うための研究推進体制の検討並びに市場調査等を行い、将来的に実用的に用いることができるものとなるかどうか実装可能性の検討を企業研究者との間で行った。また、透視X線被曝を極限までに低減するための手法について検討を行った。
日本学術振興会, 基盤研究(B), 北海道大学, 18H02758

Radiomicsを用いた肝癌に対する”個別化”陽子線治療法の確立
科学研究費助成事業 基盤研究(C)
2016年04月01日 - 2021年03月31日
加藤 徳雄, Tha KhinKhin, サザランド ケネス・リー
（1) 肝癌患者における治療前画像データ情報と再発の関連性の解析
再発に関するデータを収集するために、北海道大学病院において肝細胞癌に対する陽子線治療とX線動体追跡放射線治療を行った患者を解析した。陽子線治療では2014年12月から2018年3月の期間で43例56病変を対象とし、第61回米国放射線腫瘍学会で発表した("Initial Clinical Outcomes of Real-Time-Image Gated Spot-Scanning Proton Beam Therapy for Hepatocellular Carcinomas". 2019年9月15日-19日シカゴ、米国)。腫瘍サイズ中央値28mm、LQモデルを用いα/β=10とした生物学的実効線量（BED10）の中央値104.9Gy(RBE)、観察期間中央値20ヶ月で2年全生存率が73.9％、2年局所制御率が94.3％であった。X線動体追跡放射線治療は2005年1月から2018年7月の期間で63名74病変を対象とし、第28回日本定位放射線治療学会で発表した（「肝細胞癌に対して動体追跡放射線治療を施行した症例の治療成績 」、2019年6月14日新潟）。腫瘍サイズ中央値20mm、BED10中央値76.8Gy、観察期間中央値20ヶ月で2年全生存率が70.1％、2年局所制御率が89.7％であった。陽子線治療とX線治療とも良好な局所制御を示した。
(2) 線量増加シミュレーションプランニングの施行
陽子線治療後の肝実質変化を陽子線治療計画の段階で予測できるように、剛体と非剛体イメージフュージョンをそれぞれ用いた追加解析方法の検討を行い、引き続きデータ解析を進めている。
日本学術振興会, 基盤研究(C), 北海道大学, 16K10379

肺・肝以外の諸臓器における定位放射線治療の効果と安全性の評価
科学研究費助成事業 基盤研究(B)
2016年04月01日 - 2021年03月31日
大西 洋, 神宮 啓一, 根本 建二, 塩山 善之, 芝本 雄太, 中村 和正, 松下 晴雄, 小岩井 慶一郎, 佐藤 啓, 宇野 隆, 鈴木 修, 伊丹 純, 原田 英幸, 石川 仁, 山下 英臣, 唐澤 克之, 松尾 幸憲, 馬屋原 博, 小久保 雅樹, 木村 智樹, 高山 賢二, 大賀 才路, 野宮 琢磨, 加藤 徳雄, 吉武 忠正
【会議の開催】第5回全体会議：2019年4月13日、第6回全体会議：2019年11月22日、メール会議随時開催 【既存多施設研究の遂行】1.有転移性肺癌患者におけるNivolumabと定位放射線治療の併用の安全性試験（NIVOSTLUC-I)、2.保険外臓器腫瘍に対する定位放射線治療の観察研究、3.有転移性腎癌多発患者におけるNivolumabと定位放射線治療の併用の有無による治療効果の差についての比較研究（NIVOIGERCC)（phase II/III） 【新規多施設研究の検討】1.中枢型IA（UICC 7版）期非小細胞肺癌に対する高精度少分割放射線治療の多施設前向き登録、2.III期非小細胞肺癌の従来型化学放射線療法後の残存腫瘍に対する定位放射線治療
【各分担研究者による臨床試験継続】1. 保険適応外臓器に対する定位放射線治療の調査研究、観察研究、 2. 有転移性前立腺癌の定位照射のI/II相臨床試験、アンケート調査、 3. (1) M1前立腺癌, (2) 前立腺癌放射線治療後局所再発, (3) 前立腺癌術後マクロ再発に対する救済 定位放射線治療、 4. 膵臓癌に対する定位放射線治療、5. 子宮頸癌に対する定位放射線治療、6. 婦人科がんのPALN孤発転移へ の定位放射線治療)、7. 直腸がん術後の吻合部以外の再発（仙骨前面の軟部組織）への定位放射線治療、8. 乳癌 の根治的照射としてのブースト定位照射、9. リンパ節転移、胆管癌への定位照射、10. オリゴリンパ節転移に対する定位放射線治 療の第II相研究、11. 5cm以上の肝癌・肺癌に対する定位放射線治療
【研究発表】1.腎癌の定位放射線治療成績をまとめた。2.I期非小細胞肺癌の定位放射線治療と手術との比較論文のレビューを論文化した。3.定位放射線治療ｂにおけるマルチリーフコリメータ位置の医学物理的評価を行った。
日本学術振興会, 基盤研究(B), 山梨大学, 16H05389

4D-CBCTと治療計画CTの容積マッチング法による4D-IGRTの試み
科学研究費助成事業 基盤研究(B)
2015年04月01日 - 2018年03月31日
清水 伸一, 梅垣 菊男, 高尾 聖心, 松浦 妙子, 宮本 直樹, 西岡 健太郎, 木下 留美子, 加藤 徳雄
陽子線治療ガントリー内に設置した動体追跡装置の2軸X線透視装置を活用し、腫瘍の空間的・時間的変動や呼吸性移動を考慮したがん治療ができる4D-IGRT放射線治療システム構築を目的として、動体追跡装置の透視画像から4次元コーンビームCT(4D-CBCT)画像を得て、複数の呼吸位相で構成される4D-CBCT画像群の中から、治療計画に用いたCT画像と同じ呼吸位相にあるCT画像から選択するとともに、選択されたCBCT画像を構成する元画像群を用いてマーカーレス4D-RTを目指す発展的画像誘導システムを開発することを目標とした。
日本学術振興会, 基盤研究(B), 北海道大学, 15H04899

非小細胞肺癌に対する定位放射線治療後の放射線肺臓炎発症に関与する遺伝子多型の研究
科学研究費助成事業 基盤研究(C)
2012年04月01日 - 2016年03月31日
大西 洋, 塩山 善之, 吉武 忠正, 伊藤 陽一, 白土 博樹, 今井 高志, 鬼丸 力也, 小久保 雅樹, 栗山 健吾, 小宮山 貴史, 冨永 理人, 大栗 実彦, 野中 穂高, 青木 真一, 松本 康男, 松下 晴雄, 高山 賢二, 井上 哲也, 加藤 徳雄, 山下 英臣, 唐澤 克之, 江原 威, 植木 奈美, 松尾 幸憲
早期の非小細胞肺癌に対する定位放射線治療は、高い有効性と安全性から期待の大きい治療法である。重症の放射線肺炎のリスク因子の一つとして肺線維症が挙げられているが、詳細は明らかにされていない。そこで、放射線肺炎との関連が報告されているTGFb1遺伝子上または周辺の多型および、炎症関連遺伝子多型が定位放射線治療後の肺臓炎発症リスクと関連するか検証した。その結果、肺炎症状（CTCEA grade2以上）についてはステロイド使用歴、平均肺線量、遺伝子多型：rs1801270,rs1800470が、CT上の肺炎所見（照射体積外に発生）についてはステロイドの使用歴と遺伝子多型rs1800470が挙げられた。
日本学術振興会, 基盤研究(C), 山梨大学, 24591837

新しい”待ち伏せ”照射法の開発～複数箇所で狙い撃つ～
科学研究費助成事業 若手研究(B)
2012年04月01日 - 2015年03月31日
加藤 徳雄
動体追跡（RTRT）装置を用いて体幹部定位放射線照射を行った肺癌患者において、治療前の四次元CT（4DCT）の有用性を評価した。4DCTで計測した腫瘍移動長とRTRT装置で計測した腫瘍移動長の差異を算出した。結果、上中葉では、左右平均1.3 ± 1.1 mm, 頭尾平均0.6 ± 3.1 mm, 腹背平均1.1 ± 1.7 mmであった。下葉では、左右平均5.7 ± 8.0 mm, 頭尾平均12.5 ± 16.7 mm, 腹背平均6.8 ± 8.5mmであり、下葉の方が差異は大きいことが明らかとなった。肺下葉症例では4DCT計測で動きが過小評価されていることに注意が必要である。
日本学術振興会, 若手研究(B), 北海道大学, 24791260

動体追跡医科学研究
科学研究費助成事業 基盤研究(A)
2009年 - 2012年
白土 博樹, 本間 さと, 玉木 長良, 久下 裕司, 水田 正弘, 伊達 広行, 田中 真樹, 芳賀 永, 西岡 健, 加藤 元嗣, 茶本 健司, 大泉 聡史, 松永 尚文, 沖本 智昭, 早川 和重, 西尾 禎治, 但野 茂, 石川 正純, 小野寺 康仁, 澁谷 景子, 浜田 俊幸, 鬼丸 力也, 清水 伸一, 土屋 和彦, 加藤 徳雄, 木下 留美子, 井上 哲也, 小野寺 俊輔, 高尾 聖心, 加賀 基知三, 寺江 聡, 小野寺 祐也, 作原 祐介, 真鍋 徳子, 阿保 大介, 加藤 扶美, キンキン ター, 南 ジンミン, 佐邊 壽孝, 犬伏 正幸, 品川 尚文, ケネス サザランド
ミクロレベルから動物レベルまで種々の生体を対象にして、定位技術や動体追跡技術を加えることで、生命の空間的な情報を経時的に定量的に扱うことが可能となり、そのデータに基づく新たな病因の追及や治療法の開発につながった。"生命の動き"の膨大なデータ処理が可能になり、新たに生体内の腫瘍の実際の動きをもとにした、新たなリアルタイム放射線治療装置や正確な4次元CT装置の開発につながりつつある。
日本学術振興会, 基盤研究(A), 北海道大学, 21249065

動体追跡装置とそれを備えた放射線治療システム、プログラム、および動体の追跡方法
特許権, 梅川 徹, 宮崎 康一, 藤井 孝, 清水 伸一, ▲高▼尾 聖心, 梅垣 菊男, 宮本 直樹, 加藤 徳雄, 株式会社日立製作所, 国立大学法人北海道大学
特願2019-056069, 2019年03月25日
特開2020-156562, 2020年10月01日
202003018251233772

放射線治療システムおよび放射線治療プログラム
特許権, 宮本 直樹, 清水 伸一, 松浦 妙子, 高▼尾 聖心, 平田 雄一, 梅垣 菊男, 加藤 徳雄, 国立大学法人北海道大学
特願2015-008434, 2015年01月20日
特開2016-131737, 2016年07月25日
201603011303099827

Japanese Journal of Radiology編集委員　　　　　　　　　　　　　　　
2024年06月01日 - 現在
編集
日本医学放射線学会